Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030194399 A1
Publication typeApplication
Application numberUS 09/755,630
Publication dateOct 16, 2003
Filing dateJan 5, 2001
Priority dateJan 6, 2000
Also published asCA2396422A1, CN1411469A, EP1254167A2, US6639054, US6943002, US7238511, US7381556, US20040216187, US20060206962, US20080010700, US20080254484, WO2001049834A2, WO2001049834A3
Publication number09755630, 755630, US 2003/0194399 A1, US 2003/194399 A1, US 20030194399 A1, US 20030194399A1, US 2003194399 A1, US 2003194399A1, US-A1-20030194399, US-A1-2003194399, US2003/0194399A1, US2003/194399A1, US20030194399 A1, US20030194399A1, US2003194399 A1, US2003194399A1
InventorsMurtaza Alibhai, James Astwood, Charles McWherter, Hugh Sampson
Original AssigneeMonsanto Technology Llc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Preparation of deallergenized proteins and permuteins
US 20030194399 A1
Abstract
Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding.
Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity.
Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
Images(12)
Previous page
Next page
Claims(60)
What is claimed is:
1. An isolated deallergenized acyl lipid hydrolase protein comprising SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions:
positions 104-113 of SEQ ID NO:2 or positions 85-94 of SEQ ID NO:7;
positions 128-137 of SEQ ID NO:2 or positions 109-118 of SEQ ID NO:7;
positions 184-197 of SEQ ID NO:2 or positions 165-178 of SEQ ID NO:7;
position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7;
positions 264-277 of SEQ ID NO:2 or positions 245-258 of SEQ ID NO:7;
positions 316-325 of SEQ ID NO:2 or positions 297-306 of SEQ ID NO:7; and
positions 360-377 of SEQ ID NO:2 or positions 341-358 of SEQ ID NO:7;
wherein:
SEQ ID NO:2 or SEQ ID NO:7 is modified by replacing one or more amino acids in the regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine; and
the modified protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
2. An isolated deallergenized acyl lipid hydrolase protein comprising SEQ ID NO:2 modified by one or more of the following changes or SEQ ID NO:7 modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the asparagine at position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with alanine.
3. The deallergenized acyl lipid hydrolase protein of claim 2, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
4. The deallergenized acyl lipid hydrolase protein of claim 2, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
5. An isolated nucleic acid molecule segment comprising a structural nucleic acid sequence, the structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions:
positions 104-113 of SEQ ID NO:2 or positions 85-94 of SEQ ID NO:7;
positions 128-137 of SEQ ID NO:2 or positions 109-118 of SEQ ID NO:7;
positions 184-197 of SEQ ID NO:2 or positions 165-178 of SEQ ID NO:7;
position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7;
positions 264-277 of SEQ ID NO:2 or positions 245-258 of SEQ ID NO:7;
positions 316-325 of SEQ ID NO:2 or positions 297-306 of SEQ ID NO:7; and
positions 360-377 of SEQ ID NO:2 or positions 341-358 of SEQ ID NO:7;
wherein:
SEQ ID NO:2 or SEQ ID NO:7 is modified by replacing one or more amino acids in the regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine; and
the modified protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
6. An isolated nucleic acid molecule segment comprising a structural nucleic acid sequence, the structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with alanine.
7. The nucleic acid molecule segment of claim 6, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
8. The nucleic acid molecule segment of claim 6, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
9. A recombinant host cell comprising a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions:
positions 104-113 of SEQ ID NO:2 or positions 85-94 of SEQ ID NO:7;
positions 128-137 of SEQ ID NO:2 or positions 109-118 of SEQ ID NO:7;
positions 184-197 of SEQ ID NO:2 or positions 165-178 of SEQ ID NO:7;
position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7;
positions 264-277 of SEQ ID NO:2 or positions 245-258 of SEQ ID NO:7;
positions 316-325 of SEQ ID NO:2 or positions 297-306 of SEQ ID NO:7; and
positions 360-377 of SEQ ID NO:2 or positions 341-358 of SEQ ID NO:7;
wherein:
SEQ ID NO:2 or SEQ ID NO:7 is modified by replacing one or more amino acids in the regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine; and
the modified protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
10. A recombinant host cell comprising a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with alanine.
11. The recombinant host cell of claim 10, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
12. The recombinant host cell of claim 10, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
13. The recombinant host cell of claim 10, wherein the host cell is a bacterial cell.
14. The recombinant host cell of claim 10, wherein the host cell is a plant cell.
15. A recombinant plant comprising a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions:
positions 104-113 of SEQ ID NO:2 or positions 85-94 of SEQ ID NO:7;
positions 128-137 of SEQ ID NO:2 or positions 109-118 of SEQ ID NO:7;
positions 184-197 of SEQ ID NO:2 or positions 165-178 of SEQ ID NO:7;
position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7;
positions 264-277 of SEQ ID NO:2 or positions 245-258 of SEQ ID NO:7;
positions 316-325 of SEQ ID NO:2 or positions 297-306 of SEQ ID NO:7; and
positions 360-377 of SEQ ID NO:2 or positions 341-358 of SEQ ID NO:7;
wherein:
SEQ ID NO:2 or SEQ ID NO:7 is modified by replacing one or more amino acids in the regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine; and
the modified protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
16. A recombinant plant comprising a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with alanine.
17. The recombinant plant of claim 16, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
18. The recombinant plant of claim 16, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
19. The recombinant plant of claim 16, wherein the plant is an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
20. A method of preparing a recombinant plant transformed to produce a protein modified to exhibit reduced allergen eliciting properties when consumed in the diet of a human allergic to the unmodified protein, the method comprising:
selecting a host plant cell;
transforming the host plant cell with a recombinant vector;
obtaining recombinant host cells; and
regenerating a recombinant plant from the recombinant host plant cells; wherein the recombinant vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions:
positions 104-113 of SEQ ID NO:2 or positions 85-94 of SEQ ID NO:7;
positions 128-137 of SEQ ID NO:2 or positions 109-118 of SEQ ID NO:7;
positions 184-197 of SEQ ID NO:2 or positions 165-178 of SEQ ID NO:7;
position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7;
positions 264-277 of SEQ ID NO:2 or positions 245-258 of SEQ ID NO:7;
positions 316-325 of SEQ ID NO:2 or positions 297-306 of SEQ ID NO:7; and
positions 360-377 of SEQ ID NO:2 or positions 341-358 of SEQ ID NO:7;
wherein:
SEQ ID NO:2 or SEQ ID NO:7 is modified by replacing one or more amino acids in the regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine; and
the modified protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
21. A method of preparing a recombinant plant transformed to produce a protein modified to exhibit reduced allergen eliciting properties when consumed in the diet of a human allergic to the unmodified protein, the method comprising:
selecting a host plant cell;
transforming the host plant cell with a recombinant vector;
obtaining recombinant host cells; and
regenerating a recombinant plant from the recombinant host plant cells; wherein the recombinant vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 or position 183 of SEQ ID NO:7 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with alanine.
22. The method of claim 21, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
23. The method of claim 21, wherein SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes:
the tyrosine corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with phenylalanine.
24. The method of claim 21, wherein the plant is an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
25. An isolated protein exhibiting acyl lipid hydrolase activity comprising:
(amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2) or (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2);
said-linker-being selected from the group of linkers consisting of Gly-Pro-Gly as set forth in SEQ ID NO:277 and Gly-Gly-Gly-Ser-Gly-Gly-Gly as set forth in SEQ ID NO:276.
26. The protein of claim 25, consisting of SEQ ID NO:247.
27. The protein of claim 25, consisting of SEQ ID NO:259.
28. A recombinant host cell comprising a structural nucleic acid sequence encoding a protein selected from the group consisting of:
(amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2) and (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2);
wherein said linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276.
29. A recombinant plant comprising a structural nucleic acid sequence encoding a protein selected from the group consisting of:
(amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2) and (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2);
wherein said linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276; and
30. A method of preparing a recombinant host cell, the method comprising:
selecting a host cell;
transforming the host cell with a recombinant vector; and
obtaining recombinant host cells; wherein the recombinant vector comprises a structural nucleic acid sequence encoding a protein selected from the group consisting of SEQ ID NO:247 and SEQ ID NO:260.
31. A method of preparing a recombinant plant, the method comprising:
selecting a host plant cell;
transforming the host plant cell with a recombinant vector;
obtaining recombinant host cells; and
regenerating a recombinant plant from the recombinant host plant cells; wherein the recombinant vector comprises a structural nucleic acid sequence encoding a protein selected from the group consisting of SEQ ID NO:274 and SEQ ID NO:260.
32. The method of claim 31, wherein the plant is an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
33. An isolated protein comprising:
(amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2) or
(amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2); the protein modified by replacing one or more amino acids in the following regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine:
positions 104-113 of SEQ ID NO:2;
positions 128-137 of SEQ ID NO:2;
positions 184-197 of SEQ ID NO:2;
position 202 of SEQ ID NO:2;
positions 264-277 of SEQ ID NO:2;
positions 316-325 of SEQ ID NO:2; and
positions 360-377 of SEQ ID NO:2;
wherein the protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies; and
wherein said linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276; and
34. The protein of claim 33, modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 is replaced with alanine.
35. The protein of claim 33, wherein:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
36. The protein of claim 33, wherein:
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
37. An isolated nucleic acid molecule segment comprising a structural nucleic acid sequence, the structural nucleic acid sequence encoding a protein selected from the group consisting of (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and
(amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2); the protein modified by replacing one or more amino acids in the following regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine:
positions 104-113 of SEQ ID NO:2;
positions 128-137 of SEQ ID NO:2;
positions 184-197 of SEQ ID NO:2;
position 202 of SEQ ID NO:2;
positions 264-277 of SEQ ID NO:2;
positions 316-325 of SEQ ID NO:2; and
positions 360-377 of SEQ ID NO:2;
wherein the protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies; and
wherein the linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276; and
38. The nucleic acid molecule segment of claim 37, wherein the protein is modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 is replaced with alanine.
39. The nucleic acid molecule segment of claim 37, wherein:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
40. The nucleic acid molecule segment of claim 37, wherein:
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
41. A recombinant vector comprising operatively linked in the 5′ to 3′ orientation:
a promoter that directs transcription of a structural nucleic acid sequence;
a structural nucleic acid sequence encoding a protein selected from the group consisting of (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and
(amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2); and
a 3′ transcription terminator;
the protein modified by replacing one or more amino acids in the following regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine:
positions 104-113 of SEQ ID NO:2;
positions 128-137 of SEQ ID NO:2;
positions 184-197 of SEQ ID NO:2;
position 202 of SEQ ID NO:2;
positions 264-277 of SEQ ID NO:2;
positions 316-325 of SEQ ID NO:2; and
positions 360-377 of SEQ ID NO:2;
wherein said linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276; and
wherein the protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
42. The recombinant vector of claim 41, wherein the protein is modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 is replaced with alanine.
43. The recombinant vector of claim 41, wherein:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
44. The recombinant vector of claim 41, wherein:
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
45. A recombinant host cell comprising a structural nucleic acid sequence encoding a protein selected from the group consisting of (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and
(amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2);
the protein modified by replacing one or more amino acids in the following regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine:
positions 104-113 of SEQ ID NO:2;
positions 128-137 of SEQ ID NO:2;
positions 184-197 of SEQ ID NO:2;
position 202 of SEQ ID NO:2;
positions 264-277 of SEQ ID NO:2;
positions 316-325 of SEQ ID NO:2; and
positions 360-377 of SEQ ID NO:2;
wherein said linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276; and
wherein the protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
46. The recombinant host cell of claim 45, wherein the protein is modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 is replaced with alanine.
47. The recombinant host cell of claim 45, wherein:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
48. The recombinant host cell of claim 45, wherein:
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
49. A recombinant plant comprising a structural nucleic acid sequence encoding a protein selected from the group consisting of (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and
(amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2);
the protein modified by replacing one or more amino acids in the following regions with alanine, glutamic acid, phenylalanine, proline, serine, or glutamine:
positions 104-113 of SEQ ID NO:2;
positions 128-137 of SEQ ID NO:2;
positions 184-197 of SEQ ID NO:2;
position 202 of SEQ ID NO:2;
positions 264-277 of SEQ ID NO:2;
positions 316-325 of SEQ ID NO:2; and
positions 360-377 of SEQ ID NO:2;
wherein said linker is selected from the group consisting of SEQ ID NO:277 and SEQ ID NO:276; and
wherein the protein displays reduced binding to anti-acyl lipid hydrolase antibodies with respect to the binding of unmodified acyl lipid hydrolase protein to the anti-acyl lipid hydrolase antibodies.
50. The recombinant plant of claim 49, wherein the protein is modified by one or more of the following changes:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the isoleucine corresponding to position 113 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 137 of SEQ ID NO:2 is replaced with alanine;
the serine corresponding to position 184 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the alanine corresponding to position 188 of SEQ ID NO:2 is replaced with serine;
the threonine corresponding to position 192 of SEQ ID NO:2 is replaced with alanine or proline;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the asparagine corresponding to position 202 of SEQ ID NO:2 is replaced with glutamine;
the lysine corresponding to position 268 of SEQ ID NO:2 is replaced with alanine or glutamic acid;
the threonine corresponding to position 269 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the lysine corresponding to position 273 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 313 of SEQ ID NO:2 is replaced with glutamic acid;
the asparagine corresponding to position 314 of SEQ ID NO:2 is replaced with alanine;
the asparagine corresponding to position 315 of SEQ ID NO:2 is replaced with alanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine or alanine;
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine;
the lysine corresponding to position 367 of SEQ ID NO:2 is replaced with alanine;
the arginine corresponding to position 368 of SEQ ID NO:2 is replaced with alanine;
the phenylalanine corresponding to position 369 of SEQ ID NO:2 is replaced with alanine;
the lysine corresponding to position 371 of SEQ ID NO:2 is replaced with alanine;
the leucine corresponding to position 372 of SEQ ID NO:2 is replaced with alanine; and
the leucine corresponding to position 373 of SEQ ID NO:2 is replaced with alanine.
51. The recombinant plant of claim 49, wherein:
the tyrosine corresponding to position 106 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 129 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
52. The recombinant plant of claim 49, wherein:
the tyrosine corresponding to position 185 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 193 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 270 of SEQ ID NO:2 is replaced with phenylalanine;
the tyrosine corresponding to position 316 of SEQ ID NO:2 is replaced with phenylalanine; and
the tyrosine corresponding to position 362 of SEQ ID NO:2 is replaced with phenylalanine.
53. The recombinant plant of claim 49, wherein the plant is an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
54. A method for decreasing allergen eliciting properties of a native protein comprising the steps of:
a) identifying a patient exhibiting an allergic sensitivity to said native protein and obtaining serum from said patient;
b) exposing synthetic overlapping peptides representative of said native protein to said patient serum to identify peptides exhibiting epitopes which bind IgE present within said patient serum;
c) producing variant peptides exhibiting alanine scanning or rational scanning amino acid substitutions based on peptides from step (b), wherein said variant peptides exhibit decreased IgE binding compared to peptides from step (b), said amino acid substitutions comprising result effective substitutions;
d) modifying the amino acid sequence of said native protein to contain one or more of said result effective substitutions; and
e) isolating and purifying the modified protein comprising one or more result effective amino acid substitutions;
wherein the modified protein comprising said one or more result effective substitutions exhibits reduced binding of IgE present within said patient serum when compared with said native protein.
55. The method according to claim 54 wherein said native protein is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:284, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, and SEQ ID NO:293.
56. A method for producing a modified acyl lipid hydrolase protein comprising:
a) identifying a patient exhibiting an allergic sensitivity to a native form of said hydrolase protein and obtaining serum from said patient;
b) exposing synthetic overlapping peptides representative of said native protein to said patient serum to identify peptides exhibiting epitopes which bind immunoglobulins present within said patient serum, said immunoglobulins exhibiting a binding specificity for said native protein;
c) roducing variant peptides exhibiting alanine scanning or rational scanning amino acid substitutions based on peptides from step (b), wherein said variant peptides exhibit decreased immunoglobulin binding compared to peptides from step (b), said amino acid substitutions comprising result effective substitutions;
d) modifying the amino acid sequence of said native protein to contain one or more of said result effective substitutions; and
e) isolating and purifying the modified protein comprising one or more result effective amino acid substitutions;
wherein the modified acyl lipid hydrolase protein comprises said one or more result effective substitutions, exhibits reduced binding of immunoglobulins present within said patient serum when compared with said native protein, exhibits lipid acyl hydrolase activity no less than that of the native protein, and exhibits insecticidal activity no less than that of the native protein.
57. An isolated deallergenized acyl lipid hydrolase protein comprising phenylalanine residues substituted for tyrosine residues at one or more amino acid sequence positions corresponding to positions selected from the group consisting of positions 106, 129, 185, 193, 270, and 316 as set forth in SEQ ID NO:2 or the corresponding amino acid sequence positions in acyl lipid hydrolase protein homologs aligned with SEQ ID NO:2 (patatin_mtc) as set forth in FIG. 9.
58. An isolated deallergenized acyl lipid hydrolase protein according to claim 57 comprising a glutamine residue substituted for an asparagine residue at an amino acid sequence position selected from the group of amino acid sequence positions consisting of position 202 as set forth in SEQ ID NO:2, position 183 as set forth in SEQ ID NO:7, position 183 as set forth in SEQ ID NO:281, and position 181 as set forth in SEQ ID NO:280.
59. An isolated deallergenized acyl lipid hydrolase protein comprising a glutamine residue substituted for an asparagine residue at an amino acid sequence position selected from the group of amino acid sequence positions consisting of position 202 as set forth in SEQ ID NO:2, position 183 as set forth in SEQ ID NO:7, position 183 as set forth in SEQ ID NO:281, and position 181 as set forth in SEQ ID NO:280.
60. An isolated and purified peptide sequence exhibiting corn rootworn insect inhibitory activity and acyl lipid hydrolase activity comprising the peptide sequence as set forth in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:247, SEQ ID NO:251, SEQ ID NO:255, SEQ ID NO:259, SEQ ID NO:263, SEQ ID NO:265, SEQ ID NO:271, SEQ ID NO:275, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:284, SEQ ID NO:286, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, or SEQ ID NO:293.
Description
    FIELD OF THE INVENTION
  • [0001]
    The invention relates generally to non-naturally occurring novel proteins which have insecticidal properties, and more specifically to the design, preparation, and use of proteins that have been deallergenized while maintaining their insecticidal properties. Deallergenized patatin proteins include variants that have had allergenic sequences modified, and permuteins that have had their amino acid sequences rearranged at one or more breakpoints.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Insecticidal Proteins
  • [0003]
    The use of natural products, including proteins, is a well known method of controlling many insect, fungal, viral, bacterial, and nematode pathogens. For example, endotoxins of Bacillus thuringiensis (B.t.) are used to control both lepidopteran and coleopteran insect pests. Genes producing these endotoxins have been introduced into and expressed by various plants, including cotton, tobacco, and tomato. There are, however, several economically important insect pests such as boll weevil (BWV), Anthonomus grandis, and corn rootworm (CRW), Diabrotica spp. that are not as susceptible to B.t. endotoxins as are insects such as lepidopterans. In addition, having other, different gene products for control of insects which are susceptible to B.t. endotoxins is important, if not vital, for resistance management.
  • [0004]
    It has been recently discovered that the major storage protein of potato tubers, patatins (Gaillaird, T., Biochem. J. 121: 379-390, 1971; Racusen, D., Can. J. Bot., 62: 1640-1644, 1984; Andrews, D. L., et al., Biochem. J., 252: 199-206, 1988), will control various insects, including western rootworm (WCRW, Diabrotica virigifera), southern corn rootworm (SCRW, Diabrotica undecimpunctata), and boll weevil (BWV, Anthonomus grandis) (U.S. Pat. No. 5,743,477). Patatins are lethal to some larvae and will stunt the growth of survivors so that maturation is prevented or severely delayed, resulting in no reproduction. These proteins, have nonspecific lipid acyl hydrolase activity and studies have shown that the enzyme activity is essential for its insecticidal activity (Strickland, J. A., et al., Plant Physiol., 109: 667-674, 1995; U.S. Pat. No. 5,743,477). Patatins can be applied directly to the plants or introduced in other ways well known in the art, such as through the application of plant-colonizing microorganisms, which have been transformed to produce the enzymes, or by the plants themselves after similar transformation.
  • [0005]
    In potato, the patatins are found predominantly in tubers, but also at much lower levels in other plant organs (Hofgen, R. and Willmitzer, L., Plant Science, 66: 221-230, 1990). Genes that encode patatins have been previously isolated by Mignery, G. A., et al. (Nucleic Acids Research, 12: 7987-8000, 1984; Mignery, G. A., et al., Gene, 62: 27-44, 1988; Stiekema, et al., Plant Mol. Biol., 11: 255-269, 1988) and others. Patatins are found in other plants, particularly solanaceous species (Ganal, et al., Mol. Gen. Genetics, 225: 501-509, 1991; Vancanneyt, et al., Plant Cell, 1: 533-540, 1989) and recently Zea mays (WO 96/37615). Rosahl, et al. (EMBO J, 6: 1155-1159, 1987) transferred it to tobacco plants, and observed expression of patatin, demonstrating that the patatin genes can be heterologously expressed by plants.
  • [0006]
    Patatin is an attractive for use in planta as an insect control agent, but unfortunately a small segment of the population displays allergic reactions to patatin proteins, and in particular to potato patatin, as described below.
  • [0007]
    Food Allergens
  • [0008]
    There are a variety of proteins that cause allergic reactions. Proteins that have been identified as causing an allergic reaction in hypersensitive patients occur in many plant and animal derived foods, pollens, fungal spores, insect venoms, insect feces, and animal dander and urine (King, H. C., Ear Nose Throat J., 73(4): 237-241, 1994; Astwood, J. D., et al., Clin. Exp. Allergy, 25: 66-72, 1995; Astwood, J. D. and Fuchs R. L., Monographs in allergy Vol. 32: Highlights infood allergy, pp. 105-120, 1996; Metcalfe, D. D., et al., Critical Reviews in Food Science and Nutrition, 36S: 165-186, 1996). The offending proteins of many major sources of allergens have been characterized by clinical and molecular methods. The functions of allergenic proteins in vivo are diverse, ranging from enzymes to regulators of the cell cytoskeleton.
  • [0009]
    To understand the molecular basis of allergic disease, the important IgE binding epitopes of many allergen proteins have been mapped (Elsayed, S. and Apold, J., Allergy 38(7): 449-459, 1983; Elsayed, S. et al., Scand J. Clin. Lab. Invest. Suppl. 204: 17-31 1991; Zhang, L., et al., Mol Immunol. 29(11): 1383-1389, 1992). The optimal peptide length for IgE binding has been reported to be between 8 and 12 amino acids. Conservation of epitope sequences is observed in homologous allergens of disparate species (Astwood, J. D., et al., Clin. Exp. Allergy, 25: 66-72, 1995). Indeed, conservative substitutions introduced by site-directed mutagenesis reduce IgE binding of known epitopes when presented as peptides.
  • [0010]
    Food allergy occurs in 2-6% of the population. Eight foods or food groups (milk, eggs, fish, crustacea, wheat, peanuts, soybeans, and tree nuts) account for 90% of allergies to foods. Nevertheless, over 160 different foods have been reported to cause adverse reactions, including potato (Hefle, S., et al., Crit. Rev. in Food Sci. Nutr., 36S: 69-90, 1996).
  • [0011]
    Mode of Action of Allergens
  • [0012]
    Regardless of the identity of the allergen, it is theorized that the underlying mechanism of allergen response is the same. Immediate hypersensitivity (or anaphylactic response) is a form of allergic reaction which develops very quickly, i.e., within seconds or minutes of exposure of the patient to the causative allergen, and is mediated by B lymphocyte IgE antibody produciton. Allergic patients exhibit elevated levels of IgE, mediating hypersensitivity by priming mast cells which are abundant in the skin, lymphoid organs, in the membranes of the eye, nose and mouth, and in the respiratory tree and intestines. The IgE in allergy-suffering patients becomes bound to the IgE receptors of mast cells. When this bound IgE is subsequently contacted by the appropriate allergen, the mast cell is caused to degranulate and release various substances such as histamine into the surrounding tissue (Church et al. In: Kay, A. B. ed., Allergy and Allergic Diseases, Oxford, Blackwell Science, pp. 149-197, 1997).
  • [0013]
    It is the release of these substances which is responsible for the clinical symptoms typical of immediate hypersensitivity, namely contraction of smooth muscle in the airways or in the intestine, the dilation of small blood vessels, and the increase in their permeability to water and plasma proteins, the secretion of thick sticky mucus, and (in the skin) the stimulation of nerve endings that result in itching or pain. Immediate hypersensitivity is, at best, a nuisance to the suffer; at worst it can present very serious problems and can in rare cases even result in death.
  • [0014]
    Allergic Reactions to Potato
  • [0015]
    Food allergy to potato is considered rare in the general population (Castells, M. C., et al., Allergy Clin. Immunol., 8: 1110-1114, 1986; Hannuksela, M., et al., Contact Dermatitis, 3: 79-84, 1977; Golbert, T. M., et al., Journal of Allergy, 44: 96-107, 1969). Approximately 200 individuals have participated in published clinical accounts of potato allergy (Hefle, S. et al., Critical Reviews in Food Science and Nutrition, 36S: 69-90, 1996). A number of IgE binding proteins have been identified in potato tuber extracts (see Table 1), however the amino acid sequence and function of these proteins has not been determined (Wahl, R., et al., Intl. Arch. Allergy Appl. Immunol., 92: 168-174, 1990).
    TABLE 1
    Studies of potato tuber IgE-binding proteins (allergens)
    Study Protein Characteristics
    (Castells, M. C. et al. J. Allergy Clin. Unknown 14 to 40 kDa
    Immunol. 78, 1110-1114, 1986
    (Wahl, R. et al. Int. Arch. Allergy Appl. Unknown 42/43 kDa
    Immunol. 92: 168-174, 1990)
    Unknown 65 kDa
    Unknown 26 kDa
    Unknown 20 kDa
    Unknown 14 kDa
    Unknown < 14 kDa (˜5 kDa)
    (Ebner, C. et al. in: Wuthrich, B. & Unknown 42/43 kDa
    Ortolani, C. (eds.), Highlights in
    food allergy. Monographs in Allergy,
    Volume 32 Basil, Karger, pp. 73-77,
    1996)
    Unknown 23 kDa
    Unknown˜16 kDa
    Unknown < 14 kDa (˜5 kDa)
  • [0016]
    Improved Safety from the Use of Hypoallergenic Proteins
  • [0017]
    Patatin has been identified as an allergenic protein (Seppala, U. et al., J. Allergy Clin. Immunol. 103:165-171, 1999). Accordingly, potato allergic subjects may not be able to safely consume products containing unmodified patatin protein, such as crops to which foliar applications of patatins have been applied, or crops which have been engineered to express patatin. In addition, proliferation of food allergens in the food supply is considered hazardous (Metcalfe, D. D., et al., Critical Reviews and Food Science and Nutrition, 36S: 165-186, 1996). There are additional concerns regarding the use of potentially allergenic food proteins where workers might be exposed to airborne particulates, initiating a new allergic response (Moneret-Vautrin, D. A., et al., Rev. Med. Interne., 17(7): 551-557, 1996).
  • [0018]
    Permuteins
  • [0019]
    Novel proteins generated by the method of sequence transposition resembles that of naturally occurring pairs of proteins that are related by linear reorganization of their amino acid sequences (Cunningham, et al. Proc. Natl. Sci., U.S.A., 76: 3218-3222, 1979; Teather, et al., J. Bacteriol., 172: 3837-3841, 1990; Schimming, et al., Eur. J. Biochem., 204: 13-19, 1992; Yamiuchi, et al., FEBS Lett., 260: 127-130, 1991; MacGregor, et al., FEBS. Lett., 378: 263-266, 1996). The first in vitro application of sequence rearrangement to proteins was described by Goldenberg and Creighton (Goldenberg and Creighton, J. Mol. Biol., 165: 407-413, 1983). A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same order of amino acids as the original from the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At this point the new sequence is joined, either directly or through an additional portion or sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues with the same sequence as the original until it reaches a point that is at or near the amino acid that was N-terminal to the breakpoint site of the original sequence, this residue forming the new C-terminus of the chain. This approach has been applied to proteins which range in size from 58 to 462 amino acids and represent a broad range of structural classes (Goldenberg and Creighton, J. Mol. Biol., 165: 407-413, 1983; Li and Coffino, Mol. Cell. Biol., 13: 2377-2383, 1993; Zhang, et al., Nature Struct. Biol., 1: 434-438, 1995; Buchwalder, et al., Biochemistry, 31: 1621-1630, 1994; Protasova, et al., Prot. Eng., 7: 1373-1377, 1995; Mullins, et al., J. Am. Chem. Soc., 116: 5529-5533, 1994; Garrett, et al., Protein Science, 5: 204-211, 1996; Hahn, et al., Proc. Natl. Acad. Sci. U.S.A., 91: 10417-10421, 1994; Yang and Schachman, Proc. Natl. Acad. Sci. U.S.A., 90: 11980-11984, 1993; Luger, et al., Science, 243: 206-210, 1989; Luger, et al., Prot. Eng., 3: 249-258, 1990; Lin, et al., Protein Science, 4: 159-166, 1995; Vignais, et al., Protein Science, 4: 994-1000, 1995; Ritco-Vonsovici, et al., Biochemistry, 34: 16543-16551, 1995; Horlick, et al., Protein Eng., 5: 427-431, 1992; Kreitman, et al., Cytokine, 7: 311-318, 1995; Viguera, et al., Mol. Biol., 247: 670-681, 1995; Koebnik and Kramer, J. Mol. Biol., 250: 617-626, 1995; Kreitman, et al., Proc. Natl. Acad. Sci., 91: 6889-6893, 1994).
  • [0020]
    There exists a need for the development of plant expressible insecticidal proteins which possess minimal or no allergenic properties.
  • SUMMARY OF THE INVENTION
  • [0021]
    Novel protein sequences, and nucleic acid sequences encoding them are disclosed. The proteins maintain desirable enzymatic and insecticidal properties while displaying reduced or eliminated allergenicity.
  • [0022]
    Allergenic epitopes are identified by scanning overlapping peptide sequences with an immunoreactivity assay. Alanine scanning and ‘rational substitution’ is performed on identified peptide sequences to determine specific amino acids which contribute to antibody binding, and presumably, to the allergenic properties of the whole protein. Individual mutations are introduced into the whole protein sequence by methods such as site directed mutagenesis of the encoding nucleic acid sequence to delete or modify the allergenic sequences.
  • [0023]
    Glycosylation target residues are identified within amino acid sequences of proteins which have demonstrated allergy eliciting properties. Glycosylation target amino acid residues are rationally substutited with other amino acid residues to eliminate glycosylation and to provide a variant deglycosylated protein. The variant protein may then exhibit reduced allergen eliciting properties and may also exhibit reduced binding to IgE within serum of patients observed to be allergic to said glycosylated protein.
  • [0024]
    Permuteins of the deallergenized protein sequences can be constructed to further reduce or eliminate allergic reactions. The encoding nucleic acid sequence is modified to produce a non-naturally occurring protein having a linear amino acid sequence different from the naturally occurring protein sequence, while maintaining enzymatic and insecticidal properties. The permutein is preferably produced in plant cells, and more preferably produced at a concentration which is toxic to insects ingesting the plant cells.
  • [0025]
    Methods for reducing, eliminating, or decreasing allergen eliciting properties of a protein are specifically contemplated herein. Such methods comprise steps including identifying one or more patients exhibiting an allergic sensitivity to an allergen eliciting protein and obtaining a sample of serum from the patient; exposing the patient serum to a first set of synthetic overlapping peptides which represent the allergen eliciting protein in order to identify such peptides which exhibit epitopes which bind to IgE present within the allergic patients' serum and wherein the IgE present in the serum has a specific affinity for the said allergen eliciting protein; producing a second set of peptides which are variant peptides based on the first set of peptides which were identified to bind specifically to IgE present in patient serum, wherein the second set variant peptides exhibit alanine scanning or rational scanning amino acid substitutions which exhibit reduced, decreased, or eliminated IgE binding when compared to the first set non-variant peptides, and wherein such substitutions which reduce, eliminate or decrease IgE binding are identified as result effective substitutions; and modifying the amino acid sequence of the allergen eliciting protein to contain one or more of said result effective substitutions, wherein the modified protein is a variant of the allergen eliciting protein which lacks allergen eliciting protein or exhibits reduced allergen eliciting properties, and wherein the variant of the allergen eliciting protein comprising one or more result effective substitutions exhibits reduced, decreased, or totally eliminated binding of IgE present within said patients' serum.
  • [0026]
    The novel proteins can be used in controlling insects, as nutritional supplements, in immunotherapy protocols, and in other potential applications. Transgenic plant cells and plants containing the encoding nucleic acid sequence can be particularly beneficial in the control of insects, and as a nutritional/immunotherapy material.
  • DESCRIPTION OF THE FIGURES
  • [0027]
    The following figures form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
  • [0028]
    [0028]FIG. 1 illustrates the alignment of potato patatin PatA (acyl lipid hydrolase) with patatin (acyl lipid hydrolase) homologs and related amino acid sequences, the homologs and related sequences being from both dicot and monocot plant species.
  • [0029]
    [0029]FIG. 2 illustrates IgE binding to overlapping peptide sequences.
  • [0030]
    [0030]FIG. 3 illustrates construction of nucleic acid sequences encoding patatin permutein proteins, and in this figure for illustrative purposes a breakpoint at position 247 is shown.
  • DESCRIPTION OF THE SEQUENCE LISTINGS
  • [0031]
    The following description of the sequence listing forms part of the present specification and is included to further demonstrate certain aspects of the present invention. The invention can be better understood by reference to one or more of these sequences in combination with the detailed description of specific embodiments presented herein.
    SEQ ID NO:1 DNA sequence encoding a patatin (acyl lipid
    hydrolae) protein
    SEQ ID NO:2 potato patatin protein sequence
    SEQ ID NO:3 thermal amplification primer
    SEQ ID NO:4 thermal amplification primer
    SEQ ID NO:5 thermal amplification product
    SEQ ID NO:6 Pre-cleavage patatin protein produced in
    Pichia pastoris
    SEQ ID NO:7 Post-cleavage patatin protein produced in
    Pichia pastoris
    SEQ ID NO:8 Y106F mutagenic primer
    SEQ ID NO:9 Y129F mutagenic primer
    SEQ ID NO:10 Y185F mutagenic primer
    SEQ ID NO:11 Y193F mutagenic primer
    SEQ ID NO:12 Y185F and Y193F mutagenic primer
    SEQ ID NO:13 Y270F mutagenic primer
    SEQ ID NO:14 Y316F mutagenic primer
    SEQ ID NO:15 Y362F mutagenic primer
    SEQ ID NO:16-104 Peptide scan sequences of a patatin protein
    SEQ ID NO:105-241 Alanine and rational scan sequences of selected
    patatin peptides
    SEQ ID NO:242 thermal amplification primer 27
    SEQ ID NO:243 thermal amplification primer 48
    SEQ ID NO:244 thermal amplification primer 47
    SEQ ID NO:245 thermal amplification primer 36
    SEQ ID NO:246 pMON37402 sequence encoding permutein
    protein
    SEQ ID NO:247 Permutein protein encoded from pMON37402
    sequence
    SEQ ID NO:248 thermal amplification primer 58
    SEQ ID NO:249 thermal amplification primer 59
    SEQ ID NO:250 pMON37405 sequence encoding permutein
    protein
    SEQ ID NO:251 Permutein protein encoded by pMON37405
    sequence
    SEQ ID NO:252 thermal amplification primer 60
    SEQ ID NO:253 thermal amplification primer 61
    SEQ ID NO:254 pMON37406 sequence encoding permutein
    protein
    SEQ ID NO:255 Permutein protein encoded by pMON37406
    sequence
    SEQ ID NO:256 thermal amplification primer 62
    SEQ ID NO:257 thermal amplification primer 63
    SEQ ID NO:258 pMON37407 sequence encoding permutein
    protein
    SEQ ID NO:259 Permutein protein encoded by pMON37407
    sequence
    SEQ ID NO:260 thermal amplification primer 60
    SEQ ID NO:261 thermal amplification primer65
    SEQ ID NO:262 pMON37408 sequence encoding permutein
    protein
    SEQ ID NO:263 Permutein protein encoded by pMON37408
    sequence
    SEQ ID NO:264 pMON40701 sequence encoding permutein
    protein
    SEQ ID NO:265 Permutein protein encoded by pMON40701
    sequence
    SEQ ID NO:266 thermal amplification primer Syn1
    SEQ ID NO:267 thermal amplification primer Syn2
    SEQ ID NO:268 thermal amplification primer Syn3
    SEQ ID NO:269 thermal amplification primer Syn4
    SEQ ID NO:270 pMON40703 sequence encoding permutein
    protein
    SEQ ID NO:271 Permutein protein encoded by pMON40703
    sequence
    SEQ ID NO:272 thermal amplification primer Syn10
    SEQ ID NO:273 thermal amplification primer Syn11
    SEQ ID NO:274 pMON40705 sequence encoding permutein
    protein
    SEQ ID NO:275 Permutein protein encoded by pMON40705
    sequence
    SEQ ID NO:276-277 Permutein linker sequences
    SEQ ID NO:278 Patatin isozyme PatA + (including signal peptide)
    SEQ ID NO:279 Patatin isozyme PatB + (including signal peptide)
    SEQ ID NO:280 Patatin isozyme PatFm (mature protein lacking
    signal peptide)
    SEQ ID NO:281 Patatin isozyme PatIm (mature protein lacking
    signal peptide)
    SEQ ID NO:282 Patatin isozyme PatL + (including signal peptide)
    SEQ ID NO:283 Rational substitution peptide
    SEQ ID NO:284 Corn homolog peptide
    SEQ ID NO:285 patatin homolog Pat17 DNA coding sequence and
    amino acid translation
    SEQ ID NO:286 patatin homolog Pat17 amino acid sequence
    SEQ ID NO:287 dicot patatin homolog amino acid sequence
    pentin1_phb
    SEQ ID NO:288 dicot patatin homolog amino acid sequence
    5c9_phb
    SEQ ID NO:289 maize patatin homolog amino acid sequence
    corn1_pep
    SEQ ID NO:290 maize patatin homolog amino acid sequence
    corn2_pep
    SEQ ID NO:291 maize patatin homolog amino acid sequence
    corn3_pep
    SEQ ID NO:292 maize patatin homolog amino acid sequence
    corn4_pep
    SEQ ID NO:293 maize patatin homolog amino acid sequence
    corn5_pep
  • DEFINITIONS
  • [0032]
    The following definitions are provided in order to aid those skilled in the art in understanding the detailed description of the present invention. Some words and phrases may also be defined in other sections of the specification. No limitation should be placed on the definitions presented for the terms below, where other meanings are evidenced elseqhere in the specification in addition to those specified below.
  • [0033]
    “Allergen” refers to a biological or chemical substance that induces an allergic reaction or response. An allergic response can be an immunoglobulin E-mediated response.
  • [0034]
    Amino acid codes: A (Ala)=alanine; C (Cys)=cysteine; D (Asp)=aspartic acid; E (Glu)=glutamic acid; F (Phe)=phenylalanine; G (Gly)=glycine; H (His)=histidine; I (Ile)=isoleucine; K (Lys)=lysine; L (Leu)=leucine; M (Met)=methionine; N (Asn)=asparagine; P (Pro)=proline; Q (Gln)=glutamine; R (Arg)=arginine; S (Ser)=serine; T (Thr)=threonine; V=(Val) valine; W (Trp)=tryptophan; Y (Tyr)=tyrosine.
  • [0035]
    “Amplification: refers to increasing the number of copies of a desired molecule.
  • [0036]
    “Coding sequence”, “open reading frame”, and “structural sequence” refer to the region of continuous sequential nucleic acid base pair triplets encoding a protein, polypeptide, or peptide sequence.
  • [0037]
    “Codon” refers to a sequence of three nucleotides that specify a particular amino acid.
  • [0038]
    “Complementarity” refers to the specific binding of adenine to thymine (or uracil in RNA) and cytosine to guanine on opposite strands of DNA or RNA.
  • [0039]
    “Deallergenize” (render hypoallergenic) refers to the method of engineering or modifying a protein or the encoding DNA such that the protein has a reduced or eliminated ability to induce an allergic response with respect to the ability of the unmodified protein. A deallergenized protein can be referred to as being hypoallergenic. The degree of deallergenization of a protein can be measured in vitro by the reduced binding of IgE antibodies.
  • [0040]
    “DNA segment heterologous to the promoter region” means that the coding DNA segment does not exist in nature in the same gene with the promoter to which it is now attached.
  • [0041]
    “DNA segment” refers to a DNA molecule that has been isolated free of total genomic DNA of a particular species.
  • [0042]
    “Electroporation” refers to a method of introducing foreign DNA into cells that uses a brief, high voltage DC (direct current) charge to permeabilize the host cells, causing them to take up extra-chromosomal DNA.
  • [0043]
    “Encoding DNA” refers to chromosomal DNA, plasmid DNA, cDNA, or synthetic DNA which encodes any of the enzymes discussed herein.
  • [0044]
    “Endogenous” refers to materials originating from within an organism or cell.
  • [0045]
    “Endonuclease” refers to an enzyme that hydrolyzes double stranded DNA at internal locations.
  • [0046]
    “Epitope” refers to a region on an allergen that interacts with the cells of the immune system. Epitopes are often further defined by the type of antibody or cell with which they interact, e.g. if the region reacts with B-cells or antibodies (IgE), it is called a B-cell epitope.
  • [0047]
    “Exogenous” refers to materials originating from outside of an organism or cell. This typically applies to nucleic acid molecules used in producing transformed or transgenic host cells and plants.
  • [0048]
    “Expressibly coupled” and “expressibly linked” refer to a promoter or promoter region and a coding or structural sequence in such an orientation and distance that transcription of the coding or structural sequence can be directed by the promoter or promoter region.
  • [0049]
    “Expression” refers to the transcription of a gene to produce the corresponding mRNA and translation of this mRNA to produce the corresponding gene product, i.e., a peptide, polypeptide, or protein.
  • [0050]
    “Heterologous DNA” refers to DNA from a source different than that of the recipient cell.
  • [0051]
    “Homologous DNA” refers to DNA from the same source as that of the recipient cell.
  • [0052]
    “Identity” refers to the degree of similarity between two nucleic acid or protein sequences. An alignment of the two sequences is performed by a suitable computer program. A widely used and accepted computer program for performing sequence alignments is CLUSTALW v1.6 (Thompson, et al. Nucl. Acids Res., 22: 4673-4680, 1994). The number of matching bases or amino acids is divided by the total number of bases or amino acids, and multiplied by 100 to obtain a percent identity. For example, if two 580 base pair sequences had 145 matched bases, they would be 25 percent identical. If the two compared sequences are of different lengths, the number of matches is divided by the shorter of the two lengths. For example, if there were 100 matched amino acids between 200 and a 400 amino acid proteins, they are 50 percent identical with respect to the shorter sequence. If the shorter sequence is less than 150 bases or 50 amino acids in length, the number of matches are divided by 150 (for nucleic acid bases) or 50 (for amino acids), and multiplied by 100 to obtain a percent identity.
  • [0053]
    “IgE” (Immunoglobulin E) refers to a specific class of immunoglobulin secreted by B cells. IgE binds to specific receptors on Mast cells. Interaction of an allergen with mast cell-bound IgE may trigger allergic symptoms.
  • [0054]
    “Immunotherapy” refers to any type of treatment that targets the immune system. Allergy immunotherapy is a treatment in which a progressively increasing dose of an allergen is given in order to induce an immune response characterized by tolerance to the antigen/allergen, also known as desensitization.
  • [0055]
    “In vitro” refers to “in the laboratory” and/or “outside of a living organism”.
  • [0056]
    “In vivo” refers to “in a living organism”.
  • [0057]
    “Insecticidal polypeptide” refers to a polypeptide having insecticidal properties that adversely affects the growth and development of insect pests.
  • [0058]
    “Monocot” refers to plants having a single cotyledon (the first leaf of the embryo of seed plants); examples include cereals such as maize, rice, wheat, oats, and barley.
  • [0059]
    “Multiple cloning site” refers to an artificially constructed collection of restriction enzyme sites in a vector that facilitates insertion of foreign DNA into the vector.
  • [0060]
    “Mutation” refers to any change or alteration in a nucleic acid sequence. Several types exist, including point, frame shift, splicing, and insertion/deletions.
  • [0061]
    “Native” refers to “naturally occurring in the same organism”. For example, a native promoter is the promoter naturally found operatively linked to a given coding sequence in an organism. A native protein is one naturally found in nature and untouched or not otherwise manipulated by the hand of man.
  • [0062]
    “Nucleic acid segment” is a nucleic acid molecule that has been isolated free of total genomic DNA of a particular species, or that has been synthesized. Included with the term “nucleic acid segment” are DNA segments, recombinant vectors, plasmids, cosmids, phagemids, phage, viruses, etcetera.
  • [0063]
    “Nucleic acid” refers to deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
  • [0064]
    Nucleic acid codes: A=adenosine; C=cytosine; G=guanosine; T=thymidine; N=equimolar A, C, G, and T; I=deoxyinosine; K=equimolar G and T; R=equimolar A and G; S=equimolar C and G; W=equimolar A and T; Y=equimolar C and T.
  • [0065]
    “Open reading frame (ORF)” refers to a region of DNA or RNA encoding a peptide, polypeptide, or protein or capable of being translated to protein, or a regioiu of DNA capable of being transcribed into an RNA product.
  • [0066]
    “Plasmid” refers to a circular, extrachromosomal, self-replicating piece of DNA.
  • [0067]
    “Point mutation” refers to an alteration of a single nucleotide in a nucleic acid sequence.
  • [0068]
    “Polymerase chain reaction (PCR)” refers to an enzymatic technique to create multiple copies of one sequence of nucleic acid. Copies of DNA sequence are prepared by shuttling a DNA polymerase between two oligonucleotides. The basis of this amplification method is multiple cycles of temperature changes to denature, then re-anneal amplimers, followed by extension to synthesize new DNA strands in the region located between the flanking amplimers. Also known as thermal amplification.
  • [0069]
    “Probe” refers to a polynucleotide sequence which is complementary to a target polynucleotide sequence in the analyte. An antibody can also be used as a probe to detect the presence of an antigen. In that sense, the antigen binding domain of the antibody has some detectable affinity for the antigen and binds thereto. The binding of the antibody to the antigen can be measured by means known in the art, such as by chemiluminescence, phosphorescence, flourescence, colorimetric chemical deposition at the site of binding, or otherwise.
  • [0070]
    “Promoter” or “promoter region” refers to a DNA sequence, usually found upstream (5′) to a coding sequence, that controls expression of the coding sequence by controlling production of messenger RNA (mRNA) by providing the recognition site for RNA polymerase and/or other factors necessary for start of transcription at the correct site. As contemplated herein, a promoter or promoter region includes variations of promoters derived by means of ligation to various regulatory sequences, random or controlled mutagenesis, and addition or duplication of enhancer sequences. The promoter region disclosed herein, and biologically functional equivalents thereof, are responsible for driving the transcription of coding sequences under their control when introduced into a host as part of a suitable recombinant vector, as demonstrated by its ability to produce mRNA.
  • [0071]
    “Recombinant DNA construct” or “recombinant vector” refers to any agent such as a plasmid, cosmid, virus, autonomously replicating sequence, phage, or linear or circular single-stranded or double-stranded DNA or RNA nucleotide sequence, derived from any source, capable of genomic integration or autonomous replication, comprising a DNA molecule in which one or more DNA sequences have been linked in a functionally operative manner. Such recombinant DNA constructs or vectors are capable of introducing a 5′ regulatory sequence or promoter region and a DNA sequence for a selected gene product into a cell in such a manner that the DNA sequence is transcribed into a functional mRNA which is translated and therefore expressed. Recombinant DNA constructs or recombinant vectors can be constructed to be capable of expressing antisense RNAs, in order to inhibit translation of a specific RNA of interest.
  • [0072]
    “Recombinant proteins”, also referred to as “heterologous proteins”, are proteins which are normally not produced by the host cell.
  • [0073]
    “Regeneration” refers to the process of growing a plant from a plant cell (e.g., plant protoplast or explant).
  • [0074]
    “Regeneration” refers to the process of growing a plant from a plant cell (e.g., plant protoplast or explant).
  • [0075]
    “Regulatory sequence” refers to a nucleotide sequence located upstream (5′), within, and/or downstream (3′) to a DNA sequence encoding a selected gene product whose transcription and expression is controlled by the regulatory sequence in conjunction with the protein synthetic apparatus of the cell.
  • [0076]
    “Restriction enzyme” refers to an enzyme that recognizes a specific palindromic sequence of nucleotides in double stranded DNA and cleaves both strands; also called a restriction endonuclease. Cleavage typically occurs within the restriction site.
  • [0077]
    “Result-effective substitution” (RES) refers to an amino acid substitution within an IgE-binding region (epitope) of a target protein which reduces or eliminates the IgE binding by that epitope. Examples herein are directed to patatin protein and homologues, however, as will be readily recognized by those skilled in the art, the method is more broadly applicable to proteins other than patatins, and in particular is applicable to any protein exhibiting allergen eliciting properties.
  • [0078]
    “Selectable marker” refers to a nucleic acid sequence whose expression confers a phenotype facilitating identification of cells containing the nucleic acid sequence. Selectable markers include those which confer resistance to toxic chemicals (e.g. ampicillin resistance, kanamycin resistance), complement a nutritional deficiency (e.g. uracil, histidine, leucine), or impart a visually distinguishing characteristic (e.g. color changes or fluorescence).
  • [0079]
    “Transcription” refers to the process of producing an RNA copy from a DNA template.
  • [0080]
    “Transformation” refers to a process of introducing an exogenous nucleic acid sequence (e.g., a vector, recombinant nucleic acid molecule) into a cell or protoplast in which that exogenous nucleic acid is incorporated into a chromosome or is capable of autonomous replication.
  • [0081]
    “Transformed cell” is a cell whose DNA has been altered by the introduction of an exogenous nucleic acid molecule into that cell.
  • [0082]
    “Transgenic cell” refers to any cell derived from or regenerated from a transformed cell or derived from a transgenic cell. Exemplary transgenic cells include plant calli derived from a transformed plant cell and particular cells such as leaf, root, stem, e.g., somatic cells, or reproductive (germ) cells obtained from a transgenic plant.
  • [0083]
    “Transgenic plant” refers to a plant or progeny thereof derived from a transformed plant cell or protoplast, wherein the plant DNA contains an introduced exogenous nucleic acid sequence not originally present in a native, non-transgenic plant of the same species. Alternatively, the plant DNA can contain the introduced nucleic acid sequence in a higher copy number than in the native, non-transgenic plant of the same species.
  • [0084]
    “Translation” refers to the production of protein from messenger RNA.
  • [0085]
    “Vector” refers to a plasmid, cosmid, bacteriophage, or virus that carries foreign DNA into a host organism.
  • [0086]
    “Western blot” refers to protein or proteins that have been separated by electrophoresis, transferred and immobilized onto a solid support, then probed with an antibody.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0087]
    Design of Deallergenized Patatin Proteins
  • [0088]
    Deallergenizing a protein can be accomplished by the identification of allergenic sites, followed by modification of the sites to reduce or eliminate the binding of antibodies to the sites. The IgE-binding regions of patatin were previously unreported. Mapping of the IgE epitopes was accomplished by synthesizing 10-mer peptides based on the patatin 17 protein sequence (SEQ ID NO: 2) which overlap by six amino acids. As potato proteins are denatured upon cooking potato products, it is expected that the 10-mer peptides sufficiently mimic the unfolded full length protein for antibody binding purposes. Peptides were identified based upon their ability to bind to IgE antibodies. Individual amino acids within the identified peptides were changed to reduce or eliminate binding to IgE present in sera from potato sensitive patients. These changes are termed result-effective amino acid substitutions (RES). The RES can be subsequently introduced into the full length protein by site directed mutagenesis of the encoding nucleic acid sequence or other means known in the art. Similar strategies have been employed elsewhere to determine the dominant IgE epitopes in a major peanut allergen (Stanley, J. S., et al., Arch. Biochem. Biophys., 342(2): 244-253, 1997).
  • [0089]
    Certain amino acid residues important for allergenicity of patatin are identified. Some of the designed patatin peptides wherein single amino acid residues were replaced with alanine or phenylalanine, showed significantly reduced or no binding to sera from potato sensitive patients.
  • [0090]
    A “deallergenized patatin” refers to a patatin protein differing in at least one of the amino acid residues as defined by the result effective substitutions resulting in the patatin protein having reduced reactivity towards sera from potato sensitive patients. The deallergenized patatin preferably maintains insecticidal properties, and preferably maintains its characteristic enzymatic profile.
  • [0091]
    Summary of Method to Deallergenize a Patatin Protein
  • [0092]
    Mapping of IgE epitopes by immunoassay of synthetic overlapping peptides using sera from potato sensitive patients;
  • [0093]
    Identification of result-effective substitutions by alanine scanning and/or rational scanning;
  • [0094]
    Modification of the amino acid sequence of patatin by site-directed mutagenesis of the encoding nucleic acid sequence;
  • [0095]
    Evaluation of enzyme activity (esterase) and/or insecticidal activity of the modified protein(s); and
  • [0096]
    Evaluation of the new protein(s) for allergenicity by IgE immunoassay.
  • [0097]
    Nucleic acid sequences encoding patatin have been cloned by several investigators (e.g. Mignery, et al., Nucleic Acids Research, 12: 7987-8000, 1984; Mignery, et al., Gene, 62: 27-44, 1988; WO 94/21805; Canadian Patent Application No. 2090552). These nucleic acid sequences can then be manipulated using site directed mutagenesis to encode a hypoallergenic patatin. These nucleic acid sequences can than be used to transform bacterial, yeast or plant cells, resulting in the production of hypoallergenic patatin protein.
  • [0098]
    Deallergenized Patatin Proteins
  • [0099]
    For simplicity, individual amino acids are referred to by their single letter codes. Correlation between the single letter codes, three letter codes, and full amino acid names is presented in the definitions section above.
  • [0100]
    One embodiment of the invention is an isolated deallergenized patatin protein. The protein is modified relative to the wild-type protein sequence such that they exhibit reduced binding to anti-patatin antibodies such as those obtained from humans or animals allergic to potatoes. The reduced binding is measured relative to the binding of the unmodified patatin protein to the anti-patatin antibodies.
  • [0101]
    The deallergenized patatin protein can comprise SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7), 128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7), 184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7), 264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7),316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0102]
    Preferably, the deallergenized patatin protein comprises SEQ ID NO:2 modified by one or more changes, or SEQ ID NO:7 modified by one or more changes. SEQ ID NO:7 differs from wild type SEQ ID NO:2 in that the first 22 amino acids of SEQ ID NO:2 are replaced with EAE (Glu-Ala-Glu). For example, the changes to SEQ ID NO:2 or SEQ ID NO:7 can be: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the I corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A.
  • [0103]
    More preferably, SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0104]
    Most preferably, SEQ ID NO:2 is modified by the following changes or SEQ ID NO:7 is modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0105]
    Nucleic Acids
  • [0106]
    An additional embodiment of the invention is an isolated nucleic acid molecule segment comprising a structural nucleic acid sequence which encodes a deallergenized patatin protein.
  • [0107]
    The structural nucleic acid sequence can generally encode any deallergenized patatin protein. The structural nucleic acid sequence preferably encodes a deallergenized patatin protein comprising SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7), 128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7), 184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7), 264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7), 316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0108]
    Alternatively, the structural nucleic acid sequence encodes SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the I corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A.
  • [0109]
    More preferably, the structural nucleic acid sequence encodes SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0110]
    Most preferably, the structural nucleic acid sequence encodes SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0111]
    Recombinant Vectors
  • [0112]
    An additional embodiment is directed towards recombinant vectors comprising a structural nucleic acid sequence which encodes a deallergenized patatin protein. The recombinant vector comprises operatively linked in the 5′ to 3′ orientation: a promoter that directs transcription of a structural nucleic acid sequence; a structural nucleic acid sequence, and a 3′ transcription terminator.
  • [0113]
    The structural nucleic acid sequence can encode SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7), 128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7), 184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7), 264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7), 316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0114]
    Alternatively, the recombinant vector comprises operatively linked in the 5′ to 3′ orientation: a promoter that directs transcription of a structural nucleic acid sequence; a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the I corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A; and a 3′ transcription terminator.
  • [0115]
    More preferably, the vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0116]
    Most preferably, the vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0117]
    Recombinant Host Cells
  • [0118]
    A further embodiment of the invention is directed towards recombinant host cells comprising a structural nucleic acid sequence encoding a deallergenized patatin protein. The recombinant host cell preferably produces a deallergenized patatin protein. More preferably, the recombinant host cell produces a deallergenized patatin protein in a concentration sufficient to inhibit growth or to kill an insect which ingests the recombinant host cell. The recombinant host cell can generally comprise any structural nucleic acid sequence encoding a deallergenized patatin protein.
  • [0119]
    The recombinant host cell can comprise a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7),128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7),184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7),264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7), 316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0120]
    Alternatively, the recombinant host cell comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the I corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A.
  • [0121]
    More preferably, the recombinant host cell comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0122]
    Most preferably, the recombinant host cell comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0123]
    The recombinant host cell can generally be any type of host cell, and preferably is a bacterial, fungal, or plant cell. The bacterial cell is preferably an Escherichia coli bacterial cell. The fungal cell is preferably a Saccharomyces cerevisiae, Schizosaccharomyces pombe, or Pichia pastoris fungal cell. The plant cell can be a monocot, dicot, or conifer plant cell. The plant cell is preferably an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant cell. The recombinant host cell preferably further comprises operatively linked to the structural nucleic acid sequence a promoter that directs transcription of the structural nucleic acid sequence. The recombinant host cell preferably further comprises operatively linked to the structural nucleic acid sequence a 3′ transcription terminator and a polyadenylation site.
  • [0124]
    Recombinant Plants
  • [0125]
    An additional embodiment of the invention is a recombinant plant comprising a structural nucleic acid sequence encoding a deallergenized patatin protein. The recombinant plant preferably produces a deallergenized patatin protein. More preferably, the recombinant plant produces a deallergenized patatin protein in a concentration sufficient to inhibit growth or to kill an insect which ingests plant tissue from the recombinant plant.
  • [0126]
    The recombinant plant can comprise a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7), 128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7), 184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7), 264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7), 316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0127]
    Alternatively, the recombinant plant can comprise a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the I corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A.
  • [0128]
    More preferably, the recombinant plant comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0129]
    Most preferably, the recombinant plant comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0130]
    The recombinant plant can generally be any type of plant. The plant can be a monocot, dicot, or conifer plant. The plant is preferably an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
  • [0131]
    The recombinant plant preferably further comprises operatively linked to the structural nucleic acid sequence a promoter that directs transcription of the structural nucleic acid sequence. The recombinant plant preferably further comprises operatively linked to the structural nucleic acid sequence a 3′ transcription terminator and a polyadenylation site.
  • [0132]
    Methods of Preparation
  • [0133]
    Embodiments of the invention are further directed towards methods of preparing recombinant host cells and recombinant plants useful for the production of deallergenized patatin proteins.
  • [0134]
    A method of preparing a recombinant host cell useful for the production of deallergenized patatin proteins can comprise selecting a host cell; transforming the host cell with a recombinant vector; and obtaining recombinant host cells.
  • [0135]
    The recombinant vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7), 128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7), 184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7), 264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7), 316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0136]
    Alternatively, the recombinant vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A.
  • [0137]
    More preferably, the vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0138]
    Most preferably, the vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0139]
    The method can generally be used to prepare any type of recombinant host cell. Preferably, the method can be used to prepare a recombinant bacterial cell, a recombinant fungal cell, or a recombinant plant cell. The bacterial cell is preferably an Escherichia coli bacterial cell. The fungal cell is preferably a Saccharomyces cerevisiae, Schizosaccharomyces pombe, or Pichia pastoris fungal cell. The plant cell can be a monocot, dicot, or conifer plant cell. The plant cell is preferably an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant cell.
  • [0140]
    An additional embodiment is directed towards methods for the preparation of recombinant plants useful for the production of deallergenized patatin proteins. The method can comprise selecting a host plant cell; transforming the host plant cell with a recombinant vector; obtaining recombinant host cells; and regenerating a recombinant plant from the recombinant host plant cells.
  • [0141]
    The recombinant vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified in one or more of the following regions, or SEQ ID NO:7 modified in one or more of the following regions. The single or multiple amino acid modifications reduce the binding of the modified protein relative to the binding of the corresponding unmodified protein. The regions for modification include amino acid positions 104-113 of SEQ ID NO:2 (85-94 of SEQ ID NO:7), 128-137 of SEQ ID NO:2 (109-118 of SEQ ID NO:7),184-197 of SEQ ID NO:2 (165-178 of SEQ ID NO:7),264-277 of SEQ ID NO:2 (245-258 of SEQ ID NO:7), 316-325 of SEQ ID NO:2 (297-306 of SEQ ID NO:7), and 360-377 of SEQ ID NO:2 (341-358 of SEQ ID NO:7). The possible amino acid modifications include replacing an amino acid with A, E, F, P, or S. The modifications replace one or more amino acids in the identified regions, without increasing or decreasing the total number of amino acids in the protein.
  • [0142]
    Alternatively, the recombinant vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by one or more of the following changes or encoding SEQ ID NO:7 modified by one or more of the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F or A; the corresponding to position 113 of SEQ ID NO:2 or position 94 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 137 of SEQ ID NO:2 or position 118 of SEQ ID NO:7 is replaced with A; the S corresponding to position 184 of SEQ ID NO:2 or position 165 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F or A; the A corresponding to position 188 of SEQ ID NO:2 or position 169 of SEQ ID NO:7 is replaced with S; the T corresponding to position 192 of SEQ ID NO:2 or position 173 of SEQ ID NO:7 is replaced with A or P; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 268 of SEQ ID NO:2 or position 249 of SEQ ID NO:7 is replaced with A or E; the T corresponding to position 269 of SEQ ID NO:2 or position 250 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F or A; the K corresponding to position 273 of SEQ ID NO:2 or position 254 of SEQ ID NO:7 is replaced with A; the K corresponding to position 313 of SEQ ID NO:2 or position 294 of SEQ ID NO:7 is replaced with E; the N corresponding to position 314 of SEQ ID NO:2 or position 295 of SEQ ID NO:7 is replaced with A; the N corresponding to position 315 of SEQ ID NO:2 or position 296 of SEQ ID NO:7 is replaced with A; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F or A; the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F; the K corresponding to position 367 of SEQ ID NO:2 or position 348 of SEQ ID NO:7 is replaced with A; the R corresponding to position 368 of SEQ ID NO:2 or position 349 of SEQ ID NO:7 is replaced with A; the F corresponding to position 369 of SEQ ID NO:2 or position 350 of SEQ ID NO:7 is replaced with A; the K corresponding to position 371 of SEQ ID NO:2 or position 352 of SEQ ID NO:7 is replaced with A; the L corresponding to position 372 of SEQ ID NO:2 or position 353 of SEQ ID NO:7 is replaced with A; and the L corresponding to position 373 of SEQ ID NO:2 or position 354 of SEQ ID NO:7 is replaced with A.
  • [0143]
    More preferably, the vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 106 of SEQ ID NO:2 or position 87 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 129 of SEQ ID NO:2 or position 110 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0144]
    Most preferably, the vector comprises a structural nucleic acid sequence encoding SEQ ID NO:2 modified by the following changes or SEQ ID NO:7 modified by the following changes: the Y corresponding to position 185 of SEQ ID NO:2 or position 166 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 193 of SEQ ID NO:2 or position 174 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 270 of SEQ ID NO:2 or position 251 of SEQ ID NO:7 is replaced with F; the Y corresponding to position 316 of SEQ ID NO:2 or position 297 of SEQ ID NO:7 is replaced with F; and the Y corresponding to position 362 of SEQ ID NO:2 or position 343 of SEQ ID NO:7 is replaced with F.
  • [0145]
    The recombinant plant can generally be any type of plant. The plant can be a monocot, dicot, or conifer plant. The plant is preferably an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
  • [0146]
    Deallergenized patatin proteins can be prepared by isolating the deallergenized patatin protein from any one of the above described host cells or plants.
  • [0147]
    Deglycosylation
  • [0148]
    The examples herein provide evidence that glycosylation of can contribute to the allergenicity of a protein. Accordingly, rational substitution of amino acid residues likely to be the targets of glycosylation within a subject allergen protein may reduce or eliminate the allergenic properties of the protein without adversely affecting the enzymatic, insecticidal, antifungal or other functional properties of the protein.
  • [0149]
    Glycosylation commonly occurs as either N-linked or O-linked forms. N-linked glycosylation usually occurs at the motif Asn-Xaa-Ser/Thr, where Xaa is any amino acid except Pro (Kasturi, L. et al., Biochem J. 323: 415-519, 1997; Melquist, J. L. et al., Biochemistry 37: 6833-6837, 1998). O-linked glycosylation occurs between the hydroxyl group of serine or threonine and an amino sugar.
  • [0150]
    Site directed mutagenesis of selected asparagine, serine, or threonine may be used to reduce or eliminate the glycosylation of patatin proteins. A search of SEQ ID NO:2 for the Asn-Xaa-Ser/Thr motif reveals one occurrence at amino acid positions 202-204. Mutagenization of the nucleic acid sequence encoding this region may result in a reduced allergenicity of the encoded protein.
  • [0151]
    In order to test this conceptual approach to reducing allergenicity of patatin proteins, two sets of experiments were performed: a) production of patatin proteins in Escherichia coli, which do not glycosylate proteins; and b) production of patatin proteins with an N202Q site directed mutation.
  • [0152]
    Antibodies obtained from patients HS-07 and G15-MON (not potato allergic) did not show specific binding to wild type patatin, patatin produced in E. coli, or the N202Q variant. Antibodies obtained from patient HS-01 (potato allergic) bound to wild type patatin, but not to patatin produced in E. coli or the N202Q variant. Antibodies obtained from patient HS-02 (potato allergic) bound strongly to wild type patatin, but extremely weakly to patatin produced in E. coli, and binding to the N202Q variant resembled vector controls. Antibodies obtained from patient HS-03 (potato allergic) bound to wild type patatin, but not to patatin produced in E. coli or the N202Q variant. Antibodies obtained from patient HS-05 (potato allergic) bound to wild type patatin, but very weakly to patatin produced in E. coli and the N202Q variant. Antibodies obtained from patient HS-06 (potato allergic) strongly bound wild type patatin, the N202Q variant, and to patatin produced in E. coli. These results strongly suggest that glycosylation is at least partially responsible for the antigenic properties of patatin proteins, and that site directed mutagenesis may be used to reduce or eliminate specific antibody binding. Mutagenesis at position 202 of SEQ ID NO:2 may be useful for reducing or eliminating specific antibody binding.
  • [0153]
    Permuteins
  • [0154]
    The positions of the internal breakpoints described in the following Examples are found on the protein surface, and are distributed throughout the linear sequence without any obvious bias towards the ends or the middle. Breakpoints occurring below the protein surface can additionally be selected. The rearranged two subunits can be joined by a peptide linker. A preferred embodiment involves the linking of the N-terminal and C-terminal subunits by a three amino acid linker, although linkers of various sizes can be used. Additionally, the N-terminal and C-terminal subunits can be joined lacking a linker sequence. Furthermore, a portion of the C-terminal subunit can be deleted and the connection made from the truncated C-terminal subunit to the original N-terminal subunit and vice versa as previously described (Yang and Schachman, Proc. Natl. Acad. Sci. U.S.A., 90: 11980-11984, 1993; Viguera, et al., Mol. Biol., 247: 670-681, 1995; Protasova, et al., Prot. Eng., 7: 1373-1377, 1994).
  • [0155]
    The novel insecticidal proteins of the present invention can be represented by the formula:
  • X1-(L)a-X2
  • [0156]
    wherein;
  • [0157]
    a is 0 or 1, and if a is 0, then the permutein does not contain a linker sequence;
  • [0158]
    X1 is a polypeptide sequence corresponding to amino acids n+1 through J;
  • [0159]
    X2 is a polypeptide corresponding to amino acids 1 through n;
  • [0160]
    n is an integer ranging from 1 to J−1;
  • [0161]
    J is an integer greater than n+1; and
  • [0162]
    L is a linker.
  • [0163]
    In the formula above, the constituent amino acid residues of the novel insecticidal protein are numbered sequentially 1 through J from the original amino terminus to the original carboxyl terminus. A pair of adjacent amino acids within this protein can be numbered n and n+1 respectively where n is an integer ranging from 1 to J−1. The residue n+1 becomes the new N-terminus of the novel insecticidal protein and the residue n becomes the new C-terminus of the novel insecticidal protein.
  • [0164]
    For example, a parent protein sequence consisting of 120 amino acids can be selected as a starting point for designing a permutein (J=120). If the breakpoint is selected as being between position 40 and position 41, then n—40. If a linker is selected to join the two subunits, the resulting permutein will have the formula: (amino acids 41-120)-L-(amino acids 1-40). If a linker was not used, the resulting permutein will have the formula: (amino acids 41-120)-(amino acids 1-40).
  • [0165]
    The length of the amino acid sequence of the linker can be selected empirically, by using structural information, or by using a combination of the two approaches. When no structural information is available, a small series of linkers can be made whose length can span a range of 0 to 50 A and whose sequence is chosen in order to be substantially consistent with surface exposure (Hopp and Woods, Mol. Immunol., 20: 483-489, 1983; Kyte and Doolittle, J. Mol. Biol., 157: 105-132, 1982; Lee and Richards, J. Mol. Biol., 55: 379-400, 1971) and the ability to adopt a conformation which does not significantly affect the overall configuration of the protein (Karplus and Schulz, Naturwissenschaften, 72: 212-213, 1985). Assuming an average length of 2.0 to 3.8 A per residue, this would mean the length to test would be between about 0 to about 30 residues, with 0 to about 15 residues being the preferred range. Accordingly, there are many such sequences that vary in length or composition that can serve as linkers with the primary consideration being that they be neither excessively long nor excessively short (Sandhu, et al., Critical Rev. Biotech., 12: 437-467, 1992). If the linker is too long, entropy effects may destabilize the three-dimensional fold and may affect protein folding. If the linker is too short, it may destabilize the molecule due to torsional or steric strain.
  • [0166]
    Use of the distance between the chain ends, defined as the distance between the C-alpha carbons, can be used to define the length of the sequence to be used, or at least to limit the number of possibilities that can be tested in an empirical selection of linkers. Using the calculated length as a guide, linkers with a range of number of residues (calculated using 2 to 3.8 Å per residue) can be selected. These linkers can be composed of the original sequence, shortened or lengthened as necessary, and when lengthened the additional residues can be chosen to be flexible and hydrophilic as described above; or optionally the original sequence can be substituted for using a series of linkers, one example being Gly-Pro-Gly (SEQ ID NO:277); or optionally a combination of the original sequence and new sequence having the appropriate total length can be used. An alternative short, flexible linker sequence is Gly-Gly-Gly-Ser-Gly-Gly-Gly (SEQ ID NO:276).
  • [0167]
    Selection of Permutein Breakpoints
  • [0168]
    Sequences of novel patatin analogs capable of folding to biologically active molecules can be prepared by appropriate selection of the beginning (amino terminus) and ending (carboxyl terminus) positions from within the original polypeptide chain while optionally using a linker sequence as described above. Amino and carboxyl termini can be selected from within a common stretch of sequence, referred to as a breakpoint region, using the guidelines described below. A novel amino acid sequence is thus generated by selecting amino and carboxyl termini from within the same breakpoint region. In many cases, the selection of the new termini will be such that the original position of the carboxyl terminus immediately preceded that of the amino terminus. However, selections of termini anywhere within the region may result in a functional protein, and that these will effectively lead to either deletions or additions to the amino or carboxyl portions of the new sequence.
  • [0169]
    The primary amino acid sequence of a protein dictates folding to the three-dimensional structure beneficial for expression of its biological function. It is possible to obtain and interpret three-dimensional structural information using x-ray diffraction of single protein crystals or nuclear magnetic resonance spectroscopy of protein solutions. Examples of structural information that are relevant to the identification of breakpoint regions include the location and type of protein secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets, chain reversals and turns, and loops (Kabsch and Sander, Biopolymers, 22: 2577-2637, 1983), the degree of solvent exposure of amino acid residues, the extent and type of interactions of residues with one another (Chothia, C., Ann. Rev. Biochem., 53: 537-572, 1984), and the static and dynamic distribution of conformations along the polypeptide chain (Alber and Mathews, Methods Enzymol., 154: 511-533, 1987). In some cases additional information is known about solvent exposure of residues, one example is a site of post-translational attachment of carbohydrate which is necessarily on the surface of the protein. When experimental structural information is not available, or when it is not feasible to obtain the information, methods are available to analyze the primary amino acid sequence in order to make predictions of protein secondary and tertiary structure, solvent accessibility and the occurrence of turns and loops (Fasman, G., Ed. Plenum, New York, 1989; Robson, B. and Garnier, J. Nature 361: 506, 1993).
  • [0170]
    Biochemical methods can be applicable for empirically determining surface exposure when direct structural methods are not feasible; for example, using the identification of sites of chain scission following limited proteolysis in order to infer surface exposure (Gentile, F. and Salvatore, G., Eur. J. Biochem., 218: 603-621, 1993). Thus, using either the experimentally derived structural information or predictive methods (Srinivasan, R. and Rose, G. D. Proteins, 22: 81-99, 1995), the parental amino acid sequence can be analyzed to classify regions according to whether or not they are integral to the maintenance of secondary and tertiary structure. The sequences within regions that are known to be involved in periodic secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets) are regions that should be avoided. Similarly, regions of amino acid sequence that are observed or predicted to have a low degree of solvent exposure are more likely to be part of the so-called hydrophobic core of the protein and should also be avoided for selection of amino and carboxyl termini. Regions that are known or predicted to be in surface turns or loops, and especially those regions that are known not to be required for biological activity, can be preferred sites for new amino and carboxyl termini. Stretches of amino acid sequence that are preferred based on the above criteria can be selected as breakpoint regions.
  • [0171]
    An embodiment of the invention is directed towards patatin permutein proteins. The permutein proteins preferably maintain esterase activity and insecticidal properties. The permutein proteins preferably are less allergenic than the wild type patatin protein to individuals or animals allergic to potatoes. This can be assayed by the binding of antibodies to the wild type patatin and patatin permutein proteins.
  • [0172]
    The permutein proteins can optionally contain a linker sequence. The linker can generally be any amino acid sequence, preferably is Gly-Gly-Gly-Ser-Gly-Gly-Gly (SEQ ID NO:276) or Gly-Pro-Gly (SEQ ID NO:277), and more preferably is Gly-Pro-Gly (SEQ ID NO:277). Specific permutein proteins comprise: (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2), (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2), SEQ ID NO:247, and SEQ ID NO:259.
  • [0173]
    Embodiments of the invention also include isolated nucleic acid molecule segments comprising a structural nucleic acid sequence encoding a patatin permutein protein. The encoded permutein protein can generally be any permutein protein, and preferably comprises (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2), (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2), SEQ ID NO:247, or SEQ ID NO:259. The linker can generally be any amino acid sequence, preferably is Gly-Gly-Gly-Ser-Gly-Gly-Gly (SEQ ID NO:276) or Gly-Pro-Gly (SEQ ID NO:277), and more preferably is Gly-Pro-Gly (SEQ ID NO:277). Alternatively, the encoded patatin permutein protein can lack a linker sequence. The structural nucleic acid sequence is preferably SEQ ID NO:246 or SEQ ID NO:258.
  • [0174]
    An embodiment of the invention is directed towards recombinant vectors which encode a patatin permutein protein. The vector can comprise operatively linked in the 5′ to 3′ orientation: a promoter that directs transcription of a structural nucleic acid sequence; a structural nucleic acid sequence encoding a protein selected from the group consisting of: (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2); and a 3′ transcription terminator. The linker can comprise Gly-Pro-Gly (SEQ ID NO:277) or Gly-Gly-Gly-Ser-Gly-Gly-Gly (SEQ ID NO:276). Alternatively, the encoded patatin permutein protein can lack a linker sequence. The structural nucleic acid sequence can preferably be SEQ ID NO:246 or SEQ ID NO:258, and preferably encodes SEQ ID NO:247 or SEQ ID NO:259.
  • [0175]
    An additional embodiment of the invention is directed towards recombinant host cells useful for the production of a patatin permutein protein. The recombinant host cell preferably produces a patatin permutein protein. More preferably, the recombinant host cell produces a patatin permutein protein in a concentration sufficient to inhibit growth or to kill an insect which ingests the recombinant host cell. The recombinant host cell can comprise a structural nucleic acid sequence encoding a protein selected from the group consisting of: (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2). The linker can generally be any amino acid sequence, and preferably is Gly-Pro-Gly (SEQ ID NO:277) or Gly-Gly-Gly-Ser-Gly-Gly-Gly (SEQ ID NO:276). Alternatively, the encoded patatin permutein protein can lack a linker sequence. The structural nucleic acid sequence is preferably SEQ ID NO:246 or SEQ ID NO:258, and preferably encodes SEQ ID NO:247 or SEQ ID NO:259. The structural nucleic acid sequence can be operatively linked to a promoter sequence that directs transcription of the structural nucleic acid sequence, a 3′ transcription terminator, and a 3′ polyadenylation signal sequence. The recombinant host cell can generally be any type of host cell, and preferably is a bacterial, fungal, or plant host cell. The bacterial cell is preferably an Escherichia coli bacterial cell. The fungal cell is preferably a Saccharomyces cerevisiae, Schizosaccharomyces pombe, or Pichia pastoris fungal cell. The plant cell can be a monocot, dicot, or conifer plant cell. The plant cell is preferably an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant cell.
  • [0176]
    An additional embodiment of the invention is directed towards recombinant plants which are useful for the production of patatin permutein proteins. The recombinant plant preferably produces a patatin permutein protein. More preferably, the recombinant plant produces a patatin permutein protein in a concentration sufficient to inhibit growth or to kill an insect which ingests tissue from the recombinant plant. The recombinant plant can comprise a structural nucleic acid sequence encoding a protein selected from the group consisting of: (amino acids 247-386 of SEQ ID NO:2)-linker-(amino acids 24-246 of SEQ ID NO:2); and (amino acids 269-386 of SEQ ID NO:2)-linker-(amino acids 24-268 of SEQ ID NO:2). The linker can comprise Gly-Pro-Gly (SEQ ID NO:277) or Gly-Gly-Gly-Ser-Gly-Gly-Gly (SEQ ID NO:276). Alternatively, the encoded protein can lack a linker sequence. The structural nucleic acid sequence is preferably SEQ ID NO:246 or SEQ ID NO:258, and preferably encodes SEQ ID NO:247 or SEQ ID NO:259. The structural nucleic acid sequence can be operatively linked to a promoter sequence that directs transcription of the structural nucleic acid sequence, a 3′ transcription terminator, and a 3′ polyadenylation signal sequence. The recombinant plant can generally be any type of plant, and preferably is an alfalfa, banana, canola, corn, cotton, cucumber, peanut, potato, rice, soybean, sunflower, sweet potato, tobacco, tomato, or wheat plant.
  • [0177]
    Permutein proteins can be prepared by isolating the permutein protein from any one of the above described host cells or plants.
  • [0178]
    Immunotherapy for Potato Allergy
  • [0179]
    Immunotherapy for food allergy has been largely unsuccessful due to the lack of appropriate therapeutic reagents (Sampson, H. A., J. Allergy Clin. Immunol., 90(2): 151-152, 1992). Immunotherapy has typically involved the administration (orally or by subcutaneous injections) of increasing doses of crude protein extracts of the offending allergenic entities which usually contain variable mixes of many different proteins (Scheiner, O., Wien Klin Wochenschr., 105(22): 653-658, 1993). While there are reports of highly successful clinical applications of immunotherapy for food allergens (Romano, P. C., et al., Allergol. Immunopathol. (Madr), 12(4): 275-281, 1984), those reports are rare and the clinical literature in general recommends avoidance far more strongly than therapy (Gay, G., Allerg. Immunol. (Paris), 29(6): 169-170, 1997). One of the primary reasons for the failure of many clinical attempts to induce tolerance to allergens in general and food allergens in particular relates to anecdotal comments by numerous allergists, that patients don't tolerate the doses of allergen required to achieve tolerance. Animal studies examining the relationship of antigen dose and the induction of tolerance have demonstrated a strong positive correlation (Chen, Y., et al., Proc. Natl. Acad. Sci., U.S.A., 93: 388-391, 1996; Tokai, T., et al., Nat. Biotechnol., 15(8): 754-758, 1997). Due to the very real possibility of inducing an anaphylactic reaction in patients with native allergen, most clinical therapists are quite hesitant to use high doses therapeutically and are therefore compromising the likelihood of successful therapy.
  • [0180]
    In recent reports, recombinant technology has been used to reduce the allergenic potential of a major allergen without modifying the T cell epitopes, and allowing higher doses of protein to be used in therapy (Tokai, T., et al., Nat. Biotechnol., 15(8): 754-758, 1997). In addition, a lack of understanding about the appropriate route of administration, the uncertainty of mechanisms responsible for induction of allergy and the uncertainty of mechanisms by which immunotherapy suppresses or blocks the T cell-IgE-eosinophil/mast cell cycle have contributed to the large number of equivocal studies and clinical trials. Recent studies in animal models dealing with mechanisms, routes of administration, adjuvants and vaccine formulations have increased the likelihood that immunotherapy for allergies, including food allergies, will become a reproducibly successful clinical treatment when the appropriate therapeutic reagents are available (Sampson, H. A. and Burks, A. W., Annu. Rev. Nutr., 16: 161-177, 1996; Kaminogawa, S., Biosci. Biotechnol. Biochem., 60(11): 1749-1756, 1996; Chapman, M. D., et al., Allergy, 52: 374-379, 1997; Barbeau, W. E., Adv. Exp. Med. Biol., 415: 183-193, 1997; Cao, Y, et al., Immunology, 90(1): 46-51, 1997; Garside, P. and Mowat, A. M., Crit. Rev. Immunol., 17(2): 119-137, 1997; Rothe, M. J. and Grant-Kels, J. M., J. Am. Acad. Dermatol., 35(1): 1-13, 1996; Strobel, S., Allergy, 50(20): 18-25, 1995; Kruisbeek, A. M. and Amsen, D., Curr. Opin. Immunol., 8(2): 233-244, 1996; Herz, U., et al., Adv. Exp. Med. Biol., 409: 25-32, 1996; Litwin, A., et al., J. Allergy Clin. Immunol., 100: 30-38, 1997; Vandewalker, M. L., Mo. Med., 94(7): 311, 1997; Marshall, G. D., Jr. and Davis, F., Nat. Biotechnol., 15(8): 718-719, 1997; Van Deusen, M. A., et al., Ann. Allergy Asthma Immunol., 78: 573-580, 1997; Jacobsen, L., et al., Allergy, 52: 914-920, 1997, Scheiner, O. and Kraft, D., Allergy 50(5): 384-391, 1995).
  • [0181]
    Relative to immunotherapy, the critical aspects of the modified patatin genes described in this patent are that they can be used to synthesize purified, deallergenized-protein which can be used for patatin (potato) specific immunotherapy, with reduced potential for adverse and potentially fatal anaphylactic reactions in human or veterinary patients who have allergies to patatin or potatoes. Various strategies, including fixing or cross linking allergens, encapsulation of allergen for oral delivery, the use of small, T-cell epitope peptides and most recently, the use of engineered recombinant proteins, or modified gene vaccines are being tested in attempts to decrease the potential for anaphylactic reactions while inducing tolerance (Cao, Y., et al., Immunology, 90(1): 46-51, 1997; Chapman, M. D., et al., Allergy, 52: 374-379, 1997; Chapman, M. D., et al., Int. Arch. Allergy Immunol., 113(1-3): 102-104, 1997; Collins, S. P., et al, Clin. Exp. Allergy, 26(1): 36-42, 1996; Takai, T., et al., Mol. Immunol., 34(3): 255-261, 1997; Takai, T., et al., Nat. Biotechnol., 15(8) 754-758, 1997; Jirapongsananruk, O. and Leung, D. Y. M., Ann. Allergy Asthma Immunol., 79: 5-20, 1997; Litwin, A., et al., J. Allergy Clin. Immunol., 100: 30-38, 1997; Vandewalker, M. L., Mo. Med., 94(7): 311, 1997; Raz, E., et al., Proc. Natl. Acad. Sci., U.S.A., 93: 5141-5145, 1996; Hoyne, G. F., et al., Clin. Immunol. Immunopathol., 80: S23-30, 1996; Hoyne, G. F., et al., Int. Immunol., 9(8): 1165-1173, 1997; Vrtala, S., et al., J. Clin. Invest., 99(7): 1673-1681, 1997; Sato, Y., et al., Science, 273: 352-354, 1996; Lee, D. J., et al., Int. Arch. Allergy Immunol., 113(1-3): 227-230, 1997; Tsitoura, D. C., et al., J. Immunol., 157(5): 2160-2165, 1996; Hsu, C. H., et al., Int. Immunol., 8(9):1405-1411, 1996; Hsu, C. H., et al., Nat. Med., 2(5): 540-544, 1996).
  • [0182]
    The instant invention uses an engineered patatin protein, as expressed in any living cell, with or without post-synthesis modifications, for immunotherapy by the routes of cutaneous or subcutaneous exposure, injection, or by oral, gastro-intestinal, respiratory or nasal application, either with, or without the use of specific carriers, vehicles and adjuvants. The direct application of nucleic acid encoding recombinant patatin as the in vivo (in the patient) expression template (gene) as RNA-, DNA- or gene-vaccines is also the intended use of the engineered genetic materials defined here, coding for patatin, but with modified IgE binding sites. It is also the intent of this patent to cover the use of these modified genes described here including insertion into various DNA vectors including adenovirus, retrovirus, pox virus and replicating or non-replicating eukaryotic expression plasmids (Lee, D. J., et al., Int. Arch. Allergy Immunol., 113(1-3): 227-230, 1997) with various promoters and regulatory sequences, which can be inserted into the patient's somatic cells (dendritic cells, epithelial cells, muscle fiber-cells, fibroblasts, etc.) for the purpose of expressing the recombinant gene product to alter the patient's immune response to the patatin proteins (Lee D. J., et al., Int. Arch. Allergy Immunol., 113(1-3): 227-230, 1997). Potential routes of administration foreseen in this application include previously described methods of encapsulation, emulsion, receptor or membrane fusion mediated uptake and methods of direct permeabilization or insertion of the DNA or corresponding RNA into the host cells.
  • [0183]
    The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
  • EXAMPLES Example 1 Identification of Patatin as an Allergen
  • [0184]
    Since patatin is commonly obtained from an allergenic source (potato), it was hypothesized that patatins in fact encode an important class of offending potato allergens (patatin was reported as allergenic by Seppala, U. et al., J. Allergy Clin. Immunol. 103: 165-171, 1999). Assessment of potential allergens preferably include appropriate in vitro testing for IgE binding, in this case with potato allergic sera (Fuchs, R. L. and Astwood, J. D., Food Technology, 50: 83-88, 1996; Astwood, J. D., et al., Monographs in allergy Vol. 32: Highlights in food allergy, pp. 105-120, 1996, Metcalfe, D. D., et al., Critical Reviews in Food Science and Nutrition, 36S: 165-186, 1996). It is the recommendation of a working group organized by the IFBC and the ILSI Allergy and Immunology Institute that proteins encoded by nucleic acid sequences from allergenic sources such as potato (a “less-commonly” allergenic source) should be examined for their ability to react with IgEs of potato-allergic patients using a minimum of five individual patient sera (Metcalfe, D. D., et al., Critical Reviews in Food Science and Nutrition, 36S: 165-186, 1996). Patatin-17 protein was tested for IgE binding using standard in vitro testing with serum taken from patients with bona fide well defined clinically displayed potato allergy as described below.
  • [0185]
    Clinical Characterization of Potato Allergic Subjects (Serum Donors)
  • [0186]
    Patients who suffer from potato allergy were identified at Johns Hopkins Clinic (Baltimore, Md.) and were evaluated for potato allergy using clinical criteria outlined in Table 2.
  • [0187]
    Serum was obtained from patients with convincing clinical history of potato allergy. The convincing history was defined as being one or more of the following: a) positive potato allergic as evaluated by double-blind placebo-control food challenge b) anaphylaix and/or hospitalization due to the consumption of potatoes or c) dramatic skin test results.
    TABLE 2
    Clinical patient data
    Flare/Wheal (Skin prick
    Patient Clinical History test) DBPCFC (potato)
    HS01 Most recent hospitalization: Oct. 19, 1993 7/19, 4/14, 7/17 Not performed
    AD, A, AR, FH, MFS, IgE = 1397 KIAUa/L
    HS02 Most recent hospitalization: June 1994 20/26 Not performed
    AD, FH, Latex (+) RAST, MFS, IgE = 7544K/L
    HS03 Most recent hospitalization: Jul. 27, 1995 5/13 Yes
    AD, A, FH, MFS, IgE = N/A
    HS05 Most recent hospitalization May 30, 1995 4/9 Yes
    AD, A, FH, MFS IgE = 12341 ng/ml
    HS06 Most recent hospitalization Jun. 13, 1995 5/20, 4/13, 5/12 Yes
    AD, A FH, MFS IgE = N/A
    HS07 Not potato allergic, allergic to egg, milk, High IgE control serum, not allergic to potato.
    peanuts, seafood. AD, A, AR, FH, MFS
    HS08 Non-atopic (normal) Low IgE control serum
  • Example 2 Western Blotting of Patatin Proteins
  • [0188]
    Western blotting experiments were performed using patatin protein purified to near homogeneity from corn plants genetically engineered to produce patatin, patatin producing crude genetically engineered corn leaf extracts, crude potato tuber extracts, and non-transgenic corn leaf samples.
  • [0189]
    Protein samples were electrophoresed by SDS-PAGE (Laemmli, U. K., Nature 227: 680-685, 1970) and were electroblotted onto nitrocellulose. Protein blots were processed by standard Western blotting (immunoblotting) techniques and were incubated in potato allergic serum diluted 1:5 in PBS buffer for 1 hour. After washing the blots 3 times with PBS, the blots were incubated in biotinylated anti-IgE (Johns Hopkins Hospital, Baltimore, Md.) for 1 hour, followed by a 30 minute incubation in HRP-linked avidin (Promega, New York, N.Y.). IgE-reactive protein bands were visualized by DAB staining (3,3 diaminobenzidine). The blots were dried and photographed. Individual blots are labeled according to patient serum used. As a control, one blot was incubated in anti-IgE only.
  • [0190]
    Patatins were shown to be an allergen of potato by examining the reactivity of purified patatin to sera obtained from patients allergic to potato. Sera from five potato allergic subjects were tested by Western blotting techniques. All five sera reacted with purified patatin protein.
  • [0191]
    Patatin isozymes (SEQ ID NOS:278-282, FIG. 1) were tested for IgE binding by Western blotting. Isozymes of patatin were cloned into a yeast expression system and purified prior to analysis. The isozymes were subjected to IgE western blotting as described above with the exception that all five patient sera were pooled. The resulting Western blot of the yeast-expressed isozymes showed that all five isozymes bound IgE in a manner similar to patatin 17, and that all isozymes of patatin tested are also allergens.
  • Example 3 Western Blotting of Patatin Proteins
  • [0192]
    Eighty-nine 10-mer peptides were synthesized using the Genosys SPOTs system, each consecutive 10-mer overlapping by 6 amino acids based on the amino acid sequence of patatin 17 (SEQ ID NO:2). The peptides were evaluated for IgE binding with five different potato allergic patient sera using the same incubation procedures as described above. The results are summarized graphically in FIG. 2, showing major and minor allergenic epitopes. Interestingly, many of the immunogenic epitopes contain tyrosine. The peptide numbers, sequences, and immunoreactivity is detailed in Table 3.
    TABLE 3
    Peptide scan of patatin 17
    Peptide #
    (SEQ ID NO Peptide Sequence HS01 HS02 HS03 HS05 HS06 Cumulative Total
     1 (16) QLGEMVTVLS 0.47 0.33 0.02 0.05 0.06 0.93
     2 (17) MVTVLSIDGG 0.53 0.33 0.02 0.07 0.05 1
     3 (18) LSIDGGGIRG 0.52 0.38 0.07 0.08 0.09 1.14
     4 (19) GGGIRGIIPA 0.53 0.19 0.06 0.19 0.23 1.2
     5 (20) RGIIPATILE 0.46 0.28 0.04 0.09 0.05 0.92
     6 (21) PATILEFLEG 0.49 0.31 0.05 0.09 0.07 1.01
     7 (22) LEFLEGQLQE 0.36 0.24 0.04 0.1 0.06 0.8
     8 (23) EGQLQEMDNN 0.29 0.19 0.02 0.09 0.05 0.64
     9 (24) QEMDNNADAR 0.22 0.13 0.01 0.05 0.04 0.45
    10 (25) NNADARLADY 0.21 0.17 0.03 0.05 0.07 0.53
    11 (26) ARLADYFDVI 0.54 0.31 0.16 0.15 0.25 1.41
    12 (27) DYFDVIGGTS 0.61 0.34 0.46 0.06 0.15 1.62
    13 (28) VIGGTSTGGL 0.63 0.72 0.05 0.15 0.09 1.64
    14 (29) TSTGGLLTAM 0.3 0.17 0.03 0.06 0.09 0.65
    15 (30) GLLTAMISTP 0.63 0.41 0.05 0.24 0.12 1.45
    16 (31) AMISTPNENN 0.34 0.18 0.02 0.07 0.02 0.63
    17 (32) TPNENNRPFA 0.46 0.22 0.03 0.19 0.07 0.97
    18 (33) NNRPFAAAKE 0.37 0.21 0.05 0.07 0.06 0.76
    19 (34) FAAAKEIVPF 0.52 0.29 0.08 0.11 0.08 1.08
    20 (35) KEIVPFYFEH 0.29 0.14 0.28 0.29 0.23 1.23
    21 (36) PFYFEHGPQI 0.65 0.06 1.08 0.51 0.17 2.47
    22 (37) EHGPQIFNPS 0.34 0.15 0.03 0.05 0.06 0.63
    23 (38) QIFNPSGQIL 0.33 0.29 0.02 0.07 0.07 0.78
    24 (39) PSGQILGPKY 0 0 0.02 0 0.05 0.07
    25 (40) ILGPKYDGKY 0 0 0.07 0 0.02 0.09
    26 (41) KYDGKYLMQV 0.02 0 0.11 0.01 0.04 0.18
    27 (42) KYLMQVLQEK 0.12 0.04 1.08 0.07 0.79 2.1
    28 (43) QVLQEKLGET 0.46 0.16 0.01 0.07 0.02 0.72
    29 (44) EKLGETRVHQ 0.5 0.12 0.01 0.07 0.04 0.74
    30 (45) ETRVHQALTE 0.42 0.16 0.03 0.05 0.03 0.69
    31 (46) HQALTEVVIS 0.43 0.21 0.04 0.1 0.05 0.83
    32 (47) TEVVISSFDI 0.44 0.25 0.05 0.08 0.04 0.86
    33 (48) ISSFDIKTNK 0.1 0.02 0.04 0.06 0.13 0.35
    34 (49) DIKTNKPVIF 0.57 0.22 0.04 0.18 0.28 1.29
    35 (50) NKPVIFTKSN 0 0.01 0.02 0.07 0.24 0.34
    36 (51) IFTKSNLANS 0 0 0.03 0.06 0.17 0.26
    37 (52) SNLANSPELD 0.43 0.96 0.01 0.09 0.02 1.51
    38 (53) NSPELDAKMY 0.18 0.12 0.01 0.05 0.05 0.41
    39 (54) LDAKMYDISY 0.54 0.26 0.19 0.15 0.23 1.37
    40 (55) MYDISYSTAA 0.92 0.08 0.52 0.04 0.22 1.78
    41 (56) SYSTAAAPTY 1.15 0.25 1.04 0.33 0.55 3.32
    42 (57) AAAPTYFPPH 1.02 0.52 1.12 0.81 0.86 4.33
    43 (58) TYFPPHYFVT 0.02 0.01 0.54 0.03 0.24 0.84
    44 (59) PHYFVTNTSN 0.03 0.01 1.17 0.13 0.44 1.78
    45 (60) VTNTSNGDEY 0.23 0.15 0.04 0.03 0.03 0.48
    46 (61) SNGDEYEFNL 0.33 0.25 0.08 0.1 0.11 0.87
    47 (62) EYEFNLVDGA 0.34 0.25 0.07 0.1 0.2 0.96
    48 (63) NLVDGAVATV 0.3 0.18 0.02 0.06 0.05 0.61
    49 (64) GAVATVADPA 0.45 0.54 0.01 0.07 0.02 1.09
    50 (65) TVADPALLSI 0.48 0.29 0.01 0.07 0.03 0.88
    51 (66) PALLSISVAT 0.65 0.33 0.02 0.1 0.01 1.11
    52 (67) SISVATRLAQ 0.61 0.23 0.14 0.53 0.53 2.04
    53 (68) ATRLAQKDPA 0.87 0.34 0.05 0.29 0.22 1.77
    54 (69) AQKDPAFASI 0.86 0.32 0.04 0.12 0.03 1.37
    55 (70) PAFASIRSLN 0.81 0.15 0.05 0.51 0.59 2.11
    56 (71) SIRSLNYKKM 0.07 0.01 0.17 0.07 0.11 0.43
    57 (72) LNYKKMLLLS 0.05 0.01 0.35 0.08 0.39 0.88
    58 (73) KMLLLSLGTG 1.15 0.15 0.04 0.38 0.71 2.43
    59 (74) LSLGTGTTSE 0.34 0.23 0.02 0.04 0.03 0.66
    60 (75) TGTTSEFDKT 0.92 0.39 0.6 0.1 0.09 2.1
    61 (76) SEFDKTYTAK 1.33 1.35 1.41 0.12 0.28 4.49
    62 (77) KTYTAKEAAT 1.36 0.94 1.11 0.76 0.4 4.57
    63 (78) AKEAATWTAV 0.45 0.15 0.01 0.2 0.04 0.85
    64 (79) ATWTAVHWML 0.1 0.02 0.01 0.08 0.06 0.27
    65 (80) AVHWMLVIQK 0.69 0.05 0.03 0.43 0.62 1.82
    66 (81) MLVIQKMTDA 0.32 0.15 0.02 0.15 0.03 0.67
    67 (82) QKMTDYYLST 0.26 0.125 0.03 0.21 0.05 0.675
    68 (83) DAASSYMTDY 0.2 0.14 0.08 0.08 0.1 0.6
    69 (84) SYMTDYYLST 0.5 0.03 0.32 0.06 0.11 1.02
    70 (85) DYYLSTAFQA 0.14 0 0.22 0.03 0.13 0.52
    71 (86) STAFQALDSK 0.4 0.3 0.04 0.06 0.08 0.88
    72 (87) QALDSKNNYL 0.44 0.46 0.28 0.26 0.43 1.87
    73 (88) SKNNYLRVQE 0.44 0.05 1.31 0.07 0.21 2.08
    74 (89) YLRVQENALT 1.38 0.03 1.31 0.11 0.2 3.03
    75 (90) QENALTGTTT 0.47 0.25 0 0.06 0 0.78
    76 (91) LTGTTTEMDD 0.41 0.24 0 0.06 0 0.71
    77 (92) TTEMDDASEA 0.38 0.3 0 0.05 0 0.73
    78 (93) DDASEANMEL 0.44 0.24 0 0.06 0 0.74
    79 (94) EANMELLVQV 0.42 0.27 0 0.04 0 0.73
    80 (95) ELLVQVGENL 0.4 0.25 0 0.05 0 0.7
    81 (96) QVGENLLKKP 0.44 0.14 0 0.07 0 0.65
    82 (97) NLLKKPVSED 0.47 0.2 0 0.03 0 0.7
    83 (98) KPVSEDNPET 0.27 0.21 0 0.03 0 0.51
    84 (99) EDNPETYEEA 0.13 0.11 0 0.01 0 0.25
    85 (100) ETYEEALKRF 1.26 1.2 1.36 0.53 0.71 5.06
    86 (101) EALKRFAKLL 1.38 0.04 0 1.06 1.12 3.6
    87 (102) RFAKLLSDRK 0.98 0.05 0 0.84 0.94 2.81
    88 (103) LLSDRKKLRA 0.2 0.01 0 0.37 0.51 1.09
    89 (104) RKKLRANKAS 0.28 0 0 0.31 0.64 1.23
    Patient 41.84 20.565 18.1 14.17 16.55
    Cumulative Totals
  • Example 4 Identification of Result Effective Substitutions
  • [0193]
    For each major and several minor allergenic epitopes of patatin, result effective substitutions were identified by synthesizing peptides that were altered by individually substituting an alanine residue at each non-alanine position in the epitope. Similarly, the reported nucleic acid sequence encoding corn patatin (U.S. Pat. No. 5,882,668; clone 5c9) was evaluated for IgE binding by producing peptides at corresponding positions to the potato patatin protein.
  • [0194]
    For example, Epitope 41 was analyzed by alanine scanning and rational substitution as follows.
    Epitope 41 SEFDKTYTAK (SEQ ID NO:76)
    Alanine scan AEFDKTYTAK (SEQ ID NO:165)
    SAFDKTYTAK (SEQ ID NO:166)
    SEADKTYTAK (SEQ ID NO:167)
    SEFAKTYTAK (SEQ ID NO:168)
    SEFDATYTAK (SEQ ID NO:169)
    SEFDKAYTAK (SEQ ID NO:170)
    SEFDKTATAK (SEQ ID NO:171)
    SEFDKTYAAK (SEQ ID NO:172)
    SEFDKTYTAA (SEQ ID NO:173)
    Rational substitution AFFDKTYTAK (SEQ ID NO:283)
    SEFDKTFTAK (SEQ ID NO:176)
    Corn homolog CIFDSTYTAK (SEQ ID NO:284)
  • [0195]
    Selected epitopes were analyzed by alanine scanning and rational substitution. Immunoassay with potato-allergic serum was used as described above. Table 4 summarizes the results of these experiments to identify result effective substitutions for patatin. Blank spaces in the table indicate that binding of the peptide to patient IgE was not detectable.
    TABLE 4
    Scanning of patatin for result effective substitutions
    Binding of modified peptides by patient IgE as measured by OD
    Sequence SEQ ID NO HS03 HS06 HS01 HS02
    DYFDVIGGTS 105 0.12 0.16 0.36
    DYFDVIAGTS 106 0.14 0.17 0.4
    VIGGTSTGGL 107 0.04
    VIAGTSTGAL 108
    AFYFEHGPQI 109 0.96 0.5 0.78
    PAYFEHGPQI 110 0.75 0.41 0.69
    PFAFEHGPQI 111
    PFYAEHGPQI 112 0.7 0.43 0.79
    PFYFAHGPQI 113 0.93 1.07 0.59 1.44
    PFYFEAGPQI 114 0.08 0.93 0.65 1.34
    PFYFEHAPQI 115 0.75 0.54 1.11
    PFYFEHGAQI 116 0.63 0.29 0.6
    PFYFEHGPAI 117 0.63 0.25 0.56
    PFYFEHGPQA 118 0.27 0.16 0.33
    TFYLENGPKI 119 0.05 0.48 0.68 1.07
    PFFFEHGPQI 120
    AYLMQVLQEK 121 0.26 0.11 0.53
    KALMQVLQEK 122
    KYAMQVLQEK 123 0.11 0.43 0.1 1.25
    KYLAQVLQEK 124 0.22 0.48 0.11 1.34
    KYLMAVLQEK 125 0.22 0.83 0.16 1.33
    KYLMQALQEK 126 0.11 0.6 0.15 0.95
    KYLMQVAQEK 127 0.53 0.15 0.81
    KYLMQVLAEK 128 0.06 0.69 0.11 1.34
    KYLMQVLQAK 129 0.74 0.79 0.05 0.58
    KYLMQVLQEA 130 0.28 0.27 0.37
    VFLHDKIKSL 131 0.06 0.26 0.41
    AYSTAAAPTY 132 0.1 0.12 0.12
    SASTAAAPTY 133
    SYATAAAPTY 134 0.16 0.13 0.37
    SYSAAAAPTY 135 0.13 0.12 0.32
    SYSTAAAATY 136 0.15 0.13 0.34
    SYSTAAAPAY 137 0.15 0.14 0.29
    SYSTAAAPTA 138 0.55 0.54 1.13
    CISTSAAPTY 139 0.4
    SYSTAAAPAF 140 0.39 1.02 0.65 1.42
    AFAAAAAPTY 141 0.07
    SYSTAAAPTF 142 0.15 0.97 0.48 1.09
    STSAAPTYFP 143 0.21 0.23 0.39
    STSAAPTFFP 144 0.23
    STSAAPTAFP 145 0.08
    STAAAPTFFP 146 0.12 0.28
    AAAATYFPPH 147 0.13 0.1 0.05
    AAAPAYFPPH 148 0.07 0.04
    AAAPTAFPPH 149
    AAAPTYAPPH 150 0.23 0.14 0.21
    AAAPTYFAPH 151 0.45 0.18 0.44
    AAAPTYFPAH 152 0.15 0.07 0.18
    AAAPTYFPPA 153 0.1 0.06 0.31
    SAAPTYFPAH 154 0.77 0.73 0.96
    AAAPAFFPPH 155
    AAAPPFFPPH 156
    AAAPTFFPPH 157
    SISVATRLAQ 158 0.26 0.26
    AMSMLTKEVH 159
    PAFASIRSLN 160
    PNFNAGSPTE 161
    KMLLLSLGTG 162
    NYLIISVGTG 163 0.49 1.08 0.64 1.48
    KMLLLSLGAG 164 0.13
    AEFDKTYTAK 165 0.09 0.22 1.34
    SAFDKTYTAK 166 0.66 0.71 0.06 1.42
    SEADKTYTAK 167 0.99
    SEFAKTYTAK 168 0.5 0.57 0.91
    SEFDATYTAK 169 0.17
    SEFDKAYTAK 170 0.1 0.24 1.38
    SEFDKTATAK 171 0.81
    SEFDKTYAAK 172 0.2 0.35 1.39
    SEFDKTYTAA 173 0.1 1.18
    KQAEKYTAEQ 174 0.08 0.24
    SEFDAAFAAA 175
    SEFDKTFTAK 176 0.09 0.16 0.07 1.45
    AEKYTAEQCA 177
    ATYTAKEAAT 178 0.24 0.18
    KAYTAKEAAT 179 0.28 0.33
    KTATAKEAAT 180
    KTYAAKEAAT 181 0.1 0.32 0.73
    KTYTAAEAAT 182 0.35
    KTYTAKAAAT 183 0.4 0.59 0.82
    KTYTAKEAAA 184 0.36
    EKYTAEQCAK 185
    AAFAAAEAAT 186
    KTFTAKEAAT 187
    QALHCEKKYL 188
    QALDSKAAYL 189
    QALDSKNNFL 190
    QALHCENNFL 191
    CEKKYLRIQD 192 1.01 0.16
    SKNNFLRVQE 193
    SENNYLRVQE 194 0.31 0.96 0.42 1
    ALRVQENALT 195
    YARVQENALT 196 1.06 1.02 0.05 0.54
    YLAVQENALT 197 0.37 1.04 0.11 1.06
    YLRAQENALT 198 1.1 1 0.06 1.26
    YLRVAENALT 199 1.03 0.92 0.08 1.26
    YLRVQANALT 200 1.05 0.92 0.06 1.24
    YLRVQEAALT 201 0.93 0.92 0.07 1.11
    YLRVQENAAT 202 0.94 0.93 0.04 1.24
    YLRVQENALA 203 1.05 0.96 0.43 1.16
    YLRIQDDTLT 204 1.07 0.85 0.39 1.12
    YLTVAAAALT 205 1.05 0.86 0.28 1.33
    FLRVQENALT 206
    NNYLRVQENA 207 0.23 0.88 0.5 1.17
    KKYLRIQDDT 208 0.26 0.09 0.37
    NNFLRVQENA 209
    NAYLRVQENA 210 0.17 1.02 0.53 1.06
    ATYEEAKLRF 211 0.26 1.03 0.65
    EAYEEALKRF 212 0.06 0.43 0.33
    ETAEEALKRF 213 1.04
    ETYAEALKRF 214 0.62 1.02 1.15
    ETYEAALKRF 215 1.06 0.38 0.89
    ETYEEAAKRF 216 0.08 0.1 0.9
    ETYEEALARF 217 0.11
    ETYEEALKAF 218 0.1
    ETYEEALKRA 219 0.1
    GTNAQSLADF 220
    ETYEAALAAF 221 0.07 0.78 0.33 0.77
    ETFEEALKRF 222
    YEEALKTFAK 223 1.08 0.85 0.14 1.46
    FEEALKRFAK 224 0.46 0.72 0.67
    AALKRFAKLL 225 0.15 0.17
    EAAKRFAKLL 226 0.08 0.33 0.05
    EALARFAKLL 227 0.09
    EALKAFAKLL 228
    EALKRAAKLL 229 0.08 0.07
    EALKRFAALL 230
    EALKRFAKAL 231 0.06 0.09 0.1
    EALKRFAKLA 232 0.06 0.1
    QSLADFAKQL 233
    AALAAFAKLL 234
    LADFAKQLSD 235
    DFAKQLSDER 236 0.17
    AFAALLSDRK 237
  • [0196]
    Result effective substitutions were identified by a reduction in IgE binding ability with respect to the non-substituted peptide sequence. Table 5 shows the identified result effective substitutions. Blank spaces in the table indicate that binding of the peptide to patient IgE was not detectable. Many substitutions of alanine or phenylalanine for the original tyrosine resulted in reduced or eliminated antibody binding.
    TABLE 5
    Result effective substitutions of patatin
    Location
    (SEQ ID NO) Peptide (SEQ ID NO) HS03 HS06 HS01 HS02
    Minor PFYFEHGPQI     (36) 1.08 0.17 0.65 0.06
    Epitope 21 ::A:::::::     (111)
    ::F::::::: (r) (120)
    :::::::::A     (118) 0.27 0.16 0.33
    Minor KYLMQVLQEK     (42) 1.08 0.79 0.12 0.04
    Epitope 27 :A::::::::     (122)
    :::::::::A     (130) 0.28 0.27 0.37
    VFLHDKIKSL (c) (131) 0.06 0.26 0.41
    Major SYSTAAAPTY     (56) 1.04 0.55 1.15 0.25
    Epitope 41 A:::::::::     (132) 0.1 0.12 0.12
    :A::::::::     (133)
    AFAA:::::: (r) (141) 0.007
    CI::S::::: (c) (139) 0.04
    Overlap STAAAPTYFP     (238)
    Epitope ::S::::A:: (r) (145) 0.08
    41/42
    Major AAAPTYFPPH     (57) 1.12 0.86 1.02 0.52
    Epitope 42 ::::A:::::     (148) 0.07 0.04
    (57) :::::A::::     (149)
    ::::AF:::: (r) (155)
    :::::PF::: (r) (156)
    :::::F:::: (r) (157)
    Major SEFDKTYTAK     (76) 0.12 0.28 1.33 1.35
    Epitope 61 ::::A:::::     (169) 0.17
    KQAE:YTAEQ (c) (174) 0.08 0.24
    ::::AAFA:A (r) (175)
    Major KTYTAKEAAT     (77) 1.11 0.04 1.36 0.94
    Epitope 62 A:::::::::     (178) 0.24 0.18
    ::A:::::::     (180)
    :::::A::::     (182) 0.35
    AAFA:A:::: (r) (186)
    EK:::EQC:K (c) (185)
    Minor QALDSKNNYL     (87) 0.28 0.43 0.44 0.46
    Epitope 72 :::HCEKK:: (c) (188)
    ::::::AA:: (r) (189)
    ::::::::F: (r) (190)
    :::::E::F: (r) (240)
    Minor SKNNYLRVQE     (88) 1.31 0.21 0.44 0.05
    epitope 73 ::::F::::: (r) (193)
    Minor YLRVQENALT     (87) 1.31 0.2 1.38 0.03
    epitope 74 A:::::::::     (195)
    F::::::::: (r) (206)
    Overlap NNYLRVQENA     (207) 0.23 0.88 0.5 1.17
    epitope ::F::::::: (r) (209)
    73/74
    Major ETYEEALKRF     (100) 1.36 0.71 1.26 1.2
    epitope 85 :::::::A::     (217) 0.11
    ::::::::A:     (218) 0.1
    :::::::::A     (219) 0.1
    ::F::::::: (r) (222)
    G:NAQS:AD: (c) (220)
    Major EALKRFAKLL     (101) 0 1.12 1.38 0.04
    Epitope 86 :::A::::::     (227) 0.09
    ::::A:::::     (228)
    :::::A::::     (229) 0.08 0.07
    :::::::A::     (230)
    ::::::::A:     (231) 0.06 0.09
    :::::::::A     (232) 0.06
    SD:AD:::Q: (c) (241)
    A::AA::::: (r) (234)
    Epitope LKRFAKLLSD     (239)
    overlap (NO BINDING)
    86/87
    Major RFAKLLSDRK     (102) 0 0.94 0.98 0.05
    Epitope 87 D:::Q:::ER (c) (236) 0.17
    A::A:::::: (r) (237)
  • Example 5 Site Directed Mutagenesis
  • [0197]
    To introduce site specific mutations, the cloned DNA sequence of patatin (SEQ ID NO:1 encoding patatin protein SEQ ID NO:2; pMON 26820) was subjected to PCR with primers SEQ ID NO:3 and SEQ ID NO:4 to incorporate part of the α-factor signal sequence (Pichia expression manual, Invitrogen, Carlsbad, Calif.), and EcoRI and XhoI restriction sites to facilitate cloning into the Pichia pastoris yeast secretion vector pPIC9 (GenBank accession number Z46233; Invitrogen, Carlsbad, Calif.). Typical PCR conditions are 25 cycles 94° C. denaturation for 1 minute, 45° C. annealing for one minute and 72° C. extension for 2 minutes; plus one cycle 72° C. extension for 10 minutes. A 50 μL reaction contains 30 pmol of each primer and 1 μg of template DNA; and 1×PCR buffer with MgCl2, 200 μM dGTP, 200 μM dATP, 200 μM dTTP, 200 μM dCTP, 2.5 units of Pwo DNA polymerase. PCR reactions are performed in RoboCycler Gradient 96 Temperature Cycler (Stratagene, La Jolla, Calif.).
  • [0198]
    The amplified fragment SEQ ID NO:5 was digested with restriction enzymes XhoI and EcoRI and cloned into the pBluescript vector (Stratagene, La Jolla, Calif.), digested with the same two restriction enzymes. The resulting plasmid (pMON 26869) was used for oligonucleotide-directed mutagenesis using the Bio-Rad mutagenesis kit based on the method of Kunkel (Proc. Natl. Acad. Sci. U.S.A., 82: 477-492, 1985). Briefly, single-stranded pMON26869 was used as template for mutagenesis and was prepared by superinfection of plasmid containing cells with M13K07 (Gorman, et al., DNA Prot. Eng. Techniques, 2: 3-10, 1990). The mutagenic oligonucleotides are SEQ ID NOS:8-15 (reverse complement). DNA purified from transformed DH5α E. coli colonies was used for sequence determination. Sequencing was performed using the ABI PRISM sequencing kit (Perkin Elmer Biosystems, Foster City, Calif.). The resulting plasmid containing the mutation in the patatin gene was digested with restriction enzymes XhoI and EcoRI.
  • [0199]
    The patatin nucleic acid fragment was then ligated into the pPIC9 vector (Invitrogen, Carlsbad, Calif.), digested with the same two restriction enzymes to afford plasmid pMON37401. Pichia pastoris KM71 cells were electroporated with pMON37401 containing the appropriate mutation. The resulting transformed cells were used to produce protein in Pichia pastoris using the procedure supplied by the manufacturer (Invitrogen, Carlsbad, Calif.). The encoded protein contains an alpha factor signal cleavage site. Plasmid pMON37401 encodes SEQ ID NO:6 which is cleaved to afford SEQ ID NO:7, having four amino acids added at the N-terminus of amino acids 24-386 of SEQ ID NO:2. Position four of SEQ ID NO:7 therefore corresponds to position 23 of SEQ ID NO:2.
  • [0200]
    The concentration of patatin in the culture was determined using a patatin ELISA assay and the enzyme activity was measured using the method of Hofgen and Willmitzer (Plant Science, 66: 221-230, 1990). The variants containing multiple mutations were further purified using Mono Q and hydrophobic interaction chromatography (HIC). Each culture was purified by first sizing on Amicon YM10 membranes (Millipore, Bedford, Mass.) to a >10 kDa fraction, followed by chromatography on the Mono Q HR 10/10 column (Pharmacia, Piscataway, N.J.). For chromatography on the Mono Q column, the samples were loaded on the column in 25 mM Tris pH 7.5 and eluted with a gradient of 1.0 M KCl in 25 mM Tris pH 7.5. Fractions containing patatin protein were determined using SDS-PAGE. For chromatography on the HIC column, the appropriate fractions were pooled and dialyzed into 1 M ammonium sulfate in 25 mM Tris pH 7.5. The dialyzed sample was then loaded on 16/10 phenyl Sepharose column (Pharmacia, Piscataway, N.J.) and eluted with a gradient of 25 mM Tris pH 7.5.
  • [0201]
    The protein concentration was determined using the Bradford method, using BSA as a standard. SDS-PAGE analysis showed that these proteins were essentially pure. The esterase activity of the newly formed variants are shown in Table 6. The activity was determined using p-nitrophenyl caprate substrate as described by Hofgen and Willmitzer (Plant Science, 66: 221-230, 1990).
    TABLE 6
    Esterase activity of patatin mutants
    Activity
    Variant (mOD.min−1μg−1)
    Wild type 93.2
    Y106F 51.1
    Y129F 74.7
    Y185F 85.6
    Y193F 82.2
    Y185F/Y193F 99.4
    Y270F 163.4
    Y316F 94.88
    Y362F 130.7
    Y106F/Y129F/Y185F/Y193F/Y270F/Y316F/Y362F 57.1
    Y185F/Y193F/Y270F/Y316F/Y362F 161.5
  • [0202]
    Patatin proteins having a phenylalanine substitution at each of the amino acid positions 106, 129, 185, 193, 270, 316 and 362 (numbers correspond to positions in SEQ ID NO:2) of expressed SEQ ID NO:7 exhibit full enzyme activity. Proteins having multiple substitutions also displayed full enzyme activity.
  • [0203]
    In addition to nucleotide sequences encoding conservative amino acid changes within the fundamental polypeptide sequence, biologically functional equivalent nucleotide sequences include nucleotide sequences containing other base substitutions, additions, or deletions. These include nucleic acids containing the same inherent genetic information as that contained in the cDNA which encode peptides, polypeptides, or proteins conferring pathogen resistance the same as or similar to that of pathogen upon host cells and plants. Such nucleotide sequences can be referred to as “genetically equivalent modified forms” of the cDNA, and can be identified by the methods described herein.
  • [0204]
    Mutations made in the cDNA, plasmid DNA, genomic DNA, synthetic DNA, or other nucleic acid encoding the deallergenized gene preferably preserve the reading frame of the coding sequence. Furthermore, these mutations preferably do not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, that would adversely affect mRNA translation.
  • [0205]
    Although mutation sites can be predetermined, it is not necessary that the nature of the mutations per se be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis can be conducted at the target codon.
  • [0206]
    Alternatively, mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native cDNA sequence. Following ligation, the resulting reconstructed nucleotide sequence encodes a derivative form having the desired amino acid insertion, substitution, or deletion.
  • Example 6 Construction of Permutein Sequences
  • [0207]
    Nucleic acid sequences encoding permutein proteins having rearranged N-terminus/C-terminus protein sequences can be made by following the general method described by Mullins et al. (J. Am. Chem. Soc. 116: 5529-5533, 1994). The steps are shown in FIG. 3. The Figure and the following Examples involve the design and use of a linker region separating the original C-terminus and N-terminus, but the use of a linker is not a critical or required element of permutein design.
  • [0208]
    Two sets of oligonucleotide primers are used in the construction of a nucleic acid sequence encoding a permutein protein. In the first step, oligonucleotide primers “new N-termini” and “linker start” are used in a PCR reaction to create amplified nucleic acid molecule “new N-termini fragment” that contains the nucleic acid sequence encoding the new N-terminal portion of the permutein protein, followed by the polypeptide linker that connects the C-terminal and N-terminal ends of the original protein. In the second step, oligonucleotide primers “new C-termini” and “linker end” are used in a PCR reaction to create amplified nucleic acid molecule “new C-termini fragment” that contains the nucleic acid sequence encoding the same linker as used above, followed by the new C-termini portion of the permutein protein. The “new N-termini” and “new C-termini” oligonucleotide primers are designed to include appropriate restriction enzyme recognition sites which assist in the cloning of the nucleic acid sequence encoding the permutein protein into plasmids.
  • [0209]
    Any suitable PCR conditions and polymerase can be used. It is desirable to use a thermostable DNA polymerase with high fidelity to reduce or eliminate the introduction of sequence errors. Typical PCR conditions are 25 cycles 94° C. denaturation for 1 minute, 45° C. annealing for one minute and 72° C. extension for 2 minutes; plus one cycle 72° C. extension for 10 minutes. A 50 μL reaction contains 30 pmol of each primer and 1 μg of template DNA; and 1×PCR buffer with MgCl2, 200 μM dGTP, 200 μM dATP, 200 μM dTTP, 200 μM dCTP, 2.5 units of Pwo DNA polymerase. PCR reactions are performed in RoboCycler Gradient 96 Temperature Cycler (Stratagene, La Jolla, Calif.).
  • [0210]
    The amplified “new N-termini fragment” and “new C-termini fragment” are annealed to form a template in a third PCR reaction to amplify the full-length nucleic acid sequence encoding the permutein protein. The DNA fragments “new N-termini fragment” and “new C-termini fragment” are resolved on a 1% TAE gel, stained with ethidium bromide, and isolated using the QIAquick Gel Extraction Kit (Qiagen, Valencia, Calif.). These fragments are combined in equimolar quantities with oligonucleotide primers “new N-termini” and “new C-termini” in the third PCR reaction. The conditions for the PCR are the same as used previously. PCR reaction products can be purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.).
  • [0211]
    Alternatively, a linker sequence can be designed containing a restriction site, allowing direct ligation of the two amplified PCR products.
  • Example 7 Construction of Plasmid pMON 37402
  • [0212]
    The patatin protein contains a trypsin protease sensitive site at the arginine amino acid at position 246, as determined by electrophoresis of a trypsin digest reaction. In order to determine if the exposed protease site is an antigenic epitope, a permutein was constructed using positions 246-247 as a breakpoint.
  • [0213]
    The nucleic acid sequence encoding the permutein protein in plasmid pMON 37402 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “new N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 27 (SEQ ID NO:242) and 48 (SEQ ID NO:243). Nucleic acid molecule “new C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 47 (SEQ ID NO:244) and 36 (SEQ ID NO:245). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “new N-termini fragment” and “new C-termini fragment” using oligonucleotide primers 27 (SEQ ID NO:242) and 36 (SEQ ID NO:245).
  • [0214]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases XhoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON 26869 (derivative of pPIC9, Invitrogen, Carlsbad, Calif.) was digested with restriction endonucleases XhoI and EcoRI, and gel purified, resulting in an approximately 2900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0215]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON 37402 (containing SEQ ID NO:246, encoding protein sequence SEQ ID NO:247).
  • Example 8 Construction of Plasmid pMON 37405
  • [0216]
    Amino acids 201-202, near tyrosine 193, were chosen as a breakpoint for the construction of a permutein protein.
  • [0217]
    The nucleic acid sequence encoding the permutein protein in plasmid pMON 37405 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “New N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 48 (SEQ ID NO:243) and 58 (SEQ ID NO:249). Nucleic acid molecule “New C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 47 (SEQ ID NO:244) and 59 (SEQ ID NO:249). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “New N-termini fragment” and “New C-termini fragment” using oligonucleotide primers 58 (SEQ ID NO:248) and 59 (SEQ ID NO:249).
  • [0218]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases XhoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON 26869 (derivative of pPIC9, Invitrogen, Carlsbad, Calif.) was digested with restriction endonucleases XhoI and EcoRI, and gel purified, resulting in an approximately 2900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0219]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON 37405 (containing SEQ ID NO:250, encoding protein sequence SEQ ID NO:251).
  • Example 9 Construction of Plasmid pMON 37406
  • [0220]
    Amino acids 183-184, adjacent to tyrosine 185, were chosen as a breakpoint for the construction of a permutein protein.
  • [0221]
    The nucleic acid sequence encoding the permutein protein in plasmid pMON 37406 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “New N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 48 (SEQ ID NO:243) and 60 (SEQ ID NO:252). Nucleic acid molecule “New C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 47 (SEQ ID NO:244) and 61 (SEQ ID NO:253). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “New N-termini fragment” and “New C-termini fragment” using oligonucleotide primers 60 (SEQ ID NO:252) and 61 (SEQ ID NO:253).
  • [0222]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases XhoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON 26869 (derivative of pPIC9, Invitrogen, Carlsbad, Calif.) was digested with restriction endonucleases XhoI and EcoRI, and gel purified, resulting in an approximately 2900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0223]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON37406 (containing SEQ ID NO:254, encoding protein sequence SEQ ID NO:255).
  • Example 10 Construction of Plasmid pMON 37407
  • [0224]
    Amino acids 268-269, adjacent to tyrosine 270, were chosen as a breakpoint for the construction of a permutein protein.
  • [0225]
    The nucleic acid sequence encoding the permutein protein in plasmid pMON 37407 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “New N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 48 (SEQ ID NO:243) and 62 (SEQ ID NO:256). Nucleic acid molecule “New C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 47 (SEQ ID NO:244) and 63 (SEQ ID NO:257). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “New N-termini fragment” and “New C-termini fragment” using oligonucleotide primers 62 (SEQ ID NO:256) and 63 (SEQ ID NO:257).
  • [0226]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases XhoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON 26869 (derivative of pPIC9, Invitrogen, Carlsbad, Calif.) was digested with restriction endonucleases XhoI and EcoRI, and gel purified, resulting in an approximately 2900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0227]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON37407 (containing SEQ ID NO:258, encoding protein sequence SEQ ID NO:259).
  • Example 11 Construction of Plasmid pMON 37408
  • [0228]
    Amino acids 321-322, near tyrosine 216, were chosen as a breakpoint for the construction of a permutein protein.
  • [0229]
    The nucleic acid sequence encoding the permutein protein in plasmid pMON 37408 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “New N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 48 (SEQ ID NO:243) and 64 (SEQ ID NO:260). Nucleic acid molecule “New C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON26820 using oligonucleotide primers 47 (SEQ ID NO:244) and 65 (SEQ ID NO:261). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “New N-termini fragment” and “New C-termini fragment” using oligonucleotide primers 64 (SEQ ID NO:260) and 65 (SEQ ID NO:261).
  • [0230]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases XhoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON 26869 (derivative of pPIC9, Invitrogen, Carlsbad, Calif.) was digested with restriction endonucleases XhoI and EcoRI, and gel purified, resulting in an approximately 2900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0231]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON37408 (containing SEQ ID NO:262, encoding protein sequence SEQ ID NO:263).
  • Example 12 Production of Permutein Proteins in Pichia pastoris
  • [0232]
    Plasmids pMON37402, pMON37405, pMON37406, pMON37407, and pMON37408 were individually used to electroporate KM71 cells from Pichia pastoris according to the procedure supplied by the manufacturer (Invitrogen, Carlsbad, Calif.). The resulting transformed cells were used to produce protein in Pichia pastoris following the procedure supplied by the manufacturer (Invitrogen, Carlsbad, Calif.).
  • [0233]
    The concentration of patatin in the culture was determined using a patatin ELISA assay and the enzyme activity was measured using the method of Hofgen and Willmitzer (Plant Science, 66: 221-230, 1990). The variants containing multiple mutations were further purified using Mono Q and hydrophobic interaction chromatography (HIC). Each culture was purified by first sizing on YM10 membranes (Amicon, MA) to a [>10 kDa] fraction, followed by chromatography on the Mono Q HR 10/10 column (Pharmacia, NJ). For chromatography on the Mono Q column, the samples were loaded on the column in 25 mM Tris pH 7.5 and eluted with a gradient of 1.0 M KCl in 25 mM Tris pH 7.5. Fractions containing patatin protein were determined using SDS-PAGE. For chromatography on the HIC column, the appropriate fractions were pooled and dialyzed into 1 M ammonium sulfate in 25 mM Tris pH 7.5. The dialyzed sample was then loaded on 16/10 phenyl Sepharose column (Pharmacia, NJ) and eluted with a gradient of 25 mM Tris pH 7.5.
  • [0234]
    The protein concentration was determined using the Bradford method, using BSA as a standard. SDS-PAGE analysis showed that these proteins were essentially pure. The esterase activity of the variants are shown in Table 7.
    TABLE 7
    Activity of permuteins
    pMON Breakpoint Activity (ΔOD min−1μg−1)
    Native enzyme 83.21
    pMON37402 246/247 66.7
    pMON37405 201/202 No expression
    pMON37406 183/184 No expression
    pMON37407 268/269 12.1
    pMON37408 321/322 No expression
  • [0235]
    The activity was determined using p-nitrophenyl caprate substrate as described by Hofgen and Willmitzer (Plant Science, 66: 221-230, 1990).
  • Example 13 Insect Bioefficacy Assays
  • [0236]
    Assays for activity against larvae of SCRW are carried out by overlaying the test sample on an agar diet similar to that described by Marrone (J. Econ. Entom. 78: 290-293, 1985). Test samples were prepared in 25 mM Tris, pH 7.5 buffer. Neonate larvae are allowed to feed on the treated diet at 26° C., and mortality and growth stunting were evaluated after 5 or 6 days. The results of this assay are shown in Table 8.
    TABLE 8
    Insect bioefficacy assay
    Protein (200 ppm) Mean Survival Weight % Weight Reduction
    Tris buffer (control) 1.26 ± 0.3 
    Wild Type 0.21 ± 0.02 83
    pMON37402 0.21 ± 0.03 83
    pMON37407 0.32 ± 0.04 75
  • [0237]
    These data demonstrate that the growth of the SCRW larvae is similarly reduced upon ingestion of the proteins encoded by pMON37402 and pMON37407 as compared to the wild type patatin protein.
  • Example 14 Permutein Sequences Improved for Monocot Expression
  • [0238]
    Modification of coding sequences has been demonstrated above to improve expression of insecticidal proteins. A modified coding sequence was thus designed to improve expression in plants, especially corn (SEQ ID NO:264).
  • Example 15 Construction of pMON40701 for Monocot Expression
  • [0239]
    Plasmid pMON19767 was digested with restriction endonucleases NcoI and EcoRI and the 1100 bp gene fragment was purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON33719 was digested with restriction endonucleases NcoI and EcoRI, and gel purified, resulting in an approximately 3900 base pair vector fragment. The two purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0240]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON40700. Plasmid pMON40700 was digested with restriction endonuclease NotI and the resulting 2200 bp DNA fragment was purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON30460 was digested with restriction endonuclease NotI, and gel purified, resulting in an approximately 4200 base pair vector fragment. The two purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0241]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on kanamycin-containing plates. The resulting plasmid was designated pMON40701 (containing SEQ ID NO:264, encoding protein sequence SEQ ID NO:265).
  • Example 16 Construction of pMON40703 for Monocot Expression
  • [0242]
    The nucleic acid sequence encoding the permutein protein in plasmid pMON40703 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “New N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON19767 using oligonucleotide primers Syn1 (SEQ ID NO:266) and Syn2 (SEQ ID NO:267). Nucleic acid molecule “New C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON19767 using oligonucleotide primers Syn3 (SEQ ID NO:268) and Syn4 (SEQ ID NO:269). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “New N-termini fragment” and “New C-termini fragment” using oligonucleotide primers Syn1 (SEQ ID NO:266) and Syn4 (SEQ ID NO:269).
  • [0243]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases NcoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON33719 was digested with restriction endonucleases NcoI and EcoRI, and gel purified, resulting in an approximately 3900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0244]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON40702. Plasmid pMON40702 was digested with NotI, and the resulting 2200 bp DNA fragment was purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON30460 was digested with restriction endonuclease NotI, and gel purified, resulting in an approximately 4200 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0245]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on kanamycin-containing plates. The resulting plasmid was designated pMON40703 (containing SEQ ID NO:270, encoding protein sequence SEQ ID NO:271). Plasmid pMON40703 encodes a permutein protein with a “breakpoint” at positions 246/247 of the wild type patatin protein sequence (SEQ ID NO:2). The first 23 amino acids of SEQ ID NO:2 are a signal peptide sequence which is cleaved in the mature protein. Example 17: Construction of pMON40705 for monocot expression The nucleic acid sequence encoding the permutein protein in plasmid pMON40705 was created using the method illustrated in FIG. 3 and described in Example 6. Nucleic acid molecule “New N-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON19767 using oligonucleotide primers Syn10 (SEQ ID NO:272) and Syn2 (SEQ ID NO:267). Nucleic acid molecule “New C-termini fragment” was created and amplified from the sequence encoding patatin in plasmid pMON19767 using oligonucleotide primers Syn3 (SEQ ID NO:268) and Syn11 (SEQ ID NO:273). The full-length nucleic acid molecule encoding the permutein protein was created and amplified from annealed fragments “New N-termini fragment” and “New C-termini fragment” using oligonucleotide primers Syn10 (SEQ ID NO:272) and Syn11 (SEQ ID NO:273).
  • [0246]
    The resulting amplified nucleic acid molecule was digested with restriction endonucleases NcoI and EcoRI, and purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON33719 was digested with restriction endonucleases NcoI and EcoRI, and gel purified, resulting in an approximately 3900 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0247]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the presence of the correct insert. The resulting plasmid was designated pMON40704. Plasmid pMON40704 was digested with restriction endonuclease NotI, and the resulting 2200 bp DNA fragment was purified using the QIAquick PCR purification kit (Qiagen, Valencia, Calif.). Plasmid pMON30460 was digested with restriction endonuclease NotI, and gel purified, resulting in an approximately 4200 base pair vector fragment. The purified restriction fragments were combined and ligated using T4 DNA ligase.
  • [0248]
    The ligation reaction mixture was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on plates containing kanamycin. The resulting plasmid was designated pMON40705 (containing SEQ ID NO:274, encoding protein sequence SEQ ID NO:275). Plasmid pMON40705 encodes a permutein protein with a “breakpoint” at positions 268/269 of the wild type patatin protein sequence (SEQ ID NO:2). The first 23 amino acids of SEQ ID NO:2 are a signal peptide sequence which is cleaved in the mature protein.
  • Example 18 Transient Expression of Protein in Corn Leaf Protoplasts
  • [0249]
    Plasmids pMON40701, pMON40703, and pMON40705 (all containing the native signal sequence for vacuolar targeting) were separately electroporated into corn leaf protoplasts as described by Sheen (Plant Cell 3: 225-245, 1991). Protein was extracted with glass beads and the supernatant was assayed for protein expression using ELISA for patatin and NPTII. Expression of protein by the transformed corn protoplasts was confirmed by Western blot analysis. Expression results are shown in Table 9.
    TABLE 9
    ELISA data
    Patatin NPTII
    ELISA ELISA Normalized Expression
    Sample (μg/mL) (μg/mL) (Patatin ELISA/NPTII ELISA)
    pMON40701 1.1 0.6 1.8
    pMON40703 2.1 0.3 7.0
    pMON40705 1.3 0.6 2.2
  • [0250]
    The results indicate that the permutein encoded by plasmid pMON40703 surprisingly shows approximately 4-fold higher expression compared to the wild type enzyme.
  • Example 19 Deglycosylation of Protein Sequences
  • [0251]
    This example provides evidence that glycosylation of can contribute to the allergenicity of a protein. Accordingly, rational substitution of amino acid residues likely to be the targets of glycosylation within a subject allergen protein may reduce or eliminate the allergenic properties of the protein without adversely affecting the enzymatic, insecticidal, antifungal or other functional properties of the protein.
  • [0252]
    Glycosylation commonly occurs as either N-linked or O-linked forms. N-linked glycosylation usually occurs at the motif Asn-Xaa-Ser/Thr, where Xaa is any amino acid except Pro (Kasturi, L. et al., Biochem J. 323: 415-519, 1997; Melquist, J. L. et al., Biochemistry 37: 6833-6837, 1998). O-linked glycosylation occurs between the hydroxyl group of serine or threonine and an amino sugar.
  • [0253]
    Site directed mutagenesis of selected asparagine, serine, or threonine may be used to reduce or eliminate the glycosylation of patatin proteins. A search of SEQ ID NO:2 for the Asn-Xaa-Ser/Thr motif reveals one occurrence at amino acid positions 202-204. Mutagenization of the nucleic acid sequence encoding this region results in a reduced allergenicity of the encoded protein.
  • [0254]
    In order to test this approach to reducing allergenicity of patatin proteins, two sets of experiments were performed: a) production of patatin proteins in Escherichia coli, which do not glycosylate proteins; and b) production of patatin proteins with an N202Q site directed mutation.
  • [0255]
    Antibodies obtained from patients HS-07 and G15-MON (not potato allergic) did not show specific binding to wild type patatin, patatin produced in E. coli, or the N202Q variant. Antibodies obtained from patient HS-01 (potato allergic) bound to wild type patatin, but not to patatin produced in E. coli or the N202Q variant. Antibodies obtained from patient HS-02 (potato allergic) bound strongly to wild type patatin, but extremely weakly to patatin produced in E. coli, and binding to the N202Q variant resembled vector controls. Antibodies obtained from patient HS-03 (potato allergic) bound to wild type patatin, but not to patatin produced in E. coli or the N202Q variant. Antibodies obtained from patient HS-05 (potato allergic) bound to wild type patatin, but very weakly to patatin produced in E. coli and the N202Q variant. Antibodies obtained from patient HS-06 (potato allergic) strongly bound wild type patatin, the N202Q variant, and to patatin produced in E. coli. These results strongly suggest that glycosylation is at least partially responsible for the antigenic properties of patatin proteins, and that site directed mutagenesis may be used to reduce or eliminate specific antibody binding. Mutagenesis at position 202 of SEQ ID NO:2 may be useful for reducing or eliminating specific antibody binding. The deglycosylation approach was also tested using a patatin homolog, Pat17. As demonstrated above, patatin epitopes exhibiting IgE binding were identified, and each contained a Tyr residue. Substitution of these Tyr residues within each epitope led to loss of IgE binding. Site-directed mutagenesis was used to produce variants with individual and multiple Tyr substitutions in the protein, which was expressed in Pichia pastoris and assessed for enzyme activity. All the variants were found to have enzymatic activity no less than the wild type protein. A single variant with all 5 tyrosine residues substituted with phenylalinine was found to have insecticidal activity no less than the unsubstituted protein and was expressed in E. coli to produce the non-glycosylated version. The E. coli 5-“Tyr to Phe” variant was assessed for IgE binding. An isozyme of patatin, designated Pat17, was also expressed in corn to produce a plant glycoprotein and in E. coli to produce a nonglycosylated protein. Sera of seven patients (five exhibiting potato allergy and one exhibiting other allergies but no allergy to potatoes) were were used to assay Pat17 or Pat17 variant binding by immunoblot assay. Four of the five sera from patients exhibiting potato allergy showed either very weak or no binding to wild type patatin expressed in E. coli but did bind to the 5-Tyr variant. Serum from one patient exhibiting potato allergy showed strong binding to recombinant wild type patatin protein expressed in E. coli but weak binding to the 5-Tyr variant. Sera from all five patients exhibiting potato allergy bound strongly to patatin expressed in corn and native patatin present in potatoes. Serum from a control patient allergic to eggs, milk, peanuts and seafood, but exhibiting no allergy to potatoes showed no binding to patatin expressed in E. coli but did bind to patatin expressed in corn. Immunoblot results suggested that the sugar moiety in patatin is a non-specific IgE binding epitope and the polypeptide portion of patatin also contains immunogenic IgE epitopes.
  • [0256]
    Patients who suffer from potato allergy were identified at Johns Hopkins Clinic (Baltimore, Md.) and were evaluated for potato allergy using clinical criteria outlined in Table 2.
  • [0257]
    Serum was obtained from patients with convincing clinical history of potato allergy. The convincing history was defined as being one or more of the following: a) positive potato allergic reaction as evaluated by double-blind placebo-control food challenge b) anaphylaix and/or hospitalization due to the consumption of potatoes or c) dramatic skin test results.
  • [0258]
    Peptide Synthesis
  • [0259]
    Peptides were synthesized on cellulose membranes using the SPOTS system (Genosys Biotechnologies, TX). Membranes were stored at −20° C. until use.
  • [0260]
    Site Directed Mutagenesis
  • [0261]
    Site specific mutations were introduced into patatin by first incorporating part of the a-factor signal sequence (Pichia expression manual, Invitrogen, Carlsbad, Calif.) to the patatin gene using PCR. Primers used for the PCR were GGAGCTCGAGAAAAGAGAGGCTGAAGCTCAGTTGGGAGAAATGGTGACTGTTCT (XhoI site in italics) and GGTCTAGAG GAATTCTCATTAATAAGAAG (EcoRI site in italics). The primers contained restriction sites to facilitate cloning into Pichia pastoris yeast secretion vector pPIC9 (GenBank accession number Z46233; Invitrogen, Carlsbad, Calif.). Typical PCR conditions are 25 cycles 94° C. denaturation for 1 minute, 45° C. annealing for one minute and 72° C. extension for 2 minutes; plus one cycle 72° C. extension for 10 minutes. A 50 mL reaction contained 30 pmol of each primer and 1 mg of template DNA; and 1×PCR buffer with MgCl2, 200 mM dGTP, 200 mM dATP, 200 mM dTTP, 200 mM dCTP, 2.5 units of Pwo DNA polymerase. PCR reactions are performed in RoboCycler Gradient 96 Temperature Cycler (Stratagene, La Jolla, Calif.).
  • [0262]
    The amplified patatin gene was digested with restriction enzymes XhoI and EcoRI and cloned into the pBluescript vector (Stratagene, La Jolla, Calif.), digested with the same two restriction enzymes. The template plasmid DNA used for the PCR was pMON26820. The resulting plasmid (pMON 26869) was used for oligonucleotide-directed mutagenesis using the Bio-Rad mutagenesis kit based on the method of Kunkel et al., Proc Natl Acad Sci USA 82, 477-92 (1985). Briefly, single-stranded pMON26869 was used as template for mutagenesis and was prepared by superinfection of plasmid containing cells with M13K07 (Gorman et al., DNA and Protein Engineering techniques 2, 3-10 (1990)). DNA purified from transformed DH5α E. coli colonies was used for sequence determination. Sequencing was performed using the ABI PRISM sequencing kit (Perkin Elmer Biosystems, Foster City, Calif.).
  • [0263]
    Protein Expression in Pichia pastoris
  • [0264]
    Plasmids containing the mutations in the patatin gene were digested with restriction enzymes XhoI and EcoRI. The patatin nucleic acid fragment was then ligated into the pPIC9 vector (Invitrogen, Carlsbad, Calif.), digested with the same two restriction enzymes to afford plasmid pMON37401. Pichia pastoris KM71 cells were electroporated with pMON37401 containing the appropriate mutation. The resulting transformed cells were used to produce protein in Pichia pastoris using the procedure supplied by the manufacturer (Invitrogen, Carlsbad, Calif.). The proteins were purified in the same way as the proteins expressed in E. coli (see below).
  • [0265]
    Western Blotting of Proteins
  • [0266]
    Protein samples were electrophoresed by SDS-PAGE and electroblotted onto PVDF membrane (Millipore, Bedford Mass.). Protein blots were processed by standard Western blotting (immunoblotting) techniques and were incubated in potato allergic serum diluted 1:5 in PBS buffer for 1 hour. After washing the blots 3 times with PBS, the blots were incubated in biotinylated anti-IgE (Johns Hopkins Hospital, Baltimore Md.) for 1 hour, followed by a 30 minute incubation in HRP-linked avidin (Promega, New York, N.Y.). IgE-reactive protein bands were visualized by using the ECL system (Amersham Pharmacia Biotech, NJ). As a control, one blot was incubated in anti-IgE only. His-tagged glyphosate oxidase and potato extracts was prepared and provided for this study by Regulatory Sciences, Monsanto Company. The peptides were evaluated using the same incubation procedures as described above.
  • [0267]
    Expression and Purification of Patatin in Corn
  • [0268]
    An isozyme of patatin, Pat17, was generated for expression in corn using a modified plant optimized gene sequence as described by Brown et al (U.S. Pat. No. 5,689,052). All the constructs contained the native 23 amino acid signal peptide for vacuolar targeting. Corn was transformed by microprojectile bombardment (Morrish et al., in Transgenic plants. Fundamentals and Applications (ed. Hiatt, A.) 133-171 (Marcel Dekker, New York, 1993); Songstad et al., In Vitro Cell Dev Biol—Plant 32, 179-183 (1996)). Protein from the transformed corn plants was purified by first grinding the leaves in liquid nitrogen and extracting the protein using 25 mM Tris/HCl. The plant extract was further dialyzed against 25 mM Tris/HCl pH 7.5. The plant extract was then loaded onto Mono Q HR 10/10 anion-exchange column (Amersham Pharmacia, NJ) equilibrated with 25 mM Tris/HCl pH 7.5 (buffer A). The protein was eluted with 25 mM Tris/HCl pH 7.5, 1 M KCl (buffer B) using a linear gradient of 0-100% buffer B using an HPLC system (Shimadzu). Fractions containing protein were assayed for esterase activity and dialyzed against 25 mM Tris/HCl pH 7.5, 1 M Ammonium Sulfate (buffer C). The protein was purified to homogeneity by loading onto a phenyl-Sepharose 16/10 column (Amersham Pharmacia, NJ) equilibrated with buffer C. Esterase active fractions were pooled and dialyzed against 25 mM Tris/HCl pH 7.5.
  • [0269]
    Expression and Purification of Patatin in E. coli
  • [0270]
    Pat17 was expressed in E. coli using the pET expression system (Novagen, WI). The coding region of the mature Pat17 gene (without its signal peptide) was amplified by PCR using the primers 5′-GGGCCATGGCGCAGTTGGGAGAAATGGTG-3′ (NcoI site in italics) and 5′-AACAAAGCTTCTTATTGAGGTGCGGCCGCTTGCATGC-3′ (NotI site in italics) using standard PCR reaction conditions as described in the Gene Amp kit (Perkin-Elmer Cetus, CT) and an annealing temperature of 40° C. The template was plasmid pMON26820. The resulting DNA was digested with NcoI and NotI and cloned into a modified pET24d plasmid, designed to add an N-terminal hexa-histidine tag to the protein. The correct sequence of the PCR product was verified by sequencing, and the plasmid was transformed into E. coli BL21 (DE3), and transformants selected on LB containing 25 mg/mL kanamycin. The expression strain was grown in LB containing 25 mg/mL kanamycin and induced for 8 hrs at 28° C. with 1 mM IPTG. Cells were harvested and washed in 50 mM Tris/HCl pH 8.5, 150 mM NaCl, and lysed by French Press at 20,000 psi. His-tagged protein was recovered in the soluble fraction of lysed cells and subsequently purified using Ni-NTA resin as described in the QIAexpressionist manual (Qiagen CA). The partially purified protein was then dialyzed against 25 mM Tris/HCl pH 7.5 (buffer A) and loaded onto Mono Q HR 10/10 anion-exchange column (Amersham Pharmacia, NJ) equilibrated with buffer A. The protein was eluted with 25 mM Tris/HCl pH 7.5, 1 M KCl (buffer B) using a linear gradient of 0-100% buffer B run over 30 min at a flow rate of 4 mL/min using an HPLC system (Shimadzu). Fractions containing protein were assayed for esterase activity. Esterase active fractions were pooled, concentrated and dialyzed against 25 mM Tris/HCl pH 7.5 and stored at 4° C.
  • [0271]
    Enzyme Activity Assays
  • [0272]
    Enzyme activity was measured as described previously using p-nitrophenyl caprate (Sigma, MO) as a substrate, dissolved in dimethylsulfoxide (5 mM stock solution) and diluted in 4% Triton X-100, 1% SDS to a final concentration of 1 mM. For the assay, 20 mL of protein solution was added to a mixture of 25 mL of the 1 mM substrate solution and 80 mL of 50 mM Tris pH 8.5. The enzyme activity was monitored at 405 nm in 6 sec interval for a period of 10 min. Esterase activity was expressed as DOD min−1 mg−1 protein.
  • [0273]
    Insect Bioassay
  • [0274]
    The protein was also assayed for activity against larvae of Diabrotica virigifera (Western corn rootworm) by overlaying the test sample on an agar diet similar to that described previously (Marrone et al., J. Econ. Entom. 78, 290-3 (1985)). Proteins to be tested were diluted in 25 mM Tris/HCl pH 7.5 and overlayed on the diet surface. Neonate larvae were allowed to feed on the diet and mortality and growth stunting were evaluated after 6 days.
  • [0275]
    IgE Binding Epitopes on Patatin
  • [0276]
    A panel of eighty-nine overlapping peptides representing the amino acid sequence of patatin were synthesized to determine the regions responsible for IgE binding. Each peptide was 10 amino acids long and consisted of 6 amino acid overlap between the consecutive peptides. The peptides were evaluated for IgE binding with five different potato allergic patient sera. Patatin has 3 major epitopes. These major IgE binding regions represent amino acids 184-193, 188-197, 269-278 and 360-369. Other minor IgE binding regions represent amino acids 104-113, 138-147 and 316-325. The amino acids essential for IgE binding in each major and minor epitopes were determined by synthesizing peptides with single amino acid changes at each position by individually substituting an alanine residue at each non-alanine position in the epitopes. The resulting alanine substituted peptides were evaluated for IgE binding. Result effective substitutions were identified by a reduction in IgE binding with respect to the non-substituted peptide sequence. It was very interesting to note that all the epitopes contained a Tyr residue and substitution of this Tyr for Ala or Phe eliminated IgE binding.
  • [0277]
    Enzyme and Bioactivity
  • [0278]
    The Tyr residues identified to be critical for IgE binding in each of the epitopes were substituted with Phe either individually or in concert using site-directed mutagenesis. All the variants were expressed in Pichia pastoris and assessed for enzyme activity and insecticidal activity. The variants included Y106F, Y129F, Y185F, Y193F, Y270F, Y316F, Y362F, Y185F/Y193F, Y185F/Y193F/Y270F/Y316F/Y362F (5-Tyr) and Y106F/Y129F/Y185F/Y193F/Y270F/Y316F/Y362F (7-Tyr). All the variants maintained enzyme activity. The 5-Tyr and 7-Tyr variants were then assessed for insecticidal activity by overlaying protein (200 ppm final concentration). The proteins caused significant stunting of the larval growth as measured by the weight of the larvae after 6 days with the 5-Tyr variant showing higher insecticidal activity compared to the 7-Tyr and wild type proteins. The 7-Tyr variant was unstable upon long term storage at 4° C. and thus was not pursued further.
  • [0279]
    Immunoblotting
  • [0280]
    In order to test if the glycan moiety on patatin was important for binding of IgE, Pat17 was expressed in E. coli to produce a nonglycosylated protein and in corn to produce a plant glycosylated protein. The 5-Tyr variant was also expressed in E. coli to assess the individual contribution of the linear epitopes without the glycan moiety on the protein. The proteins were tested for binding to IgE using sera from five patients with allergy to potatoes and sera from one patient with allergies to many things but no allergy to potatoes. Proteins from both corn and E. coli were purified to homogeneity. These proteins were transferred to PVDF membrane (Millipore, MA) and subsequently probed with sera from patients with and without allergy to potatoes. A His-tagged glyphosate oxidase control was included in all the studies to verify that the His-tag did not affect the binding of IgE. Serum obtained from patient HS-07 (no allergy to potatoes) did not bind Pat17 expressed in E. coli but showed good binding to Pat17 from corn and also a protein at the same molecular weight in potato extract. It is interesting to note that this sera also showed strong binding to another protein (>46 kDa) in the potato. Sera from patients HS-01, HS—O2, HS-03, HS-05 (allergy to potatoes) shows strong binding to Pat17 expressed in corn, but very weak to no binding to Pat17 produced in E. coli. Also, the sera from patients HS-01, HS-2, HS-03 and HS-05 bound to a protein of similar molecular weight in the potato extract. Sera from patients HS-01, HS-02 and HS-03 also showed binding to another protein in potato extract of a lower molecular weight (<30 kDa). Serum obtained from patient HS-06 (allergic to potatoes) showed very strong binding to wild type patatin expressed in both corn and E. coli but weaker binding to the 5-Tyr variant expressed in E. coli. Sera from HS-06 also showed very strong binding to a protein in potato extract with similar molecular weight as patatin. The sera from all the patients showed no binding to His-tagged glyphosate oxidase indicating that the His-tag does not bind IgE. These results strongly suggest that the glycan moiety on Pat17 is responsible for IgE binding in some potato allergic patients and linear epitopes also contribute to the antigenicity of patatin.
  • Example 20 Alternative Nucleic Acid and Protein Sequences
  • [0281]
    For future variations of the patatin protein, sequences showing high similarity to the sequences disclosed herein could be used in producing deallergenized patatin proteins and permuteins. For example, a BLAST search (Altschul, S. F. et al., J. Mol. Biol. 215: 403-410, 1990) can be performed to identify additional patatin sequences. Sources other than those disclosed herein can be used to obtain a patatin nucleic acid sequence, and the encoded patatin protein. Furthermore, subunit sequences from different organisms can be combined to create a novel patatin sequence incorporating structural, regulatory, and enzymatic properties from different sources.
  • Example 21 Nucleic Acid Mutation and Hybridization
  • [0282]
    Variations in the nucleic acid sequence encoding a patatin protein may lead to mutant patatin protein sequences that display equivalent or superior enzymatic characteristics when compared to the sequences disclosed herein. This invention accordingly encompasses nucleic acid sequences which are similar to the sequences disclosed herein, protein sequences which are similar to the sequences disclosed herein, and the nucleic acid sequences that encode them. Mutations can include deletions, insertions, truncations, substitutions, fusions, shuffling of subunit sequences, and the like.
  • [0283]
    Mutations to a nucleic acid sequence can be introduced in either a specific or random manner, both of which are well known to those of skill in the art of molecular biology. A myriad of site-directed mutagenesis techniques exist, typically using oligonucleotides to introduce mutations at specific locations in a nucleic acid sequence. Examples include single strand rescue (Kunkel, T. Proc. Natl. Acad. Sci. U.S.A., 82: 488-492, 1985), unique site elimination (Deng and Nickloff, Anal. Biochem. 200: 81, 1992), nick protection (Vandeyar, et al. Gene 65: 129-133, 1988), and PCR (Costa, et al. Methods Mol. Biol. 57: 31-44, 1996). Random or non-specific mutations can be generated by chemical agents (for a general review, see Singer and Kusmierek, Ann. Rev. Biochem. 52: 655-693, 1982) such as nitrosoguanidine (Cerda-Olmedo et al., J. Mol. Biol. 33: 705-719, 1968; Guerola, et al. Nature New Biol. 230: 122-125, 1971) and 2-aminopurine (Rogan and Bessman, J. Bacteriol. 103: 622-633, 1970), or by biological methods such as passage through mutator strains (Greener et al. Mol. Biotechnol. 7: 189-195, 1997).
  • [0284]
    Nucleic acid hybridization is a technique well known to those of skill in the art of DNA manipulation. The hybridization properties of a given pair of nucleic acids is an indication of their similarity or identity. Mutated nucleic acid sequences can be selected for their similarity to the disclosed patatin nucleic acid sequences on the basis of their hybridization to the disclosed sequences. Low stringency conditions can be used to select sequences with multiple mutations. One may wish to employ conditions such as about 0.15 M to about 0.9 M sodium chloride, at temperatures ranging from about 20° C. to about 55° C. High stringency conditions can be used to select for nucleic acid sequences with higher degrees of identity to the disclosed sequences. Conditions employed may include about 0.02 M to about 0.15 M sodium chloride, about 0.5% to about 5% casein, about 0.02% SDS and/or about 0.1% N-laurylsarcosine, about 0.001 M to about 0.03 M sodium citrate, at temperatures between about 50° C. and about 70° C. More preferably, high stringency conditions are 0.02 M sodium chloride, 0.5% casein, 0.02% SDS, 0.001 M sodium citrate, at a temperature of 50° C.
  • Example 22 Determination of Homologous and Degenerate Nucleic Acid Sequences
  • [0285]
    Modification and changes can be made in the sequence of the proteins of the present invention and the nucleic acid segments which encode them and still obtain a functional molecule that encodes a protein with desirable properties. The following is a discussion based upon changing the amino acid sequence of a protein to create an equivalent, or possibly an improved, second-generation molecule. The amino acid changes can be achieved by changing the codons of the nucleic acid sequence, according to the codons given in Table 10.
    TABLE 10
    Codon degeneracies of amino acids
    Amino acid One letter Three Letter Codons
    Alanine A Ala GCA GCC GCG GCT
    Cysteine C Cys TGC TGT
    Aspartic acid D Asp GAC GAT
    Glutamic acid B Glu GAA GAG
    Phenylalanine F Phe TTC TTT
    Glycine G Gly GGA GGC GGG GGT
    Histidine H His CAC CAT
    Isoleucine I Ile ATA ATC ATT
    Lysine K Lys AAA AAG
    Leucine L Leu TTA TTG CTA CTC CTG
    CTT
    Methionine M Met ATG
    Asparagine N Asn AAC AAT
    Proline P Pro CCA CCC CCG CCT
    Glutamine Q Gln CAA CAG
    Arginine R Arg AGA AGG CGA CGC CGG
    CGT
    Serine S Ser AGC AGT TCA TCC TCG
    TCT
    Threonine T Thr ACA ACC ACG ACT
    Valine V Val GTA GTC GTG GTT
    Tryptophan W Trp TGG
    Tyrosine Y Tyr TAC TAT
  • [0286]
    Certain amino acids can be substituted for other amino acids in a protein sequence without appreciable loss of enzymatic activity. It is thus contemplated that various changes can be made in the peptide sequences of the disclosed protein sequences, or their corresponding nucleic acid sequences without appreciable loss of the biological activity.
  • [0287]
    In making such changes, the hydropathic index of amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, J. Mol. Biol., 157: 105-132, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.
  • [0288]
    Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics. These are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate/glutamine/aspartate/asparagine (−3.5); lysine (−3.9); and arginine (−4.5).
  • [0289]
    It is known in the art that certain amino acids can be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e., still obtain a biologically functional protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ±2 is preferred, those within ±1 are more preferred, and those within ±0.5 are most preferred.
  • [0290]
    It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101 (Hopp, T. P., issued Nov. 19, 1985) states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. The following hydrophilicity values have been assigned to amino acids: arginine/lysine (+3.0); aspartate/glutamate (+3.0±1); serine (+0.3); asparagine/glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5±1); alanine/histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine/isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); and tryptophan (−3.4).
  • [0291]
    It is understood that an amino acid can be substituted by another amino acid having a similar hydrophilicity score and still result in a protein with similar biological activity, i.e., still obtain a biologically functional protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ±2 is preferred, those within ±1 are more preferred, and those within ±0.5 are most preferred.
  • [0292]
    As outlined above, amino acid substitutions are therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine, and isoleucine. Changes which are not expected to be advantageous may also be used if these resulted in functional patatin proteins.
  • Example 23 Production of Patatin Proteins and Permuteins in Plants
  • [0293]
    Plant Vectors
  • [0294]
    In plants, transformation vectors capable of introducing nucleic acid sequences encoding patatin proteins and permuteins are easily designed, and generally contain one or more nucleic acid coding sequences of interest under the transcriptional control of 5′ and 3′ regulatory sequences. Such vectors generally comprise, operatively linked in sequence in the 5′ to 3′ direction, a promoter sequence that directs the transcription of a downstream heterologous structural nucleic acid sequence in a plant; optionally, a 5′ non-translated leader sequence; a nucleic acid sequence that encodes a protein of interest; and a 3′ non-translated region that encodes a polyadenylation signal which functions in plant cells to cause the termination of transcription and the addition of polyadenylate nucleotides to the 3′ end of the mRNA encoding the protein. Plant transformation vectors also generally contain a selectable marker. Typical 5′-3′ regulatory sequences include a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal. Vectors for plant transformation have been reviewed in Rodriguez et al. (Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston., 1988), Glick et al. (Methods in Plant Molecular Biology and Biotechnology, CRC Press, Boca Raton, Fla., 1993), and Croy (Plant Molecular Biology Labfax, Hames and Rickwood (Eds.), BIOS Scientific Publishers Limited, Oxford, UK., 1993).
  • [0295]
    Plant Promoters
  • [0296]
    Plant promoter sequences can be constitutive or inducible, environmentally- or developmentally-regulated, or cell- or tissue-specific. Often-used constitutive promoters include the CaMV 35S promoter (Odell, J. T. et al., Nature 313: 810-812, 1985), the enhanced CaMV 35S promoter, the Figwort Mosaic Virus (FMV) promoter (Richins et al., Nucleic Acids Res. 20: 8451-8466, 1987), the mannopine synthase (mas) promoter, the nopaline synthase (nos) promoter, and the octopine synthase (ocs) promoter. Useful inducible promoters include promoters induced by salicylic acid or polyacrylic acids (PR-1, Williams, S. W. et al, Biotechnology 10: 540-543, 1992), induced by application of safeners (substituted benzenesulfonamide herbicides, Hershey, H. P. and Stoner, T. D., Plant Mol. Biol. 17: 679-690, 1991), heat-shock promoters (Ou-Lee et al., Proc. Natl. Acad. Sci. U.S.A. 83: 6815-6819, 1986; Ainley et al., Plant Mol. Biol. 14: 949-967, 1990), a nitrate-inducible promoter derived from the spinach nitrite reductase gene (Back et al., Plant Mol. Biol. 17: 9-18, 1991), hormone-inducible promoters (Yamaguchi-Shinozaki, K. et al., Plant Mol. Biol. 15: 905-912, 1990; Kares et al., Plant Mol. Biol. 15: 225-236, 1990), and light-inducible promoters associated with the small subunit of RuBP carboxylase and LHCP gene families (Kuhlemeier et al., Plant Cell 1: 471, 1989; Feinbaum, R. L. et al., Mol. Gen. Genet. 226: 449-456, 1991; Weisshaar, B. et al., EMBO J. 10: 1777-1786, 1991; Lam, E. and Chua, N. H., J. Biol. Chem. 266: 17131-17135, 1990; Castresana, C. et al., EMBO J. 7: 1929-1936, 1988; Schulze-Lefert et al., EMBO J. 8: 651, 1989). Examples of useful tissue-specific, developmentally-regulated promoters include the β-conglycinin 7S promoter (Doyle, J. J. et al., J. Biol. Chem. 261: 9228-9238, 1986; Slighton and Beachy, Planta 172: 356-363, 1987), and seed-specific promoters (Knutzon, D. S. et al., Proc. Natl. Acad. Sci. U.S.A. 89: 2624-2628, 1992; Bustos, M. M. et al., EMBO J. 10: 1469-1479, 1991; Lam and Chua, Science 248: 471, 1991; Stayton et al., Aust. J Plant. Physiol. 18: 507, 1991). Plant functional promoters useful for preferential expression in seed plastids include those from plant storage protein genes and from genes involved in fatty acid biosynthesis in oilseeds. Examples of such promoters include the 5′ regulatory regions from such genes as napin (Kridl et al., Seed Sci. Res. 1: 209-219, 1991), phaseolin, zein, soybean trypsin inhibitor, ACP, stearoyl-ACP desaturase, and oleosin. Seed-specific gene regulation is discussed in EP 0 255 378. Promoter hybrids can also be constructed to enhance transcriptional activity (Comai, L. and Moran, P. M., U.S. Pat. No. 5,106,739, issued Apr. 21, 1992), or to combine desired transcriptional activity and tissue specificity.
  • [0297]
    Plant Transformation and Regeneration
  • [0298]
    A variety of different methods can be employed to introduce such vectors into plant protoplasts, cells, callus tissue, leaf discs, meristems, etcetera, to generate transgenic plants, including Agrobacterium-mediated transformation, particle gun delivery, microinjection, electroporation, polyethylene glycol mediated protoplast transformation, liposome-mediated transformation, etcetera (reviewed in Potrykus, I. Ann. Rev. Plant Physiol. Plant Mol. Biol. 42: 205-225, 1991). In general, transgenic plants comprising cells containing and expressing DNAs encoding patatin proteins and permuteins can be produced by transforming plant cells with a DNA construct as described above via any of the foregoing methods; selecting plant cells that have been transformed on a selective medium; regenerating plant cells that have been transformed to produce differentiated plants; and selecting a transformed plant which expresses the protein-encoding nucleotide sequence.
  • [0299]
    Specific methods for transforming a wide variety of dicots and obtaining transgenic plants are well documented in the literature (Gasser and Fraley, Science 244: 1293-1299, 1989; Fisk and Dandekar, Scientia Horticulturae 55: 5-36, 1993; Christou, Agro Food Industry Hi Tech, p. 17, 1994; and the references cited therein).
  • [0300]
    Successful transformation and plant regeneration have been reported in the monocots as follows: asparagus (Asparagus officinalis; Bytebier et al., Proc. Natl. Acad. Sci. U.S.A. 84: 5345-5349, 1987); barley (Hordeum vulgarae; Wan and Lemaux, Plant Physiol. 104: 37-48, 1994); maize (Zea mays; Rhodes, C. A. et al., Science 240: 204-207, 1988; Gordon-Kamm et al., Plant Cell 2: 603-618, 1990; Fromm, M. E. et al., Bio/Technology 8: 833-839, 1990; Koziel et al., Bio/Technology 11: 194-200, 1993); oats (Avena sativa; Somers et al., Bio/Technology 10: 1589-1594, 1992); orchardgrass (Dactylis glomerata; Horn et al., Plant Cell Rep. 7: 469-472, 1988); rice (Oryza sativa, including indica and japonica varieties; Toriyama et al., Bio/Technology 6: 10, 1988; Zhang et al., Plant Cell Rep. 7: 379-384, 1988; Luo and Wu, Plant Mol. Biol. Rep. 6: 165-174, 1988; Zhang and Wu, Theor. Appl. Genet. 76: 835-840, 1988; Christou et al., Bio/Technology 9: 957-962, 1991); rye (Secale cereale; De la Pena et al., Nature 325: 274-276, 1987); sorghum (Sorghum bicolor; Casas, A. M. et al., Proc. Natl. Acad. Sci. U.S.A. 90: 11212-11216, 1993); sugar cane (Saccharum spp.; Bower and Birch, Plant J. 2: 409-416, 1992); tall fescue (Festuca arundinacea; Wang, Z. Y. et al., Bio/Technology 10: 691-696, 1992); turfgrass (Agrostis palustris; Zhong et al., Plant Cell Rep. 13: 1-6, 1993); wheat (Triticum aestivum; Vasil et al., Bio/Technology 10: 667-674, 1992; Weeks, T. et al., Plant Physiol. 102: 1077-1084, 1993; Becker et al., Plant J. 5: 299-307, 1994), and alfalfa (Masoud, S. A. et al., Transgen. Res. 5: 313, 1996); Brassica (canola/oilseed rape) (Fry, J. Plant Cell Rep. 6: 321-325, 1987); and soybean (Hinchee, M. Bio/Technol. 6: 915-922, 1988).
  • [0301]
    All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations can be applied to the compositions and/or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related can be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.
  • 1 293 1 1158 DNA Solanum tuberosum 1 atggcaacta ctaaatcttt tttaatttta atatttatga tattagcaac tactagttca 60 acatttgctc agttgggaga aatggtgact gttcttagta ttgatggagg tggaattaga 120 gggatcattc cggctaccat tctcgaattt cttgaaggac aacttcagga aatggacaat 180 aatgcagatg caagacttgc agattacttt gatgtaattg gaggaacaag tacaggaggt 240 ttattgactg ctatgataag tactccaaat gaaaacaatc gaccctttgc tgctgccaaa 300 gaaattgtac ctttttactt cgaacatggc cctcagattt ttaatcctag tggtcaaatt 360 ttaggcccaa aatatgatgg aaaatatctt atgcaagttc ttcaagaaaa acttggagaa 420 actcgtgtgc atcaagcttt gacagaagtt gtcatctcaa gctttgacat caaaacaaat 480 aagccagtaa tattcactaa gtcaaattta gcaaactctc cagaattgga tgctaagatg 540 tatgacataa gttattccac agcagcagct ccaacatatt ttcctccgca ttactttgtt 600 actaatacta gtaatggaga tgaatatgag ttcaatcttg ttgatggtgc tgttgctact 660 gttgctgatc cggcgttatt atccattagc gttgcaacga gacttgcaca aaaggatcca 720 gcatttgctt caattaggtc attgaattac aaaaaaatgc tgttgctctc attaggcact 780 ggcactactt cagagtttga taaaacatat acagcaaaag aggcagctac ctggactgct 840 gtacattgga tgttagttat acagaaaatg actgatgcag caagttctta catgactgat 900 tattaccttt ctactgcttt tcaagctctt gattcaaaaa acaattacct cagggttcaa 960 gaaaatgcat taacaggcac aactactgaa atggatgatg cttctgaggc taatatggaa 1020 ttattagtac aagttggtga aaacttattg aagaaaccag tttccgaaga caatcctgaa 1080 acctatgagg aagctctaaa gaggtttgca aaattgctct ctgataggaa gaaactccga 1140 gcaaacaaag cttcttat 1158 2 386 PRT Solanum tuberosum 2 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Ile Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Phe Ala Gln Leu Gly Glu Met Val Thr Val Leu 20 25 30 Ser Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr Ile Leu 35 40 45 Glu Phe Leu Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala Asp Ala 50 55 60 Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly 65 70 75 80 Leu Leu Thr Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg Pro Phe 85 90 95 Ala Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly Pro Gln 100 105 110 Ile Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp Gly Lys 115 120 125 Tyr Leu Met Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His 130 135 140 Gln Ala Leu Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys Thr Asn 145 150 155 160 Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro Glu Leu 165 170 175 Asp Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala Pro Thr 180 185 190 Tyr Phe Pro Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly Asp Glu 195 200 205 Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro 210 215 220 Ala Leu Leu Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys Asp Pro 225 230 235 240 Ala Phe Ala Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu 245 250 255 Ser Leu Gly Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr Thr Ala 260 265 270 Lys Glu Ala Ala Thr Trp Thr Ala Val His Trp Met Leu Val Ile Gln 275 280 285 Lys Met Thr Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser 290 295 300 Thr Ala Phe Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln 305 310 315 320 Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu 325 330 335 Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu Lys Lys 340 345 350 Pro Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg 355 360 365 Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala 370 375 380 Ser Tyr 385 3 54 DNA Artificial Sequence Synthetic construct 3 ggagctcgag aaaagagagg ctgaagctca gttgggagaa atggtgactg ttct 54 4 29 DNA Artificial Sequence Synthetic construct 4 ggtctagagg aattctcatt aataagaag 29 5 1138 DNA Artificial Sequence Synthetic construct 5 ggagctcgag aaaagagagg ctgaagctca gttgggagaa atggtgactg ttcttagtat 60 tgatggaggt ggaattagag ggatcattcc ggctaccatt ctcgaatttc ttgaaggaca 120 acttcaggaa atggacaata atgcagatgc aagacttgca gattactttg atgtaattgg 180 aggaacaagt acaggaggtt tattgactgc tatgataagt actccaaatg aaaacaatcg 240 accctttgct gctgccaaag aaattgtacc tttttacttc gaacatggcc ctcagatttt 300 taatcctagt ggtcaaattt taggcccaaa atatgatgga aaatatctta tgcaagttct 360 tcaagaaaaa cttggagaaa ctcgtgtgca tcaagctttg acagaagttg tcatctcaag 420 ctttgacatc aaaacaaata agccagtaat attcactaag tcaaatttag caaactctcc 480 agaattggat gctaagatgt atgacataag ttattccaca gcagcagctc caacatattt 540 tcctccgcat tactttgtta ctaatactag taatggagat gaatatgagt tcaatcttgt 600 tgatggtgct gttgctactg ttgctgatcc ggcgttatta tccattagcg ttgcaacgag 660 acttgcacaa aaggatccag catttgcttc aattaggtca ttgaattaca aaaaaatgct 720 gttgctctca ttaggcactg gcactacttc agagtttgat aaaacatata cagcaaaaga 780 ggcagctacc tggactgctg tacattggat gttagttata cagaaaatga ctgatgcagc 840 aagttcttac atgactgatt attacctttc tactgctttt caagctcttg attcaaaaaa 900 caattacctc agggttcaag aaaatgcatt aacaggcaca actactgaaa tggatgatgc 960 ttctgaggct aatatggaat tattagtaca agttggtgaa aacttattga agaaaccagt 1020 ttccgaagac aatcctgaaa cctatgagga agctctaaag aggtttgcaa aattgctctc 1080 tgataggaag aaactccgag caaacaaagc ttcttattaa tgagaattcc tctagacc 1138 6 452 PRT Artificial Sequence Synthetic polypeptide 6 Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser 1 5 10 15 Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln 20 25 30 Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe 35 40 45 Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu 50 55 60 Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val 65 70 75 80 Ser Leu Glu Lys Arg Glu Ala Glu Ala Gln Leu Gly Glu Met Val Thr 85 90 95 Val Leu Ser Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr 100 105 110 Ile Leu Glu Phe Leu Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala 115 120 125 Asp Ala Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr 130 135 140 Gly Gly Leu Leu Thr Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg 145 150 155 160 Pro Phe Ala Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly 165 170 175 Pro Gln Ile Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp 180 185 190 Gly Lys Tyr Leu Met Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg 195 200 205 Val His Gln Ala Leu Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys 210 215 220 Thr Asn Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro 225 230 235 240 Glu Leu Asp Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala 245 250 255 Pro Thr Tyr Phe Pro Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly 260 265 270 Asp Glu Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala 275 280 285 Asp Pro Ala Leu Leu Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys 290 295 300 Asp Pro Ala Phe Ala Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu 305 310 315 320 Leu Leu Ser Leu Gly Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr 325 330 335 Thr Ala Lys Glu Ala Ala Thr Trp Thr Ala Val His Trp Met Leu Val 340 345 350 Ile Gln Lys Met Thr Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr 355 360 365 Leu Ser Thr Ala Phe Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg 370 375 380 Val Gln Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala 385 390 395 400 Ser Glu Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu 405 410 415 Lys Lys Pro Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu 420 425 430 Lys Arg Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn 435 440 445 Lys Ala Ser Tyr 450 7 367 PRT Artificial Sequence Synthetic polypeptide 7 Glu Ala Glu Ala Gln Leu Gly Glu Met Val Thr Val Leu Ser Ile Asp 1 5 10 15 Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr Ile Leu Glu Phe Leu 20 25 30 Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala Asp Ala Arg Leu Ala 35 40 45 Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr 50 55 60 Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala 65 70 75 80 Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly Pro Gln Ile Phe Asn 85 90 95 Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp Gly Lys Tyr Leu Met 100 105 110 Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His Gln Ala Leu 115 120 125 Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys Pro Val 130 135 140 Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro Glu Leu Asp Ala Lys 145 150 155 160 Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro 165 170 175 Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly Asp Glu Tyr Glu Phe 180 185 190 Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro Ala Leu Leu 195 200 205 Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys Asp Pro Ala Phe Ala 210 215 220 Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly 225 230 235 240 Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr Thr Ala Lys Glu Ala 245 250 255 Ala Thr Trp Thr Ala Val His Trp Met Leu Val Ile Gln Lys Met Thr 260 265 270 Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr Ala Phe 275 280 285 Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala 290 295 300 Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu Ala Asn Met 305 310 315 320 Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu Lys Lys Pro Val Ser 325 330 335 Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys 340 345 350 Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser Tyr 355 360 365 8 24 DNA Artificial Sequence Synthetic construct 8 atgttcgaag aaaaaaggta caat 24 9 24 DNA Artificial Sequence Synthetic construct 9 ttgcataaga aattttccat cata 24 10 24 DNA Artificial Sequence Synthetic construct 10 tgctgtggaa aaacttatgt cata 24 11 24 DNA Artificial Sequence Synthetic construct 11 cggaggaaaa aatgttggag ctgc 24 12 51 DNA Artificial Sequence Synthetic construct 12 atgcggagga aaaaatgttg gagctgctgc tgtggaaaaa cttatgtcat a 51 13 24 DNA Artificial Sequence Synthetic construct 13 ttttgctgta aatgttttat caaa 24 14 24 DNA Artificial Sequence Synthetic construct 14 aaccctgagg aaattgtttt ttga 24 15 24 DNA Artificial Sequence Synthetic construct 15 agcttcctca aaggtttcag gatt 24 16 10 PRT Artificial Sequence Synthetic polypeptide 16 Gln Leu Gly Glu Met Val Thr Val Leu Ser 1 5 10 17 10 PRT Artificial Sequence Synthetic polypeptide 17 Met Val Thr Val Leu Ser Ile Asp Gly Gly 1 5 10 18 10 PRT Artificial Sequence Synthetic polypeptide 18 Leu Ser Ile Asp Gly Gly Gly Ile Arg Gly 1 5 10 19 10 PRT Artificial Sequence Synthetic polypeptide 19 Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala 1 5 10 20 10 PRT Artificial Sequence Synthetic polypeptide 20 Arg Gly Ile Ile Pro Ala Thr Ile Leu Glu 1 5 10 21 10 PRT Artificial Sequence Synthetic polypeptide 21 Pro Ala Thr Ile Leu Glu Phe Leu Glu Gly 1 5 10 22 10 PRT Artificial Sequence Synthetic polypeptide 22 Leu Glu Phe Leu Glu Gly Gln Leu Gln Glu 1 5 10 23 10 PRT Artificial Sequence Synthetic polypeptide 23 Glu Gly Gln Leu Gln Glu Met Asp Asn Asn 1 5 10 24 10 PRT Artificial Sequence Synthetic polypeptide 24 Gln Glu Met Asp Asn Asn Ala Asp Ala Arg 1 5 10 25 10 PRT Artificial Sequence Synthetic polypeptide 25 Asn Asn Ala Asp Ala Arg Leu Ala Asp Tyr 1 5 10 26 10 PRT Artificial Sequence Synthetic polypeptide 26 Ala Arg Leu Ala Asp Tyr Phe Asp Val Ile 1 5 10 27 10 PRT Artificial Sequence Synthetic polypeptide 27 Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser 1 5 10 28 10 PRT Artificial Sequence Synthetic polypeptide 28 Val Ile Gly Gly Thr Ser Thr Gly Gly Leu 1 5 10 29 10 PRT Artificial Sequence Synthetic polypeptide 29 Thr Ser Thr Gly Gly Leu Leu Thr Ala Met 1 5 10 30 10 PRT Artificial Sequence Synthetic polypeptide 30 Gly Leu Leu Thr Ala Met Ile Ser Thr Pro 1 5 10 31 10 PRT Artificial Sequence Synthetic polypeptide 31 Ala Met Ile Ser Thr Pro Asn Glu Asn Asn 1 5 10 32 10 PRT Artificial Sequence Synthetic polypeptide 32 Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala 1 5 10 33 10 PRT Artificial Sequence Synthetic polypeptide 33 Asn Asn Arg Pro Phe Ala Ala Ala Lys Glu 1 5 10 34 10 PRT Artificial Sequence Synthetic polypeptide 34 Phe Ala Ala Ala Lys Glu Ile Val Pro Phe 1 5 10 35 10 PRT Artificial Sequence Synthetic polypeptide 35 Lys Glu Ile Val Pro Phe Tyr Phe Glu His 1 5 10 36 10 PRT Artificial Sequence Synthetic polypeptide 36 Pro Phe Tyr Phe Glu His Gly Pro Gln Ile 1 5 10 37 10 PRT Artificial Sequence Synthetic polypeptide 37 Glu His Gly Pro Gln Ile Phe Asn Pro Ser 1 5 10 38 10 PRT Artificial Sequence Synthetic polypeptide 38 Gln Ile Phe Asn Pro Ser Gly Gln Ile Leu 1 5 10 39 10 PRT Artificial Sequence Synthetic polypeptide 39 Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr 1 5 10 40 10 PRT Artificial Sequence Synthetic polypeptide 40 Ile Leu Gly Pro Lys Tyr Asp Gly Lys Tyr 1 5 10 41 10 PRT Artificial Sequence Synthetic polypeptide 41 Lys Tyr Asp Gly Lys Tyr Leu Met Gln Val 1 5 10 42 10 PRT Artificial Sequence Synthetic polypeptide 42 Lys Tyr Leu Met Gln Val Leu Gln Glu Lys 1 5 10 43 10 PRT Artificial Sequence Synthetic polypeptide 43 Gln Val Leu Gln Glu Lys Leu Gly Glu Thr 1 5 10 44 10 PRT Artificial Sequence Synthetic polypeptide 44 Glu Lys Leu Gly Glu Thr Arg Val His Gln 1 5 10 45 10 PRT Artificial Sequence Synthetic polypeptide 45 Glu Thr Arg Val His Gln Ala Leu Thr Glu 1 5 10 46 10 PRT Artificial Sequence Synthetic polypeptide 46 His Gln Ala Leu Thr Glu Val Val Ile Ser 1 5 10 47 10 PRT Artificial Sequence Synthetic polypeptide 47 Thr Glu Val Val Ile Ser Ser Phe Asp Ile 1 5 10 48 10 PRT Artificial Sequence Synthetic polypeptide 48 Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys 1 5 10 49 10 PRT Artificial Sequence Synthetic polypeptide 49 Asp Ile Lys Thr Asn Lys Pro Val Ile Phe 1 5 10 50 10 PRT Artificial Sequence Synthetic polypeptide 50 Asn Lys Pro Val Ile Phe Thr Lys Ser Asn 1 5 10 51 10 PRT Artificial Sequence Synthetic polypeptide 51 Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser 1 5 10 52 10 PRT Artificial Sequence Synthetic polypeptide 52 Ser Asn Leu Ala Asn Ser Pro Glu Leu Asp 1 5 10 53 10 PRT Artificial Sequence Synthetic polypeptide 53 Asn Ser Pro Glu Leu Asp Ala Lys Met Tyr 1 5 10 54 10 PRT Artificial Sequence Synthetic polypeptide 54 Leu Asp Ala Lys Met Tyr Asp Ile Ser Tyr 1 5 10 55 10 PRT Artificial Sequence Synthetic polypeptide 55 Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala 1 5 10 56 10 PRT Artificial Sequence Synthetic polypeptide 56 Ser Tyr Ser Thr Ala Ala Ala Pro Thr Tyr 1 5 10 57 10 PRT Artificial Sequence Synthetic polypeptide 57 Ala Ala Ala Pro Thr Tyr Phe Pro Pro His 1 5 10 58 10 PRT Artificial Sequence Synthetic polypeptide 58 Thr Tyr Phe Pro Pro His Tyr Phe Val Thr 1 5 10 59 10 PRT Artificial Sequence Synthetic polypeptide 59 Pro His Tyr Phe Val Thr Asn Thr Ser Asn 1 5 10 60 10 PRT Artificial Sequence Synthetic polypeptide 60 Val Thr Asn Thr Ser Asn Gly Asp Glu Tyr 1 5 10 61 10 PRT Artificial Sequence Synthetic polypeptide 61 Ser Asn Gly Asp Glu Tyr Glu Phe Asn Leu 1 5 10 62 10 PRT Artificial Sequence Synthetic polypeptide 62 Glu Tyr Glu Phe Asn Leu Val Asp Gly Ala 1 5 10 63 10 PRT Artificial Sequence Synthetic polypeptide 63 Asn Leu Val Asp Gly Ala Val Ala Thr Val 1 5 10 64 10 PRT Artificial Sequence Synthetic polypeptide 64 Gly Ala Val Ala Thr Val Ala Asp Pro Ala 1 5 10 65 10 PRT Artificial Sequence Synthetic polypeptide 65 Thr Val Ala Asp Pro Ala Leu Leu Ser Ile 1 5 10 66 10 PRT Artificial Sequence Synthetic polypeptide 66 Pro Ala Leu Leu Ser Ile Ser Val Ala Thr 1 5 10 67 10 PRT Artificial Sequence Synthetic polypeptide 67 Ser Ile Ser Val Ala Thr Arg Leu Ala Gln 1 5 10 68 10 PRT Artificial Sequence Synthetic polypeptide 68 Ala Thr Arg Leu Ala Gln Lys Asp Pro Ala 1 5 10 69 10 PRT Artificial Sequence Synthetic polypeptide 69 Ala Gln Lys Asp Pro Ala Phe Ala Ser Ile 1 5 10 70 10 PRT Artificial Sequence Synthetic polypeptide 70 Pro Ala Phe Ala Ser Ile Arg Ser Leu Asn 1 5 10 71 10 PRT Artificial Sequence Synthetic polypeptide 71 Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met 1 5 10 72 10 PRT Artificial Sequence Synthetic polypeptide 72 Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser 1 5 10 73 10 PRT Artificial Sequence Synthetic polypeptide 73 Lys Met Leu Leu Leu Ser Leu Gly Thr Gly 1 5 10 74 10 PRT Artificial Sequence Synthetic polypeptide 74 Leu Ser Leu Gly Thr Gly Thr Thr Ser Glu 1 5 10 75 10 PRT Artificial Sequence Synthetic polypeptide 75 Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr 1 5 10 76 10 PRT Artificial Sequence Synthetic polypeptide 76 Ser Glu Phe Asp Lys Thr Tyr Thr Ala Lys 1 5 10 77 10 PRT Artificial Sequence Synthetic polypeptide 77 Lys Thr Tyr Thr Ala Lys Glu Ala Ala Thr 1 5 10 78 10 PRT Artificial Sequence Synthetic polypeptide 78 Ala Lys Glu Ala Ala Thr Trp Thr Ala Val 1 5 10 79 10 PRT Artificial Sequence Synthetic polypeptide 79 Ala Thr Trp Thr Ala Val His Trp Met Leu 1 5 10 80 10 PRT Artificial Sequence Synthetic polypeptide 80 Ala Val His Trp Met Leu Val Ile Gln Lys 1 5 10 81 10 PRT Artificial Sequence Synthetic polypeptide 81 Met Leu Val Ile Gln Lys Met Thr Asp Ala 1 5 10 82 10 PRT Artificial Sequence Synthetic polypeptide 82 Gln Lys Met Thr Asp Tyr Tyr Leu Ser Thr 1 5 10 83 10 PRT Artificial Sequence Synthetic polypeptide 83 Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr 1 5 10 84 10 PRT Artificial Sequence Synthetic polypeptide 84 Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr 1 5 10 85 10 PRT Artificial Sequence Synthetic polypeptide 85 Asp Tyr Tyr Leu Ser Thr Ala Phe Gln Ala 1 5 10 86 10 PRT Artificial Sequence Synthetic polypeptide 86 Ser Thr Ala Phe Gln Ala Leu Asp Ser Lys 1 5 10 87 10 PRT Artificial Sequence Synthetic polypeptide 87 Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu 1 5 10 88 10 PRT Artificial Sequence Synthetic polypeptide 88 Ser Lys Asn Asn Tyr Leu Arg Val Gln Glu 1 5 10 89 10 PRT Artificial Sequence Synthetic polypeptide 89 Tyr Leu Arg Val Gln Glu Asn Ala Leu Thr 1 5 10 90 10 PRT Artificial Sequence Synthetic polypeptide 90 Gln Glu Asn Ala Leu Thr Gly Thr Thr Thr 1 5 10 91 10 PRT Artificial Sequence Synthetic polypeptide 91 Leu Thr Gly Thr Thr Thr Glu Met Asp Asp 1 5 10 92 10 PRT Artificial Sequence Synthetic polypeptide 92 Thr Thr Glu Met Asp Asp Ala Ser Glu Ala 1 5 10 93 10 PRT Artificial Sequence Synthetic polypeptide 93 Asp Asp Ala Ser Glu Ala Asn Met Glu Leu 1 5 10 94 10 PRT Artificial Sequence Synthetic polypeptide 94 Glu Ala Asn Met Glu Leu Leu Val Gln Val 1 5 10 95 10 PRT Artificial Sequence Synthetic polypeptide 95 Glu Leu Leu Val Gln Val Gly Glu Asn Leu 1 5 10 96 10 PRT Artificial Sequence Synthetic polypeptide 96 Gln Val Gly Glu Asn Leu Leu Lys Lys Pro 1 5 10 97 10 PRT Artificial Sequence Synthetic polypeptide 97 Asn Leu Leu Lys Lys Pro Val Ser Glu Asp 1 5 10 98 10 PRT Artificial Sequence Synthetic polypeptide 98 Lys Pro Val Ser Glu Asp Asn Pro Glu Thr 1 5 10 99 10 PRT Artificial Sequence Synthetic polypeptide 99 Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala 1 5 10 100 10 PRT Artificial Sequence Synthetic polypeptide 100 Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe 1 5 10 101 10 PRT Artificial Sequence Synthetic polypeptide 101 Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu 1 5 10 102 10 PRT Artificial Sequence Synthetic polypeptide 102 Arg Phe Ala Lys Leu Leu Ser Asp Arg Lys 1 5 10 103 10 PRT Artificial Sequence Synthetic polypeptide 103 Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala 1 5 10 104 10 PRT Artificial Sequence Synthetic polypeptide 104 Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser 1 5 10 105 10 PRT Artificial Sequence Synthetic polypeptide 105 Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser 1 5 10 106 10 PRT Artificial Sequence Synthetic polypeptide 106 Asp Tyr Phe Asp Val Ile Ala Gly Thr Ser 1 5 10 107 10 PRT Artificial Sequence Synthetic polypeptide 107 Val Ile Gly Gly Thr Ser Thr Gly Gly Leu 1 5 10 108 10 PRT Artificial Sequence Synthetic polypeptide 108 Val Ile Ala Gly Thr Ser Thr Gly Ala Leu 1 5 10 109 10 PRT Artificial Sequence Synthetic polypeptide 109 Ala Phe Tyr Phe Glu His Gly Pro Gln Ile 1 5 10 110 10 PRT Artificial Sequence Synthetic polypeptide 110 Pro Ala Tyr Phe Glu His Gly Pro Gln Ile 1 5 10 111 10 PRT Artificial Sequence Synthetic polypeptide 111 Pro Phe Ala Phe Glu His Gly Pro Gln Ile 1 5 10 112 10 PRT Artificial Sequence Synthetic polypeptide 112 Pro Phe Tyr Ala Glu His Gly Pro Gln Ile 1 5 10 113 10 PRT Artificial Sequence Synthetic polypeptide 113 Pro Phe Tyr Phe Ala His Gly Pro Gln Ile 1 5 10 114 10 PRT Artificial Sequence Synthetic polypeptide 114 Pro Phe Tyr Phe Glu Ala Gly Pro Gln Ile 1 5 10 115 10 PRT Artificial Sequence Synthetic polypeptide 115 Pro Phe Tyr Phe Glu His Ala Pro Gln Ile 1 5 10 116 10 PRT Artificial Sequence Synthetic polypeptide 116 Pro Phe Tyr Phe Glu His Gly Ala Gln Ile 1 5 10 117 10 PRT Artificial Sequence Synthetic polypeptide 117 Pro Phe Tyr Phe Glu His Gly Pro Ala Ile 1 5 10 118 10 PRT Artificial Sequence Synthetic polypeptide 118 Pro Phe Tyr Phe Glu His Gly Pro Gln Ala 1 5 10 119 10 PRT Artificial Sequence Synthetic polypeptide 119 Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile 1 5 10 120 10 PRT Artificial Sequence Synthetic polypeptide 120 Pro Phe Phe Phe Glu His Gly Pro Gln Ile 1 5 10 121 10 PRT Artificial Sequence Synthetic polypeptide 121 Ala Tyr Leu Met Gln Val Leu Gln Glu Lys 1 5 10 122 10 PRT Artificial Sequence Synthetic polypeptide 122 Lys Ala Leu Met Gln Val Leu Gln Glu Lys 1 5 10 123 10 PRT Artificial Sequence Synthetic polypeptide 123 Lys Tyr Ala Met Gln Val Leu Gln Glu Lys 1 5 10 124 10 PRT Artificial Sequence Synthetic polypeptide 124 Lys Tyr Leu Ala Gln Val Leu Gln Glu Lys 1 5 10 125 10 PRT Artificial Sequence Synthetic polypeptide 125 Lys Tyr Leu Met Ala Val Leu Gln Glu Lys 1 5 10 126 10 PRT Artificial Sequence Synthetic polypeptide 126 Lys Tyr Leu Met Gln Ala Leu Gln Glu Lys 1 5 10 127 10 PRT Artificial Sequence Synthetic polypeptide 127 Lys Tyr Leu Met Gln Val Ala Gln Glu Lys 1 5 10 128 10 PRT Artificial Sequence Synthetic polypeptide 128 Lys Tyr Leu Met Gln Val Leu Ala Glu Lys 1 5 10 129 10 PRT Artificial Sequence Synthetic polypeptide 129 Lys Tyr Leu Met Gln Val Leu Gln Ala Lys 1 5 10 130 10 PRT Artificial Sequence Synthetic polypeptide 130 Lys Tyr Leu Met Gln Val Leu Gln Glu Ala 1 5 10 131 10 PRT Artificial Sequence Synthetic polypeptide 131 Val Phe Leu His Asp Lys Ile Lys Ser Leu 1 5 10 132 10 PRT Artificial Sequence Synthetic polypeptide 132 Ala Tyr Ser Thr Ala Ala Ala Pro Thr Tyr 1 5 10 133 10 PRT Artificial Sequence Synthetic polypeptide 133 Ser Ala Ser Thr Ala Ala Ala Pro Thr Tyr 1 5 10 134 10 PRT Artificial Sequence Synthetic polypeptide 134 Ser Tyr Ala Thr Ala Ala Ala Pro Thr Tyr 1 5 10 135 10 PRT Artificial Sequence Synthetic polypeptide 135 Ser Tyr Ser Ala Ala Ala Ala Pro Thr Tyr 1 5 10 136 10 PRT Artificial Sequence Synthetic polypeptide 136 Ser Tyr Ser Thr Ala Ala Ala Ala Thr Tyr 1 5 10 137 10 PRT Artificial Sequence Synthetic polypeptide 137 Ser Tyr Ser Thr Ala Ala Ala Pro Ala Tyr 1 5 10 138 10 PRT Artificial Sequence Synthetic polypeptide 138 Ser Tyr Ser Thr Ala Ala Ala Pro Thr Ala 1 5 10 139 10 PRT Artificial Sequence Synthetic polypeptide 139 Cys Ile Ser Thr Ser Ala Ala Pro Thr Tyr 1 5 10 140 10 PRT Artificial Sequence Synthetic polypeptide 140 Ser Tyr Ser Thr Ala Ala Ala Pro Ala Phe 1 5 10 141 10 PRT Artificial Sequence Synthetic polypeptide 141 Ala Phe Ala Ala Ala Ala Ala Pro Thr Tyr 1 5 10 142 10 PRT Artificial Sequence Synthetic polypeptide 142 Ser Tyr Ser Thr Ala Ala Ala Pro Thr Phe 1 5 10 143 10 PRT Artificial Sequence Synthetic polypeptide 143 Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro 1 5 10 144 10 PRT Artificial Sequence Synthetic polypeptide 144 Ser Thr Ser Ala Ala Pro Thr Phe Phe Pro 1 5 10 145 10 PRT Artificial Sequence Synthetic polypeptide 145 Ser Thr Ser Ala Ala Pro Thr Ala Phe Pro 1 5 10 146 10 PRT Artificial Sequence Synthetic polypeptide 146 Ser Thr Ala Ala Ala Pro Thr Phe Phe Pro 1 5 10 147 10 PRT Artificial Sequence Synthetic polypeptide 147 Ala Ala Ala Ala Thr Tyr Phe Pro Pro His 1 5 10 148 10 PRT Artificial Sequence Synthetic polypeptide 148 Ala Ala Ala Pro Ala Tyr Phe Pro Pro His 1 5 10 149 10 PRT Artificial Sequence Synthetic polypeptide 149 Ala Ala Ala Pro Thr Ala Phe Pro Pro His 1 5 10 150 10 PRT Artificial Sequence Synthetic polypeptide 150 Ala Ala Ala Pro Thr Tyr Ala Pro Pro His 1 5 10 151 10 PRT Artificial Sequence Synthetic polypeptide 151 Ala Ala Ala Pro Thr Tyr Phe Ala Pro His 1 5 10 152 10 PRT Artificial Sequence Synthetic polypeptide 152 Ala Ala Ala Pro Thr Tyr Phe Pro Ala His 1 5 10 153 10 PRT Artificial Sequence Synthetic polypeptide 153 Ala Ala Ala Pro Thr Tyr Phe Pro Pro Ala 1 5 10 154 10 PRT Artificial Sequence Synthetic polypeptide 154 Ser Ala Ala Pro Thr Tyr Phe Pro Ala His 1 5 10 155 10 PRT Artificial Sequence Synthetic polypeptide 155 Ala Ala Ala Pro Ala Phe Phe Pro Pro His 1 5 10 156 10 PRT Artificial Sequence Synthetic polypeptide 156 Ala Ala Ala Pro Pro Phe Phe Pro Pro His 1 5 10 157 10 PRT Artificial Sequence Synthetic polypeptide 157 Ala Ala Ala Pro Thr Phe Phe Pro Pro His 1 5 10 158 10 PRT Artificial Sequence Synthetic polypeptide 158 Ser Ile Ser Val Ala Thr Arg Leu Ala Gln 1 5 10 159 10 PRT Artificial Sequence Synthetic polypeptide 159 Ala Met Ser Met Leu Thr Lys Glu Val His 1 5 10 160 10 PRT Artificial Sequence Synthetic polypeptide 160 Pro Ala Phe Ala Ser Ile Arg Ser Leu Asn 1 5 10 161 10 PRT Artificial Sequence Synthetic polypeptide 161 Pro Asn Phe Asn Ala Gly Ser Pro Thr Glu 1 5 10 162 10 PRT Artificial Sequence Synthetic polypeptide 162 Lys Met Leu Leu Leu Ser Leu Gly Thr Gly 1 5 10 163 10 PRT Artificial Sequence Synthetic polypeptide 163 Asn Tyr Leu Ile Ile Ser Val Gly Thr Gly 1 5 10 164 10 PRT Artificial Sequence Synthetic polypeptide 164 Lys Met Leu Leu Leu Ser Leu Gly Ala Gly 1 5 10 165 10 PRT Artificial Sequence Synthetic polypeptide 165 Ala Glu Phe Asp Lys Thr Tyr Thr Ala Lys 1 5 10 166 10 PRT Artificial Sequence Synthetic polypeptide 166 Ser Ala Phe Asp Lys Thr Tyr Thr Ala Lys 1 5 10 167 10 PRT Artificial Sequence Synthetic polypeptide 167 Ser Glu Ala Asp Lys Thr Tyr Thr Ala Lys 1 5 10 168 10 PRT Artificial Sequence Synthetic polypeptide 168 Ser Glu Phe Ala Lys Thr Tyr Thr Ala Lys 1 5 10 169 10 PRT Artificial Sequence Synthetic polypeptide 169 Ser Glu Phe Asp Ala Thr Tyr Thr Ala Lys 1 5 10 170 10 PRT Artificial Sequence Synthetic polypeptide 170 Ser Glu Phe Asp Lys Ala Tyr Thr Ala Lys 1 5 10 171 10 PRT Artificial Sequence Synthetic polypeptide 171 Ser Glu Phe Asp Lys Thr Ala Thr Ala Lys 1 5 10 172 10 PRT Artificial Sequence Synthetic polypeptide 172 Ser Glu Phe Asp Lys Thr Tyr Ala Ala Lys 1 5 10 173 10 PRT Artificial Sequence Synthetic polypeptide 173 Ser Glu Phe Asp Lys Thr Tyr Thr Ala Ala 1 5 10 174 10 PRT Artificial Sequence Synthetic polypeptide 174 Lys Gln Ala Glu Lys Tyr Thr Ala Glu Gln 1 5 10 175 10 PRT Artificial Sequence Synthetic polypeptide 175 Ser Glu Phe Asp Ala Ala Phe Ala Ala Ala 1 5 10 176 10 PRT Artificial Sequence Synthetic polypeptide 176 Ser Glu Phe Asp Lys Thr Phe Thr Ala Lys 1 5 10 177 10 PRT Artificial Sequence Synthetic polypeptide 177 Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala 1 5 10 178 10 PRT Artificial Sequence Synthetic polypeptide 178 Ala Thr Tyr Thr Ala Lys Glu Ala Ala Thr 1 5 10 179 10 PRT Artificial Sequence Synthetic polypeptide 179 Lys Ala Tyr Thr Ala Lys Glu Ala Ala Thr 1 5 10 180 10 PRT Artificial Sequence Synthetic polypeptide 180 Lys Thr Ala Thr Ala Lys Glu Ala Ala Thr 1 5 10 181 10 PRT Artificial Sequence Synthetic polypeptide 181 Lys Thr Tyr Ala Ala Lys Glu Ala Ala Thr 1 5 10 182 10 PRT Artificial Sequence Synthetic polypeptide 182 Lys Thr Tyr Thr Ala Ala Glu Ala Ala Thr 1 5 10 183 10 PRT Artificial Sequence Synthetic polypeptide 183 Lys Thr Tyr Thr Ala Lys Ala Ala Ala Thr 1 5 10 184 10 PRT Artificial Sequence Synthetic polypeptide 184 Lys Thr Tyr Thr Ala Lys Glu Ala Ala Ala 1 5 10 185 10 PRT Artificial Sequence Synthetic polypeptide 185 Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys 1 5 10 186 10 PRT Artificial Sequence Synthetic polypeptide 186 Ala Ala Phe Ala Ala Ala Glu Ala Ala Thr 1 5 10 187 10 PRT Artificial Sequence Synthetic polypeptide 187 Lys Thr Phe Thr Ala Lys Glu Ala Ala Thr 1 5 10 188 10 PRT Artificial Sequence Synthetic polypeptide 188 Gln Ala Leu His Cys Glu Lys Lys Tyr Leu 1 5 10 189 10 PRT Artificial Sequence Synthetic polypeptide 189 Gln Ala Leu Asp Ser Lys Ala Ala Tyr Leu 1 5 10 190 10 PRT Artificial Sequence Synthetic polypeptide 190 Gln Ala Leu Asp Ser Lys Asn Asn Phe Leu 1 5 10 191 10 PRT Artificial Sequence Synthetic polypeptide 191 Gln Ala Leu His Cys Glu Asn Asn Phe Leu 1 5 10 192 10 PRT Artificial Sequence Synthetic polypeptide 192 Cys Glu Lys Lys Tyr Leu Arg Ile Gln Asp 1 5 10 193 10 PRT Artificial Sequence Synthetic polypeptide 193 Ser Lys Asn Asn Phe Leu Arg Val Gln Glu 1 5 10 194 10 PRT Artificial Sequence Synthetic polypeptide 194 Ser Glu Asn Asn Tyr Leu Arg Val Gln Glu 1 5 10 195 10 PRT Artificial Sequence Synthetic polypeptide 195 Ala Leu Arg Val Gln Glu Asn Ala Leu Thr 1 5 10 196 10 PRT Artificial Sequence Synthetic polypeptide 196 Tyr Ala Arg Val Gln Glu Asn Ala Leu Thr 1 5 10 197 10 PRT Artificial Sequence Synthetic polypeptide 197 Tyr Leu Ala Val Gln Glu Asn Ala Leu Thr 1 5 10 198 10 PRT Artificial Sequence Synthetic polypeptide 198 Tyr Leu Arg Ala Gln Glu Asn Ala Leu Thr 1 5 10 199 10 PRT Artificial Sequence Synthetic polypeptide 199 Tyr Leu Arg Val Ala Glu Asn Ala Leu Thr 1 5 10 200 10 PRT Artificial Sequence Synthetic polypeptide 200 Tyr Leu Arg Val Gln Ala Asn Ala Leu Thr 1 5 10 201 10 PRT Artificial Sequence Synthetic polypeptide 201 Tyr Leu Arg Val Gln Glu Ala Ala Leu Thr 1 5 10 202 10 PRT Artificial Sequence Synthetic polypeptide 202 Tyr Leu Arg Val Gln Glu Asn Ala Ala Thr 1 5 10 203 10 PRT Artificial Sequence Synthetic polypeptide 203 Tyr Leu Arg Val Gln Glu Asn Ala Leu Ala 1 5 10 204 10 PRT Artificial Sequence Synthetic polypeptide 204 Tyr Leu Arg Ile Gln Asp Asp Thr Leu Thr 1 5 10 205 10 PRT Artificial Sequence Synthetic polypeptide 205 Tyr Leu Thr Val Ala Ala Ala Ala Leu Thr 1 5 10 206 10 PRT Artificial Sequence Synthetic polypeptide 206 Phe Leu Arg Val Gln Glu Asn Ala Leu Thr 1 5 10 207 10 PRT Artificial Sequence Synthetic polypeptide 207 Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala 1 5 10 208 10 PRT Artificial Sequence Synthetic polypeptide 208 Lys Lys Tyr Leu Arg Ile Gln Asp Asp Thr 1 5 10 209 10 PRT Artificial Sequence Synthetic polypeptide 209 Asn Asn Phe Leu Arg Val Gln Glu Asn Ala 1 5 10 210 10 PRT Artificial Sequence Synthetic polypeptide 210 Asn Ala Tyr Leu Arg Val Gln Glu Asn Ala 1 5 10 211 10 PRT Artificial Sequence Synthetic polypeptide 211 Ala Thr Tyr Glu Glu Ala Lys Leu Arg Phe 1 5 10 212 10 PRT Artificial Sequence Synthetic polypeptide 212 Glu Ala Tyr Glu Glu Ala Leu Lys Arg Phe 1 5 10 213 10 PRT Artificial Sequence Synthetic polypeptide 213 Glu Thr Ala Glu Glu Ala Leu Lys Arg Phe 1 5 10 214 10 PRT Artificial Sequence Synthetic polypeptide 214 Glu Thr Tyr Ala Glu Ala Leu Lys Arg Phe 1 5 10 215 10 PRT Artificial Sequence Synthetic polypeptide 215 Glu Thr Tyr Glu Ala Ala Leu Lys Arg Phe 1 5 10 216 10 PRT Artificial Sequence Synthetic polypeptide 216 Glu Thr Tyr Glu Glu Ala Ala Lys Arg Phe 1 5 10 217 10 PRT Artificial Sequence Synthetic polypeptide 217 Glu Thr Tyr Glu Glu Ala Leu Ala Arg Phe 1 5 10 218 10 PRT Artificial Sequence Synthetic polypeptide 218 Glu Thr Tyr Glu Glu Ala Leu Lys Ala Phe 1 5 10 219 10 PRT Artificial Sequence Synthetic polypeptide 219 Glu Thr Tyr Glu Glu Ala Leu Lys Arg Ala 1 5 10 220 10 PRT Artificial Sequence Synthetic polypeptide 220 Gly Thr Asn Ala Gln Ser Leu Ala Asp Phe 1 5 10 221 10 PRT Artificial Sequence Synthetic polypeptide 221 Glu Thr Tyr Glu Ala Ala Leu Ala Ala Phe 1 5 10 222 10 PRT Artificial Sequence Synthetic polypeptide 222 Glu Thr Phe Glu Glu Ala Leu Lys Arg Phe 1 5 10 223 10 PRT Artificial Sequence Synthetic polypeptide 223 Tyr Glu Glu Ala Leu Lys Thr Phe Ala Lys 1 5 10 224 10 PRT Artificial Sequence Synthetic polypeptide 224 Phe Glu Glu Ala Leu Lys Arg Phe Ala Lys 1 5 10 225 10 PRT Artificial Sequence Synthetic polypeptide 225 Ala Ala Leu Lys Arg Phe Ala Lys Leu Leu 1 5 10 226 10 PRT Artificial Sequence Synthetic polypeptide 226 Glu Ala Ala Lys Arg Phe Ala Lys Leu Leu 1 5 10 227 10 PRT Artificial Sequence Synthetic polypeptide 227 Glu Ala Leu Ala Arg Phe Ala Lys Leu Leu 1 5 10 228 10 PRT Artificial Sequence Synthetic polypeptide 228 Glu Ala Leu Lys Ala Phe Ala Lys Leu Leu 1 5 10 229 10 PRT Artificial Sequence Synthetic polypeptide 229 Glu Ala Leu Lys Arg Ala Ala Lys Leu Leu 1 5 10 230 10 PRT Artificial Sequence Synthetic polypeptide 230 Glu Ala Leu Lys Arg Phe Ala Ala Leu Leu 1 5 10 231 10 PRT Artificial Sequence Synthetic polypeptide 231 Glu Ala Leu Lys Arg Phe Ala Lys Ala Leu 1 5 10 232 10 PRT Artificial Sequence Synthetic polypeptide 232 Glu Ala Leu Lys Arg Phe Ala Lys Leu Ala 1 5 10 233 10 PRT Artificial Sequence Synthetic polypeptide 233 Gln Ser Leu Ala Asp Phe Ala Lys Gln Leu 1 5 10 234 10 PRT Artificial Sequence Synthetic polypeptide 234 Ala Ala Leu Ala Ala Phe Ala Lys Leu Leu 1 5 10 235 10 PRT Artificial Sequence Synthetic polypeptide 235 Leu Ala Asp Phe Ala Lys Gln Leu Ser Asp 1 5 10 236 10 PRT Artificial Sequence Synthetic polypeptide 236 Asp Phe Ala Lys Gln Leu Ser Asp Glu Arg 1 5 10 237 10 PRT Artificial Sequence Synthetic polypeptide 237 Ala Phe Ala Ala Leu Leu Ser Asp Arg Lys 1 5 10 238 10 PRT Artificial Sequence Synthetic polypeptide 238 Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro 1 5 10 239 10 PRT Artificial Sequence Synthetic polypeptide 239 Leu Lys Arg Phe Ala Lys Leu Leu Ser Asp 1 5 10 240 10 PRT Artificial Sequence Synthetic polypeptide 240 Gln Ala Leu Asp Ser Glu Asn Asn Phe Leu 1 5 10 241 10 PRT Artificial Sequence Synthetic polypeptide 241 Ser Asp Leu Ala Asp Phe Ala Lys Gln Leu 1 5 10 242 55 DNA Artificial Sequence Synthetic construct 242 ggagctcgag aaaagagagg ctgaagcttc attgaattac aaaaaaatgc tgttg 55 243 42 DNA Artificial Sequence Synthetic construct 243 tcccaactgt cctggtccat aagaagcttt gtttgctcgg ag 42 244 36 DNA Artificial Sequence Synthetic construct 244 gcttcttatg gaccaggaca gttgggagaa atggtg 36 245 39 DNA Artificial Sequence Synthetic construct 245 ggtctagagg aattctcatt acctaattga agcaaatgc 39 246 1128 DNA Artificial Sequence Synthetic construct 246 tcgagaaaag agaggctgaa gcttcattga attacaaaaa aatgctgttg ctctcattag 60 gcactggcac tacttcagag tttgataaaa catatacagc aaaagaggca gctacctgga 120 ctgctgtaca ttggatgtta gttatacaga aaatgactga tgcagcaagt tcttacatga 180 ctgattatta cctttctact gcttttcaag ctcttgattc aaaaaacaat tacctcaggg 240 ttcaagaaaa tgcattaaca ggcacaacta ctgaaatgga tgatgcttct gaggctaata 300 tggaattatt agtacaagtt ggtgaaaact tattgaagaa accagtttcc gaagacaatc 360 ctgaaaccta tgaggaagct ctaaagaggt ttgcaaaatt gctctctgat aggaagaaac 420 tccgagcaaa caaagcttct tatggaccag gacagttggg agaaatggtg actgttctta 480 gtattgatgg aggtggaatt agagggatca ttccggctac cattctcgaa tttcttgaag 540 gacaacttca ggaaatggac aataatgcag atgcaagact tgcagattac tttgatgtaa 600 ttggaggaac aagtacagga ggtttattga ctgctatgat aagtactcca aatgaaaaca 660 atcgaccctt tgctgctgcc aaagaaattg taccttttta cttcgaacat ggccctcaga 720 tttttaatcc tagtggtcaa attttaggcc caaaatatga tggaaaatat cttatgcaag 780 ttcttcaaga aaaacttgga gaaactcgtg tgcatcaagc tttgacagaa gttgtcatct 840 caagctttga catcaaaaca aataagccag taatattcac taagtcaaat ttagcaaact 900 ctccagaatt ggatgctaag atgtatgaca taagttattc cacagcagca gctccaacat 960 attttcctcc gcattacttt gttactaata ctagtaatgg agatgaatat gagttcaatc 1020 ttgttgatgg tgctgttgct actgttgctg atccggcgtt attatccatt agcgttgcaa 1080 cgagacttgc acaaaaggat ccagcatttg cttcaattag gtaatgag 1128 247 366 PRT Artificial Sequence Synthetic polypeptide 247 Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly Thr Gly Thr 1 5 10 15 Thr Ser Glu Phe Asp Lys Thr Tyr Thr Ala Lys Glu Ala Ala Thr Trp 20 25 30 Thr Ala Val His Trp Met Leu Val Ile Gln Lys Met Thr Asp Ala Ala 35 40 45 Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr Ala Phe Gln Ala Leu 50 55 60 Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala Leu Thr Gly 65 70 75 80 Thr Thr Thr Glu Met Asp Asp Ala Ser Glu Ala Asn Met Glu Leu Leu 85 90 95 Val Gln Val Gly Glu Asn Leu Leu Lys Lys Pro Val Ser Glu Asp Asn 100 105 110 Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu Ser 115 120 125 Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser Tyr Gly Pro Gly Gln 130 135 140 Leu Gly Glu Met Val Thr Val Leu Ser Ile Asp Gly Gly Gly Ile Arg 145 150 155 160 Gly Ile Ile Pro Ala Thr Ile Leu Glu Phe Leu Glu Gly Gln Leu Gln 165 170 175 Glu Met Asp Asn Asn Ala Asp Ala Arg Leu Ala Asp Tyr Phe Asp Val 180 185 190 Ile Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr Ala Met Ile Ser Thr 195 200 205 Pro Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala Lys Glu Ile Val Pro 210 215 220 Phe Tyr Phe Glu His Gly Pro Gln Ile Phe Asn Pro Ser Gly Gln Ile 225 230 235 240 Leu Gly Pro Lys Tyr Asp Gly Lys Tyr Leu Met Gln Val Leu Gln Glu 245 250 255 Lys Leu Gly Glu Thr Arg Val His Gln Ala Leu Thr Glu Val Val Ile 260 265 270 Ser Ser Phe Asp Ile Lys Thr Asn Lys Pro Val Ile Phe Thr Lys Ser 275 280 285 Asn Leu Ala Asn Ser Pro Glu Leu Asp Ala Lys Met Tyr Asp Ile Ser 290 295 300 Tyr Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro Pro His Tyr Phe Val 305 310 315 320 Thr Asn Thr Ser Asn Gly Asp Glu Tyr Glu Phe Asn Leu Val Asp Gly 325 330 335 Ala Val Ala Thr Val Ala Asp Pro Ala Leu Leu Ser Ile Ser Val Ala 340 345 350 Thr Arg Leu Ala Gln Lys Asp Pro Ala Phe Ala Ser Ile Arg 355 360 365 248 55 DNA Artificial Sequence Synthetic construct 248 ggagctcgag aaaagagagg ctgaagctaa tactagtaat ggagatgaat atgag 55 249 39 DNA Artificial Sequence Synthetic construct 249 ggtctagagg aattctcatt aagtaacaaa gtaatgcgg 39 250 1128 DNA Artificial Sequence Synthetic construct 250 tcgagaaaag agaggctgaa gctaatacta gtaatggaga tgaatatgag ttcaatcttg 60 ttgatggtgc tgttgctact gttgctgatc cggcgttatt atccattagc gttgcaacga 120 gacttgcaca aaaggatcca gcatttgctt caattaggtc attgaattac aaaaaaatgc 180 tgttgctctc attaggcact ggcactactt cagagtttga taaaacatat acagcaaaag 240 aggcagctac ctggactgct gtacattgga tgttagttat acagaaaatg actgatgcag 300 caagttctta catgactgat tattaccttt ctactgcttt tcaagctctt gattcaaaaa 360 acaattacct cagggttcaa gaaaatgcat taacaggcac aactactgaa atggatgatg 420 cttctgaggc taatatggaa ttattagtac aagttggtga aaacttattg aagaaaccag 480 tttccgaaga caatcctgaa acctatgagg aagctctaaa gaggtttgca aaattgctct 540 ctgataggaa gaaactccga gcaaacaaag cttcttatgg accaggacag ttgggagaaa 600 tggtgactgt tcttagtatt gatggaggtg gaattagagg gatcattccg gctaccattc 660 tcgaatttct tgaaggacaa cttcaggaaa tggacaataa tgcagatgca agacttgcag 720 attactttga tgtaattgga ggaacaagta caggaggttt attgactgct atgataagta 780 ctccaaatga aaacaatcga ccctttgctg ctgccaaaga aattgtacct ttttacttcg 840 aacatggccc tcagattttt aatcctagtg gtcaaatttt aggcccaaaa tatgatggaa 900 aatatcttat gcaagttctt caagaaaaac ttggagaaac tcgtgtgcat caagctttga 960 cagaagttgt catctcaagc tttgacatca aaacaaataa gccagtaata ttcactaagt 1020 caaatttagc aaactctcca gaattggatg ctaagatgta tgacataagt tattccacag 1080 cagcagctcc aacatatttt cctccgcatt actttgttac ttaatgag 1128 251 366 PRT Artificial Sequence Synthetic polypeptide 251 Asn Thr Ser Asn Gly Asp Glu Tyr Glu Phe Asn Leu Val Asp Gly Ala 1 5 10 15 Val Ala Thr Val Ala Asp Pro Ala Leu Leu Ser Ile Ser Val Ala Thr 20 25 30 Arg Leu Ala Gln Lys Asp Pro Ala Phe Ala Ser Ile Arg Ser Leu Asn 35 40 45 Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly Thr Gly Thr Thr Ser Glu 50 55 60 Phe Asp Lys Thr Tyr Thr Ala Lys Glu Ala Ala Thr Trp Thr Ala Val 65 70 75 80 His Trp Met Leu Val Ile Gln Lys Met Thr Asp Ala Ala Ser Ser Tyr 85 90 95 Met Thr Asp Tyr Tyr Leu Ser Thr Ala Phe Gln Ala Leu Asp Ser Lys 100 105 110 Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala Leu Thr Gly Thr Thr Thr 115 120 125 Glu Met Asp Asp Ala Ser Glu Ala Asn Met Glu Leu Leu Val Gln Val 130 135 140 Gly Glu Asn Leu Leu Lys Lys Pro Val Ser Glu Asp Asn Pro Glu Thr 145 150 155 160 Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu Ser Asp Arg Lys 165 170 175 Lys Leu Arg Ala Asn Lys Ala Ser Tyr Gly Pro Gly Gln Leu Gly Glu 180 185 190 Met Val Thr Val Leu Ser Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile 195 200 205 Pro Ala Thr Ile Leu Glu Phe Leu Glu Gly Gln Leu Gln Glu Met Asp 210 215 220 Asn Asn Ala Asp Ala Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly 225 230 235 240 Thr Ser Thr Gly Gly Leu Leu Thr Ala Met Ile Ser Thr Pro Asn Glu 245 250 255 Asn Asn Arg Pro Phe Ala Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe 260 265 270 Glu His Gly Pro Gln Ile Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro 275 280 285 Lys Tyr Asp Gly Lys Tyr Leu Met Gln Val Leu Gln Glu Lys Leu Gly 290 295 300 Glu Thr Arg Val His Gln Ala Leu Thr Glu Val Val Ile Ser Ser Phe 305 310 315 320 Asp Ile Lys Thr Asn Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala 325 330 335 Asn Ser Pro Glu Leu Asp Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr 340 345 350 Ala Ala Ala Pro Thr Tyr Phe Pro Pro His Tyr Phe Val Thr 355 360 365 252 55 DNA Artificial Sequence Synthetic construct 252 ggagctcgag aaaagagagg ctgaagctag ttattccaca gcagcagctc caaca 55 253 39 DNA Artificial Sequence Synthetic construct 253 ggtctagagg aattctcatt atatgtcata catcttagc 39 254 1128 DNA Artificial Sequence Synthetic construct 254 tcgagaaaag agaggctgaa gctagttatt ccacagcagc agctccaaca tattttcctc 60 cgcattactt tgttactaat actagtaatg gagatgaata tgagttcaat cttgttgatg 120 gtgctgttgc tactgttgct gatccggcgt tattatccat tagcgttgca acgagacttg 180 cacaaaagga tccagcattt gcttcaatta ggtcattgaa ttacaaaaaa atgctgttgc 240 tctcattagg cactggcact acttcagagt ttgataaaac atatacagca aaagaggcag 300 ctacctggac tgctgtacat tggatgttag ttatacagaa aatgactgat gcagcaagtt 360 cttacatgac tgattattac ctttctactg cttttcaagc tcttgattca aaaaacaatt 420 acctcagggt tcaagaaaat gcattaacag gcacaactac tgaaatggat gatgcttctg 480 aggctaatat ggaattatta gtacaagttg gtgaaaactt attgaagaaa ccagtttccg 540 aagacaatcc tgaaacctat gaggaagctc taaagaggtt tgcaaaattg ctctctgata 600 ggaagaaact ccgagcaaac aaagcttctt atggaccagg acagttggga gaaatggtga 660 ctgttcttag tattgatgga ggtggaatta gagggatcat tccggctacc attctcgaat 720 ttcttgaagg acaacttcag gaaatggaca ataatgcaga tgcaagactt gcagattact 780 ttgatgtaat tggaggaaca agtacaggag gtttattgac tgctatgata agtactccaa 840 atgaaaacaa tcgacccttt gctgctgcca aagaaattgt acctttttac ttcgaacatg 900 gccctcagat ttttaatcct agtggtcaaa ttttaggccc aaaatatgat ggaaaatatc 960 ttatgcaagt tcttcaagaa aaacttggag aaactcgtgt gcatcaagct ttgacagaag 1020 ttgtcatctc aagctttgac atcaaaacaa ataagccagt aatattcact aagtcaaatt 1080 tagcaaactc tccagaattg gatgctaaga tgtatgacat ataatgag 1128 255 366 PRT Artificial Sequence Synthetic polypeptide 255 Ser Tyr Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro Pro His Tyr Phe 1 5 10 15 Val Thr Asn Thr Ser Asn Gly Asp Glu Tyr Glu Phe Asn Leu Val Asp 20 25 30 Gly Ala Val Ala Thr Val Ala Asp Pro Ala Leu Leu Ser Ile Ser Val 35 40 45 Ala Thr Arg Leu Ala Gln Lys Asp Pro Ala Phe Ala Ser Ile Arg Ser 50 55 60 Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly Thr Gly Thr Thr 65 70 75 80 Ser Glu Phe Asp Lys Thr Tyr Thr Ala Lys Glu Ala Ala Thr Trp Thr 85 90 95 Ala Val His Trp Met Leu Val Ile Gln Lys Met Thr Asp Ala Ala Ser 100 105 110 Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr Ala Phe Gln Ala Leu Asp 115 120 125 Ser Lys Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala Leu Thr Gly Thr 130 135 140 Thr Thr Glu Met Asp Asp Ala Ser Glu Ala Asn Met Glu Leu Leu Val 145 150 155 160 Gln Val Gly Glu Asn Leu Leu Lys Lys Pro Val Ser Glu Asp Asn Pro 165 170 175 Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu Ser Asp 180 185 190 Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser Tyr Gly Pro Gly Gln Leu 195 200 205 Gly Glu Met Val Thr Val Leu Ser Ile Asp Gly Gly Gly Ile Arg Gly 210 215 220 Ile Ile Pro Ala Thr Ile Leu Glu Phe Leu Glu Gly Gln Leu Gln Glu 225 230 235 240 Met Asp Asn Asn Ala Asp Ala Arg Leu Ala Asp Tyr Phe Asp Val Ile 245 250 255 Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr Ala Met Ile Ser Thr Pro 260 265 270 Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala Lys Glu Ile Val Pro Phe 275 280 285 Tyr Phe Glu His Gly Pro Gln Ile Phe Asn Pro Ser Gly Gln Ile Leu 290 295 300 Gly Pro Lys Tyr Asp Gly Lys Tyr Leu Met Gln Val Leu Gln Glu Lys 305 310 315 320 Leu Gly Glu Thr Arg Val His Gln Ala Leu Thr Glu Val Val Ile Ser 325 330 335 Ser Phe Asp Ile Lys Thr Asn Lys Pro Val Ile Phe Thr Lys Ser Asn 340 345 350 Leu Ala Asn Ser Pro Glu Leu Asp Ala Lys Met Tyr Asp Ile 355 360 365 256 55 DNA Artificial Sequence Synthetic construct 256 ggagctcgag aaaagagagg ctgaagctac atatacagca aaagaggcag ctacc 55 257 39 DNA Artificial Sequence Synthetic construct 257 ggtctagagg aattctcatt atttatcaaa ctctgaagt 39 258 1128 DNA Artificial Sequence Synthetic construct 258 tcgagaaaag agaggctgaa gctacatata cagcaaaaga ggcagctacc tggactgctg 60 tacattggat gttagttata cagaaaatga ctgatgcagc aagttcttac atgactgatt 120 attacctttc tactgctttt caagctcttg attcaaaaaa caattacctc agggttcaag 180 aaaatgcatt aacaggcaca actactgaaa tggatgatgc ttctgaggct aatatggaat 240 tattagtaca agttggtgaa aacttattga agaaaccagt ttccgaagac aatcctgaaa 300 cctatgagga agctctaaag aggtttgcaa aattgctctc tgataggaag aaactccgat 360 caaacaaagc ttcttatgga ccaggacagt tgggagaaat ggtgactgtt cttagtattg 420 atggaggtgg aattagaggg atcattccgg ctaccattct cgaatttctt gaaggacaac 480 ttcaggaaat ggacaataat gcagatgcaa gacttgcaga ttactttgat gtaattggag 540 gaacaagtac aggaggttta ttgactgcta tgataagtac tccaaatgaa aacaatcgac 600 cctttgctgc tgccaaagaa attgtacctt tttacttcga acatggccct cagattttta 660 atcctagtgg tcaaatttta ggcccaaaat atgatggaaa atatcttatg caagttcttc 720 aagaaaaact tggagaaact cgtgtgcatc aagctttgac agaagttgtc atctcaagct 780 ttgacatcaa aacaaataag ccagtaatat tcactaagtc aaatttagca aactctccag 840 aattggatgc taagatgtat gacataagtt attccacagc agcagctcca acatattttc 900 ctccgcatta ctttgttact aatactagta atggagatga atatgagttc aatcttgttg 960 atggtgctgt tgctactgtt gctgatccgg cgttattatc cattagcgtt gcaacgagac 1020 ttgcacaaaa ggatccagca tttgcttcaa ttaggtcatt gaattacaaa aaaatgctgt 1080 tgctctcatt aggcactggc actacttcag agtttgataa ataatgag 1128 259 366 PRT Artificial Sequence Synthetic polypeptide 259 Thr Tyr Thr Ala Lys Glu Ala Ala Thr Trp Thr Ala Val His Trp Met 1 5 10 15 Leu Val Ile Gln Lys Met Thr Asp Ala Ala Ser Ser Tyr Met Thr Asp 20 25 30 Tyr Tyr Leu Ser Thr Ala Phe Gln Ala Leu Asp Ser Lys Asn Asn Tyr 35 40 45 Leu Arg Val Gln Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp 50 55 60 Asp Ala Ser Glu Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn 65 70 75 80 Leu Leu Lys Lys Pro Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu 85 90 95 Ala Leu Lys Arg Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg 100 105 110 Ser Asn Lys Ala Ser Tyr Gly Pro Gly Gln Leu Gly Glu Met Val Thr 115 120 125 Val Leu Ser Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr 130 135 140 Ile Leu Glu Phe Leu Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala 145 150 155 160 Asp Ala Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr 165 170 175 Gly Gly Leu Leu Thr Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg 180 185 190 Pro Phe Ala Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly 195 200 205 Pro Gln Ile Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp 210 215 220 Gly Lys Tyr Leu Met Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg 225 230 235 240 Val His Gln Ala Leu Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys 245 250 255 Thr Asn Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro 260 265 270 Glu Leu Asp Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala 275 280 285 Pro Thr Tyr Phe Pro Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly 290 295 300 Asp Glu Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala 305 310 315 320 Asp Pro Ala Leu Leu Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys 325 330 335 Asp Pro Ala Phe Ala Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu 340 345 350 Leu Leu Ser Leu Gly Thr Gly Thr Thr Ser Glu Phe Asp Lys 355 360 365 260 55 DNA Artificial Sequence Synthetic construct 260 ggagctcgag aaaagagagg ctgaagctaa tgcattaaca ggcacaacta ctgaa 55 261 39 DNA Artificial Sequence Synthetic construct 261 ggtctagagg aattctcatt attcttgaac cctgaggta 39 262 1128 DNA Artificial Sequence Synthetic construct 262 tcgagaaaag agaggctgaa gctaatgcat taacaggcac aactactgaa atggatgatg 60 cttctgaggc taatatggaa ttattagtac aagttggtga aaacttattg aagaaaccag 120 tttccgaaga caatcctgaa acctatgagg aagctctaaa gaggtttgca aaattgctct 180 ctgataggaa gaaactccga gcaaacaaag cttcttatgg accaggacag ttgggagaaa 240 tggtgactgt tcttagtatt gatggaggtg gaattagagg gatcattccg gctaccattc 300 tcgaatttct tgaaggacaa cttcaggaaa tggacaataa tgcagatgca agacttgcag 360 attactttga tgtaattgga ggaacaagta caggaggttt attgactgct atgataagta 420 ctccaaatga aaacaatcga ccctttgctg ctgccaaaga aattgtacct ttttacttcg 480 aacatggccc tcagattttt aatcctagtg gtcaaatttt aggcccaaaa tatgatggaa 540 aatatcttat gcaagttctt caagaaaaac ttggagaaac tcgtgtgcat caagctttga 600 cagaagttgt catctcaagc tttgacatca aaacaaataa gccagtaata ttcactaagt 660 caaatttagc aaactctcca gaattggatg ctaagatgta tgacataagt tattccacag 720 cagcagctcc aacatatttt cctccgcatt actttgttac taatactagt aatggagatg 780 aatatgagtt caatcttgtt gatggtgctg ttgctactgt tgctgatccg gcgttattat 840 ccattagcgt tgcaacgaga cttgcacaaa aggatccagc atttgcttca attaggtcat 900 tgaattacaa aaaaatgctg ttgctctcat taggcactgg cactacttca gagtttgata 960 aaacatatac agcaaaagag gcagctacct ggactgctgt acattggatg ttagttatac 1020 agaaaatgac tgatgcagca agttcttaca tgactgatta ttacctttct actgcttttc 1080 aagctcttga ttcaaaaaac aattacctca gggttcaaga ataatgag 1128 263 366 PRT Artificial Sequence Synthetic polypeptide 263 Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu Ala 1 5 10 15 Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu Lys Lys Pro 20 25 30 Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe 35 40 45 Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser 50 55 60 Tyr Gly Pro Gly Gln Leu Gly Glu Met Val Thr Val Leu Ser Ile Asp 65 70 75 80 Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr Ile Leu Glu Phe Leu 85 90 95 Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala Asp Ala Arg Leu Ala 100 105 110 Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr 115 120 125 Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala 130 135 140 Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly Pro Gln Ile Phe Asn 145 150 155 160 Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp Gly Lys Tyr Leu Met 165 170 175 Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His Gln Ala Leu 180 185 190 Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys Pro Val 195 200 205 Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro Glu Leu Asp Ala Lys 210 215 220 Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro 225 230 235 240 Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly Asp Glu Tyr Glu Phe 245 250 255 Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro Ala Leu Leu 260 265 270 Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys Asp Pro Ala Phe Ala 275 280 285 Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly 290 295 300 Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr Thr Ala Lys Glu Ala 305 310 315 320 Ala Thr Trp Thr Ala Val His Trp Met Leu Val Ile Gln Lys Met Thr 325 330 335 Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr Ala Phe 340 345 350 Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln Glu 355 360 365 264 1158 DNA Artificial Sequence Synthetic construct 264 atggccacca ccaagagctt cctcatcctg atcttcatga tcctggccac caccagcagc 60 accttcgccc agctcggcga gatggtgacc gtgctctcca tcgacggcgg tggcatcagg 120 ggcatcatcc cggccaccat cctggagttc ctggagggcc aactccagga gatggacaac 180 aacgccgacg cccgcctggc cgactacttc gacgtgatcg gtggcaccag caccggcggt 240 ctcctgaccg ccatgatctc cactccgaac gagaacaacc gccccttcgc cgctgcgaag 300 gagatcgtcc cgttctactt cgaacacggc cctcagattt tcaacccctc gggtcaaatc 360 ctgggcccca agtacgacgg caagtacctt atgcaagtgc ttcaggagaa gctgggcgag 420 actagggtgc accaggcgct gaccgaggtc gtcatctcca gcttcgacat caagaccaac 480 aagccagtca tcttcaccaa gtccaacctg gccaacagcc cggagctgga cgctaagatg 540 tacgacatct cctactccac tgctgccgct cccacgtact tccctccgca ctacttcgtc 600 accaacacca gcaacggcga cgagtacgag ttcaaccttg ttgacggtgc ggtggctacg 660 gtggcggacc cggcgctcct gtccatcagc gtcgccacgc gcctggccca gaaggatcca 720 gccttcgcta gcattaggag cctcaactac aagaagatgc tgctgctcag cctgggcact 780 ggcacgacct ccgagttcga caagacctac actgccaagg aggccgctac ctggaccgcc 840 gtccattgga tgctggtcat ccagaagatg acggacgccg cttccagcta catgaccgac 900 tactacctct ccactgcgtt ccaggcgctt gactccaaga acaactacct ccgtgttcag 960 gagaatgccc tcactggcac cacgaccgag atggacgatg cctccgaggc caacatggag 1020 ctgctcgtcc aggtgggtga gaacctcctg aagaagcccg tctccgaaga caatcccgag 1080 acctatgagg aagcgctcaa gcgctttgcc aagctgctct ctgataggaa gaaactccgc 1140 gctaacaagg ccagctac 1158 265 386 PRT Artificial Sequence Synthetic polypeptide 265 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Ile Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Phe Ala Gln Leu Gly Glu Met Val Thr Val Leu 20 25 30 Ser Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr Ile Leu 35 40 45 Glu Phe Leu Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala Asp Ala 50 55 60 Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly 65 70 75 80 Leu Leu Thr Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg Pro Phe 85 90 95 Ala Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly Pro Gln 100 105 110 Ile Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp Gly Lys 115 120 125 Tyr Leu Met Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His 130 135 140 Gln Ala Leu Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys Thr Asn 145 150 155 160 Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro Glu Leu 165 170 175 Asp Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala Pro Thr 180 185 190 Tyr Phe Pro Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly Asp Glu 195 200 205 Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro 210 215 220 Ala Leu Leu Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys Asp Pro 225 230 235 240 Ala Phe Ala Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu 245 250 255 Ser Leu Gly Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr Thr Ala 260 265 270 Lys Glu Ala Ala Thr Trp Thr Ala Val His Trp Met Leu Val Ile Gln 275 280 285 Lys Met Thr Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser 290 295 300 Thr Ala Phe Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln 305 310 315 320 Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu 325 330 335 Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu Lys Lys 340 345 350 Pro Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg 355 360 365 Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala 370 375 380 Ser Tyr 385 266 55 DNA Artificial Sequence Synthetic construct 266 ggagctcgag aaaagagagg ctgaagctag cctcaactac aagaagatgc tgctg 55 267 42 DNA Artificial Sequence Synthetic construct 267 gccgagctgt cctggtccgt agctggcctt gttagcgcgg ag 42 268 36 DNA Artificial Sequence Synthetic construct 268 gccagctacg gaccaggaca gctcggcgag atggtg 36 269 39 DNA Artificial Sequence Synthetic construct 269 ggtctagagg aattctcatt acctaatgct agcgaaggc 39 270 1167 DNA Artificial Sequence Synthetic construct 270 atggccacca ccaagagctt cctcatcctg atcttcatga tcctggccac caccagcagc 60 accttcgcca gcctcaacta caagaagatg ctgctgctca gcctgggcac tggcacgacc 120 tccgagttcg acaagaccta cactgccaag gaggccgcta cctggaccgc cgtccattgg 180 atgctggtca tccagaagat gacggacgcc gcttccagct acatgaccga ctactacctc 240 tccactgcgt tccaggcgct tgactccaag aacaactacc tccgtgttca ggagaatgcc 300 ctcactggca ccacgaccga gatggacgat gcctccgagg ccaacatgga gctgctcgtc 360 caggtgggtg agaacctcct gaagaagccc gtctccgaag acaatcccga gacctatgag 420 gaagcgctca agcgctttgc caagctgctc tctgatagga agaaactccg cgctaacaag 480 gccagctacg gaccaggaca gctcggcgag atggtgaccg tgctctccat cgacggcggt 540 ggcatcaggg gcatcatccc ggccaccatc ctggagttcc tggagggcca actccaggag 600 atggacaaca acgccgacgc ccgcctggcc gactacttcg acgtgatcgg tggcaccagc 660 accggcggtc tcctgaccgc catgatctcc actccgaacg agaacaaccg ccccttcgcc 720 gctgcgaagg agatcgtccc gttctacttc gaacacggcc ctcagatttt caacccctcg 780 ggtcaaatcc tgggccccaa gtacgacggc aagtacctta tgcaagtgct tcaggagaag 840 ctgggcgaga ctagggtgca ccaggcgctg accgaggtcg tcatctccag cttcgacatc 900 aagaccaaca agccagtcat cttcaccaag tccaacctgg ccaacagccc ggagctggac 960 gctaagatgt acgacatctc ctactccact gctgccgctc ccacgtactt ccctccgcac 1020 tacttcgtca ccaacaccag caacggcgac gagtacgagt tcaaccttgt tgacggtgcg 1080 gtggctacgg tggcggaccc ggcgctcctg tccatcagcg tcgccacgcg cctggcccag 1140 aaggatccag ccttcgctag cattagg 1167 271 389 PRT Artificial Sequence Synthetic polypeptide 271 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Ile Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Phe Ala Ser Leu Asn Tyr Lys Lys Met Leu Leu 20 25 30 Leu Ser Leu Gly Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr Thr 35 40 45 Ala Lys Glu Ala Ala Thr Trp Thr Ala Val His Trp Met Leu Val Ile 50 55 60 Gln Lys Met Thr Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu 65 70 75 80 Ser Thr Ala Phe Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val 85 90 95 Gln Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser 100 105 110 Glu Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu Lys 115 120 125 Lys Pro Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys 130 135 140 Arg Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys 145 150 155 160 Ala Ser Tyr Gly Pro Gly Gln Leu Gly Glu Met Val Thr Val Leu Ser 165 170 175 Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr Ile Leu Glu 180 185 190 Phe Leu Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala Asp Ala Arg 195 200 205 Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly Leu 210 215 220 Leu Thr Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala 225 230 235 240 Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly Pro Gln Ile 245 250 255 Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp Gly Lys Tyr 260 265 270 Leu Met Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His Gln 275 280 285 Ala Leu Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys 290 295 300 Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro Glu Leu Asp 305 310 315 320 Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala Pro Thr Tyr 325 330 335 Phe Pro Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly Asp Glu Tyr 340 345 350 Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro Ala 355 360 365 Leu Leu Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys Asp Pro Ala 370 375 380 Phe Ala Ser Ile Arg 385 272 55 DNA Artificial Sequence Synthetic construct 272 ggagctcgag aaaagagagg ctgaagctac tgccaaggag gccgctacct ggacc 55 273 39 DNA Artificial Sequence Synthetic construct 273 ggtctagagg aattctcatt acttgtcgaa ctcggaggt 39 274 1167 DNA Artificial Sequence Synthetic construct 274 atggccacca ccaagagctt cctcatcctg atcttcatga tcctggccac caccagcagc 60 accttcgcca cctacactgc caaggaggcc gctacctgga ccgccgtcca ttggatgctg 120 gtcatccaga agatgacgga cgccgcttcc agctacatga ccgactacta cctctccact 180 gcgttccagg cgcttgactc caagaacaac tacctccgtg ttcaggagaa tgccctcact 240 ggcaccacga ccgagatgga cgatgcctcc gaggccaaca tggagctgct cgtccaggtg 300 ggtgagaacc tcctgaagaa gcccgtctcc gaagacaatc ccgagaccta tgaggaagcg 360 ctcaagcgct ttgccaagct gctctctgat aggaagaaac tccgcgctaa caaggccagc 420 tacggaccag gacagctcgg cgagatggtg accgtgctct ccatcgacgg cggtggcatc 480 aggggcatca tcccggccac catcctggag ttcctggagg gccaactcca ggagatggac 540 aacaacgccg acgcccgcct ggccgactac ttcgacgtga tcggtggcac cagcaccggc 600 ggtctcctga ccgccatgat ctccactccg aacgagaaca accgcccctt cgccgctgcg 660 aaggagatcg tcccgttcta cttcgaacac ggccctcaga ttttcaaccc ctcgggtcaa 720 atcctgggcc ccaagtacga cggcaagtac cttatgcaag tgcttcagga gaagctgggc 780 gagactaggg tgcaccaggc gctgaccgag gtcgtcatct ccagcttcga catcaagacc 840 aacaagccag tcatcttcac caagtccaac ctggccaaca gcccggagct ggacgctaag 900 atgtacgaca tctcctactc cactgctgcc gctcccacgt acttccctcc gcactacttc 960 gtcaccaaca ccagcaacgg cgacgagtac gagttcaacc ttgttgacgg tgcggtggct 1020 acggtggcgg acccggcgct cctgtccatc agcgtcgcca cgcgcctggc ccagaaggat 1080 ccagccttcg ctagcattag gagcctcaac tacaagaaga tgctgctgct cagcctgggc 1140 actggcacga cctccgagtt cgacaag 1167 275 389 PRT Artificial Sequence Synthetic polypeptide 275 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Ile Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Phe Ala Thr Tyr Thr Ala Lys Glu Ala Ala Thr 20 25 30 Trp Thr Ala Val His Trp Met Leu Val Ile Gln Lys Met Thr Asp Ala 35 40 45 Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr Ala Phe Gln Ala 50 55 60 Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala Leu Thr 65 70 75 80 Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu Ala Asn Met Glu Leu 85 90 95 Leu Val Gln Val Gly Glu Asn Leu Leu Lys Lys Pro Val Ser Glu Asp 100 105 110 Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu 115 120 125 Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser Tyr Gly Pro Gly 130 135 140 Gln Leu Gly Glu Met Val Thr Val Leu Ser Ile Asp Gly Gly Gly Ile 145 150 155 160 Arg Gly Ile Ile Pro Ala Thr Ile Leu Glu Phe Leu Glu Gly Gln Leu 165 170 175 Gln Glu Met Asp Asn Asn Ala Asp Ala Arg Leu Ala Asp Tyr Phe Asp 180 185 190 Val Ile Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr Ala Met Ile Ser 195 200 205 Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala Lys Glu Ile Val 210 215 220 Pro Phe Tyr Phe Glu His Gly Pro Gln Ile Phe Asn Pro Ser Gly Gln 225 230 235 240 Ile Leu Gly Pro Lys Tyr Asp Gly Lys Tyr Leu Met Gln Val Leu Gln 245 250 255 Glu Lys Leu Gly Glu Thr Arg Val His Gln Ala Leu Thr Glu Val Val 260 265 270 Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys Pro Val Ile Phe Thr Lys 275 280 285 Ser Asn Leu Ala Asn Ser Pro Glu Leu Asp Ala Lys Met Tyr Asp Ile 290 295 300 Ser Tyr Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro Pro His Tyr Phe 305 310 315 320 Val Thr Asn Thr Ser Asn Gly Asp Glu Tyr Glu Phe Asn Leu Val Asp 325 330 335 Gly Ala Val Ala Thr Val Ala Asp Pro Ala Leu Leu Ser Ile Ser Val 340 345 350 Ala Thr Arg Leu Ala Gln Lys Asp Pro Ala Phe Ala Ser Ile Arg Ser 355 360 365 Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly Thr Gly Thr Thr 370 375 380 Ser Glu Phe Asp Lys 385 276 7 PRT Artificial Sequence Synthetic polypeptide 276 Gly Gly Gly Ser Gly Gly Gly 1 5 277 3 PRT Artificial Sequence Synthetic polypeptide 277 Gly Pro Gly 1 278 386 PRT Solanum tuberosum 278 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Phe Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Cys Ala Lys Leu Glu Glu Met Val Thr Val Leu 20 25 30 Ser Ile Asp Gly Gly Gly Ile Lys Gly Ile Ile Pro Ala Ile Ile Leu 35 40 45 Glu Phe Leu Glu Gly Gln Leu Gln Glu Val Asp Asn Asn Lys Asp Ala 50 55 60 Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly 65 70 75 80 Leu Leu Thr Ala Met Ile Thr Thr Pro Asn Glu Asn Asn Arg Pro Phe 85 90 95 Ala Ala Ala Lys Asp Ile Val Pro Phe Tyr Phe Glu His Gly Pro His 100 105 110 Ile Phe Asn Tyr Ser Gly Ser Ile Ile Gly Pro Met Tyr Asp Gly Lys 115 120 125 Tyr Leu Leu Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His 130 135 140 Gln Ala Leu Thr Glu Val Ala Ile Ser Ser Phe Asp Ile Lys Thr Asn 145 150 155 160 Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Lys Ser Pro Glu Leu 165 170 175 Asp Ala Lys Met Tyr Asp Ile Cys Tyr Ser Thr Ala Ala Ala Pro Ile 180 185 190 Tyr Phe Pro Pro His Tyr Phe Ile Thr His Thr Ser Asn Gly Asp Ile 195 200 205 Tyr Glu Phe Asn Leu Val Asp Gly Gly Val Ala Thr Val Gly Asp Pro 210 215 220 Ala Leu Leu Ser Leu Ser Val Ala Thr Arg Leu Ala Gln Glu Asp Pro 225 230 235 240 Ala Phe Ser Ser Ile Lys Ser Leu Asp Tyr Lys Gln Met Leu Leu Leu 245 250 255 Ser Leu Gly Thr Gly Thr Asn Ser Glu Phe Asp Lys Thr Tyr Thr Ala 260 265 270 Gln Glu Ala Ala Lys Trp Gly Pro Leu Arg Trp Met Leu Ala Ile Gln 275 280 285 Gln Met Thr Asn Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Ile Ser 290 295 300 Thr Val Phe Gln Ala Arg His Ser Gln Asn Asn Tyr Leu Arg Val Gln 305 310 315 320 Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu 325 330 335 Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Thr Leu Leu Lys Lys 340 345 350 Pro Val Ser Lys Asp Ser Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg 355 360 365 Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala 370 375 380 Ser Tyr 385 279 386 PRT Solanum tuberosum 279 Met Ala Thr Thr Lys Ser Val Leu Val Leu Phe Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Cys Ala Thr Leu Gly Glu Met Val Thr Val Leu 20 25 30 Ser Ile Asp Gly Gly Gly Ile Lys Gly Ile Ile Pro Ala Thr Ile Leu 35 40 45 Glu Phe Leu Glu Gly Gln Leu Gln Glu Val Asp Asn Asn Lys Asp Ala 50 55 60 Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly 65 70 75 80 Leu Leu Thr Ala Met Ile Thr Thr Pro Asn Glu Asn Asn Arg Pro Phe 85 90 95 Ala Ala Ala Lys Asp Ile Val Pro Phe Tyr Phe Glu His Gly Pro His 100 105 110 Ile Phe Asn Ser Ser Gly Ser Ile Phe Gly Pro Met Tyr Asp Gly Lys 115 120 125 Tyr Phe Leu Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His 130 135 140 Gln Ala Leu Thr Glu Val Ala Ile Ser Ser Phe Asp Ile Lys Thr Asn 145 150 155 160 Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Lys Ser Pro Glu Leu 165 170 175 Asp Ala Lys Met Asn Asp Ile Cys Tyr Ser Thr Ala Ala Ala Pro Thr 180 185 190 Tyr Phe Pro Pro His Tyr Phe Val Thr His Thr Ser Asn Gly Asp Lys 195 200 205 Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Gly Asp Pro 210 215 220 Ala Leu Leu Ser Leu Ser Val Arg Thr Lys Leu Ala Gln Val Asp Pro 225 230 235 240 Lys Phe Ala Ser Ile Lys Ser Leu Asn Tyr Asn Glu Met Leu Leu Leu 245 250 255 Ser Leu Gly Thr Gly Thr Asn Ser Glu Phe Asp Lys Thr Tyr Thr Ala 260 265 270 Glu Glu Ala Ala Lys Trp Gly Pro Leu Arg Trp Ile Leu Ala Ile Gln 275 280 285 Gln Met Thr Asn Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser 290 295 300 Thr Val Phe Gln Ala Arg His Ser Gln Asn Asn Tyr Leu Arg Val Gln 305 310 315 320 Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu 325 330 335 Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Lys Leu Leu Lys Lys 340 345 350 Pro Val Ser Lys Asp Ser Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg 355 360 365 Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala 370 375 380 Ser Tyr 385 280 365 PRT Solanum tuberosum 280 Met Ala Leu Glu Glu Met Val Ala Val Leu Ser Ile Asp Gly Gly Gly 1 5 10 15 Ile Lys Gly Ile Ile Pro Gly Thr Ile Leu Glu Phe Leu Glu Gly Gln 20 25 30 Leu Gln Lys Met Asp Asn Asn Ala Asp Ala Arg Leu Ala Asp Tyr Phe 35 40 45 Asp Val Ile Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr Ala Met Ile 50 55 60 Thr Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala Asn Glu Ile 65 70 75 80 Val Pro Phe Tyr Phe Glu His Gly Pro His Ile Phe Asn Ser Arg Tyr 85 90 95 Trp Pro Ile Phe Trp Pro Lys Tyr Asp Gly Lys Tyr Leu Met Gln Val 100 105 110 Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His Gln Ala Leu Thr Glu 115 120 125 Val Ala Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys Pro Val Ile Phe 130 135 140 Thr Lys Ser Asn Leu Ala Lys Ser Pro Glu Leu Asp Ala Lys Thr Tyr 145 150 155 160 Asp Ile Cys Tyr Ser Thr Ala Ala Ala Pro Thr Tyr Phe Pro Pro His 165 170 175 Tyr Phe Ala Thr Asn Thr Ile Asn Gly Asp Lys Tyr Glu Phe Asn Leu 180 185 190 Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro Ala Leu Leu Ser Val 195 200 205 Ser Val Ala Thr Arg Arg Ala Gln Glu Asp Pro Ala Phe Ala Ser Ile 210 215 220 Arg Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu Ser Leu Gly Thr Gly 225 230 235 240 Thr Thr Ser Glu Phe Asp Lys Thr His Thr Ala Glu Glu Thr Ala Lys 245 250 255 Trp Gly Ala Leu Gln Trp Met Leu Val Ile Gln Gln Met Thr Glu Ala 260 265 270 Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser Thr Val Phe Gln Asp 275 280 285 Leu His Ser Gln Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala Leu Thr 290 295 300 Gly Thr Thr Thr Lys Ala Asp Asp Ala Ser Glu Ala Asn Met Glu Leu 305 310 315 320 Leu Ala Gln Val Gly Glu Asn Leu Leu Lys Lys Pro Val Ser Lys Asp 325 330 335 Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu 340 345 350 Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser Tyr 355 360 365 281 364 PRT Solanum tuberosum 281 Pro Trp Leu Glu Glu Met Val Thr Val Leu Ser Ile Asp Gly Gly Gly 1 5 10 15 Ile Lys Gly Ile Ile Pro Ala Ile Ile Leu Glu Phe Leu Glu Gly Gln 20 25 30 Leu Gln Glu Val Asp Asn Asn Lys Asp Ala Arg Leu Ala Asp Tyr Phe 35 40 45 Asp Val Ile Gly Gly Thr Ser Thr Gly Gly Leu Leu Thr Ala Met Ile 50 55 60 Thr Thr Pro Asn Glu Asn Asn Arg Pro Phe Ala Ala Ala Lys Asp Ile 65 70 75 80 Val Pro Phe Tyr Phe Glu His Gly Pro His Ile Phe Asn Tyr Ser Gly 85 90 95 Ser Ile Leu Gly Pro Met Tyr Asp Gly Lys Tyr Leu Leu Gln Val Leu 100 105 110 Gln Glu Lys Leu Gly Glu Thr Arg Val His Gln Ala Leu Thr Glu Val 115 120 125 Ala Ile Ser Ser Phe Asp Ile Lys Thr Asn Lys Pro Val Ile Phe Thr 130 135 140 Lys Ser Asn Leu Ala Lys Ser Pro Glu Leu Asp Ala Lys Met Tyr Asp 145 150 155 160 Ile Cys Tyr Ser Thr Ala Ala Ala Pro Ile Tyr Phe Pro Pro His His 165 170 175 Phe Val Thr His Thr Ser Asn Gly Ala Arg Tyr Glu Phe Asn Leu Val 180 185 190 Asp Gly Ala Val Ala Thr Val Gly Asp Pro Ala Leu Leu Ser Leu Ser 195 200 205 Val Ala Thr Arg Leu Ala Gln Glu Asp Pro Ala Phe Ser Ser Ile Lys 210 215 220 Ser Leu Asp Tyr Lys Gln Met Leu Leu Leu Ser Leu Gly Thr Gly Thr 225 230 235 240 Asn Ser Glu Phe Asp Lys Thr Tyr Thr Ala Glu Glu Ala Ala Lys Trp 245 250 255 Gly Pro Leu Arg Trp Met Leu Ala Ile Gln Gln Met Thr Asn Ala Ala 260 265 270 Ser Phe Tyr Met Thr Asp Tyr Tyr Ile Ser Thr Val Phe Gln Ala Arg 275 280 285 His Ser Gln Asn Asn Tyr Leu Arg Val Gln Glu Asn Ala Leu Asn Gly 290 295 300 Thr Thr Thr Glu Met Asp Asp Ala Ser Glu Ala Asn Met Glu Leu Leu 305 310 315 320 Val Gln Val Gly Glu Thr Leu Leu Lys Lys Pro Val Ser Arg Asp Ser 325 330 335 Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg Phe Ala Lys Leu Leu Ser 340 345 350 Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala Ser Tyr 355 360 282 386 PRT Solanum tuberosum 282 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Phe Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Cys Ala Lys Leu Glu Glu Met Val Thr Val Leu 20 25 30 Ser Ile Asp Gly Gly Gly Ile Lys Gly Ile Ile Pro Ala Ile Ile Leu 35 40 45 Glu Phe Leu Glu Gly Gln Leu Gln Glu Val Asp Asn Asn Lys Asp Ala 50 55 60 Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly 65 70 75 80 Leu Leu Thr Ala Met Ile Thr Thr Pro Asn Glu Asn Asn Arg Pro Phe 85 90 95 Ala Ala Ala Lys Asp Ile Val Pro Phe Tyr Phe Glu His Gly Pro His 100 105 110 Ile Phe Asn Tyr Ser Gly Ser Ile Leu Gly Pro Met Tyr Asp Gly Lys 115 120 125 Tyr Leu Leu Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His 130 135 140 Gln Ala Leu Thr Glu Val Ala Ile Ser Ser Phe Asp Ile Lys Thr Asn 145 150 155 160 Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Lys Ser Pro Glu Leu 165 170 175 Asp Ala Lys Met Tyr Asp Ile Cys Tyr Ser Thr Ala Ala Ala Pro Ile 180 185 190 Tyr Phe Pro Pro His His Phe Val Thr His Thr Ser Asn Gly Ala Arg 195 200 205 Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Gly Asp Pro 210 215 220 Ala Leu Leu Ser Leu Ser Val Ala Thr Arg Leu Ala Gln Glu Asp Pro 225 230 235 240 Ala Phe Ser Ser Ile Lys Ser Leu Asp Tyr Lys Gln Met Leu Leu Leu 245 250 255 Ser Leu Gly Thr Gly Thr Asn Ser Glu Phe Asp Lys Thr Tyr Thr Ala 260 265 270 Glu Glu Ala Ala Lys Trp Gly Pro Leu Arg Trp Met Leu Ala Ile Gln 275 280 285 Gln Met Thr Asn Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Ile Ser 290 295 300 Thr Val Phe Gln Ala Arg His Ser Gln Asn Asn Tyr Leu Arg Val Gln 305 310 315 320 Glu Asn Ala Leu Asn Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu 325 330 335 Ala Asn Met Glu Leu Leu Val Gln Val Gly Ala Thr Leu Leu Lys Lys 340 345 350 Pro Val Ser Lys Asp Ser Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg 355 360 365 Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala 370 375 380 Ser Tyr 385 283 10 PRT Artificial Sequence Synthetic polypeptide 283 Ala Phe Phe Asp Lys Thr Tyr Thr Ala Lys 1 5 10 284 10 PRT Artificial Sequence Synthetic polypeptide 284 Cys Ile Phe Asp Ser Thr Tyr Thr Ala Lys 1 5 10 285 1161 DNA Solanum tuberosum 285 atggcaacta ctaaatcttt tttaatttta atatttatga tattagcaac tactagttca 60 acatttgctc agttgggaga aatggtgact gttcttagta ttgatggagg tggaattaga 120 gggatcattc cggctaccat tctcgaattt cttgaaggac aacttcagga aatggacaat 180 aatgcagatg caagacttgc agattacttt gatgtaattg gaggaacaag tacaggaggt 240 ttattgactg ctatgataag tactccaaat gaaaacaatc gaccctttgc tgctgccaaa 300 gaaattgtac ctttttactt cgaacatggc cctcagattt ttaatcctag tggtcaaatt 360 ttaggcccaa aatatgatgg aaaatatctt atgcaagttc ttcaagaaaa acttggagaa 420 actcgtgtgc atcaagcttt gacagaagtt gtcatctcaa gctttgacat caaaacaaat 480 aagccagtaa tattcactaa gtcaaattta gcaaactctc cagaattgga tgctaagatg 540 tatgacataa gttattccac agcagcagct ccaacatatt ttcctccgca ttactttgtt 600 actaatacta gtaatggaga tgaatatgag ttcaatcttg ttgatggtgc tgttgctact 660 gttgctgatc cggcgttatt atccattagc gttgcaacga gacttgcaca aaaggatcca 720 gcatttgctt caattaggtc attgaattac aaaaaaatgc tgttgctctc attaggcact 780 ggcactactt cagagtttga taaaacatat acagcaaaag aggcagctac ctggactgct 840 gtacattgga tgttagttat acagaaaatg actgatgcag caagttctta catgactgat 900 tattaccttt ctactgcttt tcaagctctt gattcaaaaa acaattacct cagggttcaa 960 gaaaatgcat taacaggcac aactactgaa atggatgatg cttctgaggc taatatggaa 1020 ttattagtac aagttggtga aaacttattg aagaaaccag tttccgaaga caatcctgaa 1080 acctatgagg aagctctaaa gaggtttgca aaattgctct ctgataggaa gaaactccga 1140 gcaaacaaag cttcttatta a 1161 286 386 PRT Solanum tuberosum 286 Met Ala Thr Thr Lys Ser Phe Leu Ile Leu Ile Phe Met Ile Leu Ala 1 5 10 15 Thr Thr Ser Ser Thr Phe Ala Gln Leu Gly Glu Met Val Thr Val Leu 20 25 30 Ser Ile Asp Gly Gly Gly Ile Arg Gly Ile Ile Pro Ala Thr Ile Leu 35 40 45 Glu Phe Leu Glu Gly Gln Leu Gln Glu Met Asp Asn Asn Ala Asp Ala 50 55 60 Arg Leu Ala Asp Tyr Phe Asp Val Ile Gly Gly Thr Ser Thr Gly Gly 65 70 75 80 Leu Leu Thr Ala Met Ile Ser Thr Pro Asn Glu Asn Asn Arg Pro Phe 85 90 95 Ala Ala Ala Lys Glu Ile Val Pro Phe Tyr Phe Glu His Gly Pro Gln 100 105 110 Ile Phe Asn Pro Ser Gly Gln Ile Leu Gly Pro Lys Tyr Asp Gly Lys 115 120 125 Tyr Leu Met Gln Val Leu Gln Glu Lys Leu Gly Glu Thr Arg Val His 130 135 140 Gln Ala Leu Thr Glu Val Val Ile Ser Ser Phe Asp Ile Lys Thr Asn 145 150 155 160 Lys Pro Val Ile Phe Thr Lys Ser Asn Leu Ala Asn Ser Pro Glu Leu 165 170 175 Asp Ala Lys Met Tyr Asp Ile Ser Tyr Ser Thr Ala Ala Ala Pro Thr 180 185 190 Tyr Phe Pro Pro His Tyr Phe Val Thr Asn Thr Ser Asn Gly Asp Glu 195 200 205 Tyr Glu Phe Asn Leu Val Asp Gly Ala Val Ala Thr Val Ala Asp Pro 210 215 220 Ala Leu Leu Ser Ile Ser Val Ala Thr Arg Leu Ala Gln Lys Asp Pro 225 230 235 240 Ala Phe Ala Ser Ile Arg Ser Leu Asn Tyr Lys Lys Met Leu Leu Leu 245 250 255 Ser Leu Gly Thr Gly Thr Thr Ser Glu Phe Asp Lys Thr Tyr Thr Ala 260 265 270 Lys Glu Ala Ala Thr Trp Thr Ala Val His Trp Met Leu Val Ile Gln 275 280 285 Lys Met Thr Asp Ala Ala Ser Ser Tyr Met Thr Asp Tyr Tyr Leu Ser 290 295 300 Thr Ala Phe Gln Ala Leu Asp Ser Lys Asn Asn Tyr Leu Arg Val Gln 305 310 315 320 Glu Asn Ala Leu Thr Gly Thr Thr Thr Glu Met Asp Asp Ala Ser Glu 325 330 335 Ala Asn Met Glu Leu Leu Val Gln Val Gly Glu Asn Leu Leu Lys Lys 340 345 350 Pro Val Ser Glu Asp Asn Pro Glu Thr Tyr Glu Glu Ala Leu Lys Arg 355 360 365 Phe Ala Lys Leu Leu Ser Asp Arg Lys Lys Leu Arg Ala Asn Lys Ala 370 375 380 Ser Tyr 385 287 408 PRT Artificial Sequence Synthetic polypeptide 287 Met Lys Ser Lys Met Ala Met Leu Leu Leu Leu Phe Cys Val Leu Ser 1 5 10 15 Asn Gln Leu Val Ala Ala Phe Ser Thr Gln Ala Lys Ala Ser Lys Asp 20 25 30 Gly Asn Leu Val Thr Val Leu Ala Ile Asp Gly Gly Gly Ile Arg Gly 35 40 45 Ile Ile Pro Gly Val Ile Leu Lys Gln Leu Glu Ala Thr Leu Gln Arg 50 55 60 Trp Asp Ser Ser Ala Arg Leu Ala Glu Tyr Phe Asp Val Val Ala Gly 65 70 75 80 Thr Ser Thr Gly Gly Ile Ile Thr Ala Ile Leu Thr Ala Pro Asp Pro 85 90 95 Gln Asn Lys Asp Arg Pro Leu Tyr Ala Ala Glu Glu Ile Ile Asp Phe 100 105 110 Tyr Ile Glu His Gly Pro Ser Ile Phe Asn Lys Ser Thr Ala Cys Ser 115 120 125 Leu Pro Gly Ile Phe Cys Pro Lys Tyr Asp Gly Lys Tyr Leu Gln Glu 130 135 140 Ile Ile Ser Gln Lys Leu Asn Glu Thr Leu Leu Asp Gln Thr Thr Thr 145 150 155 160 Asn Val Val Ile Pro Ser Phe Asp Ile Lys Leu Leu Arg Pro Thr Ile 165 170 175 Phe Ser Thr Phe Lys Leu Glu Glu Val Pro Glu Leu Asn Val Lys Leu 180 185 190 Ser Asp Val Cys Met Gly Thr Ser Ala Ala Pro Ile Val Phe Pro Pro 195 200 205 Tyr Tyr Phe Lys His Gly Asp Thr Glu Phe Asn Leu Val Asp Gly Ala 210 215 220 Ile Ile Ala Asp Ile Pro Ala Pro Val Ala Leu Ser Glu Val Leu Gln 225 230 235 240 Gln Glu Lys Tyr Lys Asn Lys Glu Ile Leu Leu Leu Ser Ile Gly Thr 245 250 255 Gly Val Val Lys Pro Gly Glu Gly Tyr Ser Ala Asn Arg Thr Trp Thr 260 265 270 Ile Phe Asp Trp Ser Ser Glu Thr Leu Ile Gly Leu Met Gly His Gly 275 280 285 Thr Arg Ala Met Ser Asp Tyr Tyr Val Gly Ser His Phe Lys Ala Leu 290 295 300 Gln Pro Gln Asn Asn Tyr Leu Arg Ile Gln Glu Tyr Asp Leu Asp Pro 305 310 315 320 Ala Leu Glu Ser Ile Asp Asp Ala Ser Thr Glu Asn Met Glu Asn Leu 325 330 335 Glu Lys Val Gly Gln Ser Leu Leu Asn Glu Pro Val Lys Arg Met Asn 340 345 350 Leu Asn Thr Phe Val Val Glu Glu Thr Gly Glu Gly Thr Asn Ala Glu 355 360 365 Ala Leu Asp Arg Leu Ala Gln Ile Leu Tyr Glu Glu Lys Ile Thr Arg 370 375 380 Gly Leu Gly Lys Ile Ser Leu Glu Val Asp Asn Ile Asp Pro Tyr Thr 385 390 395 400 Glu Arg Val Arg Lys Leu Leu Phe 405 288 410 PRT Zea mays 288 Met Gly Ser Ile Gly Arg Gly Thr Ala Asn Cys Ala Thr Val Pro Gln 1 5 10 15 Pro Pro Pro Ser Thr Gly Lys Leu Ile Thr Ile Leu Ser Ile Asp Gly 20 25 30 Gly Gly Ile Arg Gly Leu Ile Pro Ala Thr Ile Ile Ala Tyr Leu Glu 35 40 45 Ala Lys Leu Gln Glu Leu Asp Gly Pro Asp Ala Arg Ile Ala Asp Tyr 50 55 60 Phe Asp Val Ile Ala Gly Thr Ser Thr Gly Ala Leu Leu Ala Ser Met 65 70 75 80 Leu Ala Ala Pro Asp Glu Asn Asn Arg Pro Leu Phe Ala Ala Lys Asp 85 90 95 Leu Thr Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile Phe Pro Gln Lys 100 105 110 Lys Ala Gly Leu Leu Thr Pro Leu Arg Asn Leu Leu Gly Leu Val Arg 115 120 125 Gly Pro Lys Tyr Asp Gly Val Phe Leu His Asp Lys Ile Lys Ser Leu 130 135 140 Thr His Asp Val Arg Val Ala Asp Thr Val Thr Asn Val Ile Val Pro 145 150 155 160 Ala Phe Asp Val Lys Tyr Leu Gln Pro Ile Ile Phe Ser Thr Tyr Glu 165 170 175 Ala Lys Thr Asp Thr Leu Lys Asn Ala His Leu Ser Asp Ile Cys Ile 180 185 190 Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro Ala His Phe Phe Lys Thr 195 200 205 Glu Ala Thr Asp Gly Arg Pro Pro Arg Glu Tyr His Leu Val Asp Gly 210 215 220 Gly Val Ala Ala Asn Asn Pro Thr Met Val Ala Met Ser Met Leu Thr 225 230 235 240 Lys Glu Val His Arg Arg Asn Pro Asn Phe Asn Ala Gly Ser Pro Thr 245 250 255 Glu Tyr Thr Asn Tyr Leu Ile Ile Ser Val Gly Thr Gly Ser Ala Lys 260 265 270 Gln Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys Trp Gly Leu Ile 275 280 285 Gln Trp Leu Tyr Asn Gly Gly Phe Thr Pro Ile Ile Asp Ile Phe Ser 290 295 300 His Ala Ser Ser Asp Met Val Asp Ile His Ala Ser Ile Leu Phe Gln 305 310 315 320 Ala Leu His Cys Glu Lys Lys Tyr Leu Arg Ile Gln Asp Asp Thr Leu 325 330 335 Thr Gly Asn Ala Ser Ser Val Asp Ile Ala Thr Lys Glu Asn Met Glu 340 345 350 Ser Leu Ile Ser Ile Gly Gln Glu Leu Leu Lys Lys Pro Val Ala Arg 355 360 365 Val Asn Ile Asp Thr Gly Val Tyr Glu Ser Cys Asp Gly Glu Gly Thr 370 375 380 Asn Ala Gln Ser Leu Ala Asp Phe Ala Lys Gln Leu Ser Asp Glu Arg 385 390 395 400 Lys Leu Arg Lys Ser Asn Leu Asn Ser Asn 405 410 289 508 PRT Zea mays 289 Arg Pro Thr Arg Pro Arg His Pro Arg Asn Thr Gln Lys Arg Gly Ala 1 5 10 15 Leu Leu Val Gly Trp Ile Leu Phe Ser Leu Ala Ala Ser Pro Val Lys 20 25 30 Phe Gln Thr His Met Gly Ser Ile Gly Arg Gly Thr Ala Asn Cys Ala 35 40 45 Thr Val Pro Gln Pro Pro Pro Ser Thr Gly Lys Leu Ile Thr Ile Leu 50 55 60 Ser Ile Asp Gly Gly Gly Ile Arg Gly Leu Ile Pro Ala Thr Ile Ile 65 70 75 80 Ala Tyr Leu Glu Ala Lys Leu Gln Glu Leu Asp Gly Pro Asp Ala Arg 85 90 95 Ile Ala Asp Tyr Phe Asp Val Ile Ala Gly Thr Ser Thr Gly Ala Leu 100 105 110 Leu Ala Ser Met Leu Ala Ala Pro Asp Glu Asn Asn Arg Pro Leu Phe 115 120 125 Ala Ala Lys Asp Leu Thr Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile 130 135 140 Phe Pro Gln Lys Lys Ala Gly Leu Leu Thr Pro Leu Arg Asn Leu Leu 145 150 155 160 Gly Leu Val Arg Gly Pro Lys Tyr Asp Gly Val Phe Leu His Asp Lys 165 170 175 Ile Lys Ser Leu Thr His Asp Val Arg Val Ala Asp Thr Val Thr Asn 180 185 190 Val Ile Val Pro Ala Phe Asp Val Lys Tyr Leu Gln Pro Ile Ile Phe 195 200 205 Ser Thr Tyr Glu Ala Lys Thr Asp Ala Leu Lys Asn Ala His Leu Ser 210 215 220 Asp Ile Cys Ile Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro Ala His 225 230 235 240 Phe Phe Lys Thr Glu Ala Thr Asp Gly Arg Pro Pro Arg Glu Tyr His 245 250 255 Leu Val Asp Gly Gly Val Ala Ala Asn Asn Pro Thr Met Val Ala Met 260 265 270 Ser Met Leu Thr Lys Glu Val His Arg Arg Asn Pro Asn Phe Asn Ala 275 280 285 Gly Ser Pro Thr Glu Tyr Thr Asn Tyr Leu Ile Ile Ser Val Gly Thr 290 295 300 Gly Ser Ala Lys Gln Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys 305 310 315 320 Trp Gly Leu Ile Gln Trp Leu Tyr Asn Gly Gly Phe Thr Pro Ile Ile 325 330 335 Asp Ile Phe Ser His Ala Ser Ser Asp Met Val Asp Ile His Ala Ser 340 345 350 Ile Leu Phe Gln Ala Leu His Cys Glu Lys Lys Tyr Leu Arg Ile Gln 355 360 365 Leu Tyr Tyr Ala Gly Tyr Phe Asp Trp Glu Arg Ile Val Arg Gly His 370 375 380 Arg His Gln Gly Glu His Gly Val Ser Asp Ile Asp Arg Pro Gly Ala 385 390 395 400 Ala Gln Glu Ala Ser Gly Glu Ser Glu His Arg His Arg Ala Val Arg 405 410 415 Val Leu Arg Arg Gly His Lys Cys Thr Val Ala Ser Leu Arg Gln Ala 420 425 430 Thr Leu Arg Ala Gln Ala Thr Gln Glu Gln Ser Gln Leu Gln Leu Ile 435 440 445 Asn Thr Ser Leu Ser His Ser Met Cys Ser Phe Arg Arg Phe Thr Val 450 455 460 Ser Tyr Phe Phe Asn Phe Asn Ser Val Cys Val Leu Cys Val Leu Cys 465 470 475 480 Val Tyr Gln Thr Phe Lys Phe Asn Gln Lys Lys Lys Lys Lys Lys Lys 485 490 495 Lys Lys Lys Lys Lys Lys Lys Lys Lys Arg Ala Ala 500 505 290 410 PRT Zea mays 290 Met Gly Ser Ile Gly Arg Gly Thr Ala Asn Cys Ala Thr Val Pro Gln 1 5 10 15 Pro Pro Pro Ser Thr Gly Lys Leu Ile Thr Ile Leu Ser Ile Asp Gly 20 25 30 Gly Gly Ile Arg Gly Leu Ile Pro Ala Thr Ile Ile Ala Tyr Leu Glu 35 40 45 Ala Lys Leu Gln Glu Leu Asp Gly Pro Asp Ala Arg Ile Ala Asp Tyr 50 55 60 Phe Asp Val Ile Ala Gly Thr Ser Thr Gly Ala Leu Leu Ala Ser Met 65 70 75 80 Leu Ala Ala Pro Asp Glu Asn Asn Arg Pro Leu Phe Ala Ala Lys Asp 85 90 95 Leu Thr Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile Phe Pro Gln Lys 100 105 110 Lys Ala Gly Leu Leu Thr Pro Leu Arg Asn Leu Leu Gly Leu Val Arg 115 120 125 Gly Pro Lys Tyr Asp Gly Val Phe Leu His Asp Lys Ile Lys Ser Leu 130 135 140 Thr His Asp Val Arg Val Ala Asp Thr Val Thr Asn Val Ile Val Pro 145 150 155 160 Ala Phe Asp Val Lys Ser Leu Gln Pro Ile Ile Phe Ser Thr Tyr Glu 165 170 175 Ala Lys Thr Asp Thr Leu Lys Asn Ala His Leu Ser Asp Ile Cys Ile 180 185 190 Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro Ala His Phe Phe Lys Thr 195 200 205 Glu Ala Thr Asp Gly Arg Pro Pro Arg Glu Tyr His Leu Val Asp Gly 210 215 220 Gly Val Ala Ala Asn Asn Pro Thr Met Val Ala Met Ser Met Leu Thr 225 230 235 240 Lys Glu Val His Arg Arg Asn Pro Asn Phe Asn Ala Gly Ser Pro Thr 245 250 255 Glu Tyr Thr Asn Tyr Leu Ile Ile Ser Val Gly Thr Gly Ser Ala Lys 260 265 270 Gln Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys Trp Gly Leu Ile 275 280 285 Gln Trp Leu Tyr Asn Gly Gly Phe Thr Pro Ile Ile Asp Ile Phe Ser 290 295 300 His Ala Ser Ser Asp Met Val Asp Ile His Ala Ser Ile Leu Phe Gln 305 310 315 320 Ala Leu His Cys Glu Lys Lys Tyr Leu Arg Ile Gln Asp Asp Thr Leu 325 330 335 Thr Gly Asn Ala Ser Ser Val Asp Ile Ala Thr Lys Glu Asn Met Glu 340 345 350 Ser Leu Ile Ser Ile Gly Gln Glu Leu Leu Asn Lys Pro Val Ala Arg 355 360 365 Val Asn Ile Asp Thr Gly Leu Tyr Glu Ser Cys Glu Gly Glu Gly Thr 370 375 380 Asn Ala Gln Ser Leu Ala Asp Phe Ala Lys Gln Leu Ser Asp Glu Arg 385 390 395 400 Lys Leu Arg Lys Ser Asn Leu Asn Ser Asn 405 410 291 410 PRT Zea mays 291 Met Gly Ser Ile Gly Arg Gly Thr Ala Asn Cys Ala Thr Val Pro Gln 1 5 10 15 Pro Pro Pro Ser Thr Gly Lys Leu Ile Thr Ile Leu Ser Ile Asp Gly 20 25 30 Gly Gly Ile Arg Gly Leu Ile Pro Ala Thr Ile Ile Ala Tyr Leu Glu 35 40 45 Ala Lys Leu Gln Glu Leu Asp Gly Pro Asp Ala Arg Ile Ala Asp Tyr 50 55 60 Phe Asp Val Ile Ala Gly Thr Ser Thr Gly Ala Leu Leu Ala Ser Met 65 70 75 80 Leu Ala Ala Pro Asp Glu Asn Asn Arg Pro Leu Phe Ala Ala Lys Asp 85 90 95 Leu Thr Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile Phe Pro Gln Lys 100 105 110 Lys Ala Gly Leu Leu Thr Pro Leu Arg Asn Leu Leu Gly Leu Val Arg 115 120 125 Gly Pro Lys Tyr Asp Gly Val Phe Leu His Asp Lys Ile Lys Ser Leu 130 135 140 Thr His Asp Val Arg Val Ala Asp Thr Val Thr Asn Val Ile Val Pro 145 150 155 160 Ala Phe Asp Val Lys Tyr Leu Gln Pro Ile Ile Phe Ser Thr Tyr Glu 165 170 175 Ala Lys Thr Asp Ala Leu Lys Asn Ala His Leu Ser Asp Ile Cys Ile 180 185 190 Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro Ala His Phe Phe Lys Thr 195 200 205 Glu Ala Thr Asp Gly Arg Pro Pro Arg Glu Tyr His Leu Val Asp Gly 210 215 220 Gly Val Ala Ala Asn Asn Pro Thr Met Val Ala Met Ser Met Leu Thr 225 230 235 240 Lys Glu Val His Arg Arg Asn Pro Asn Phe Asn Ala Gly Ser Pro Thr 245 250 255 Glu Tyr Thr Asn Tyr Leu Ile Ile Ser Val Gly Thr Gly Ser Ala Lys 260 265 270 Gln Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys Trp Gly Leu Ile 275 280 285 Gln Trp Leu Tyr Asn Gly Gly Phe Thr Pro Ile Ile Asp Ile Phe Ser 290 295 300 His Ala Ser Ser Asp Met Val Asp Ile His Ala Ser Ile Leu Phe Gln 305 310 315 320 Ala Leu His Cys Glu Lys Lys Tyr Leu Arg Ile Gln Asp Asp Thr Leu 325 330 335 Thr Gly Asn Ala Ser Ser Val Asp Ile Ala Thr Lys Glu Asn Met Glu 340 345 350 Ser Leu Ile Ser Ile Gly Gln Glu Leu Leu Lys Lys Pro Val Ala Arg 355 360 365 Val Asn Ile Asp Thr Gly Leu Tyr Glu Ser Cys Asp Gly Glu Gly Thr 370 375 380 Asn Ala Gln Ser Leu Ala Asp Phe Ala Lys Gln Leu Ser Asp Glu Arg 385 390 395 400 Lys Leu Arg Lys Ser Asn Leu Asn Ser Asn 405 410 292 410 PRT Zea mays 292 Met Gly Ser Ile Gly Arg Gly Thr Ala Asn Cys Ala Thr Val Pro Gln 1 5 10 15 Pro Pro Pro Ser Thr Gly Lys Leu Ile Thr Ile Leu Ser Ile Asp Gly 20 25 30 Gly Gly Ile Arg Gly Leu Ile Pro Ala Thr Ile Ile Ala Tyr Leu Glu 35 40 45 Ala Lys Leu Gln Glu Leu Asp Gly Pro Asp Ala Arg Ile Ala Asp Tyr 50 55 60 Phe Asp Val Ile Ala Gly Thr Ser Thr Gly Ala Leu Leu Ala Ser Met 65 70 75 80 Leu Ala Ala Pro Asp Glu Asn Asn Arg Pro Leu Phe Ala Ala Lys Asp 85 90 95 Leu Thr Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile Phe Pro Gln Lys 100 105 110 Lys Ala Gly Leu Leu Thr Pro Leu Arg Asn Leu Leu Gly Leu Val Arg 115 120 125 Gly Pro Lys Tyr Asp Gly Val Phe Leu His Asp Lys Ile Lys Ser Leu 130 135 140 Thr His Asp Val Arg Val Ala Asp Thr Val Thr Asn Val Ile Val Pro 145 150 155 160 Ala Phe Asp Val Lys Ser Leu Gln Pro Ile Ile Phe Ser Thr Tyr Glu 165 170 175 Ala Lys Thr Asp Thr Leu Lys Asn Ala His Leu Ser Asp Ile Cys Ile 180 185 190 Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro Ala His Phe Phe Lys Ile 195 200 205 Glu Ala Thr Asp Gly Arg Pro Pro Arg Glu Tyr His Leu Val Asp Gly 210 215 220 Gly Val Ala Ala Asn Asn Pro Thr Met Val Ala Met Ser Met Leu Thr 225 230 235 240 Lys Glu Val His Arg Arg Asn Pro Asn Phe Asn Ala Gly Ser Pro Thr 245 250 255 Glu Tyr Thr Asn Tyr Leu Ile Ile Ser Val Gly Thr Gly Ser Ala Lys 260 265 270 Gln Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys Trp Gly Leu Ile 275 280 285 Gln Trp Leu Tyr Asn Gly Gly Phe Thr Pro Ile Ile Asp Ile Phe Ser 290 295 300 His Ala Ser Ser Asp Met Val Asp Ile His Ala Ser Ile Leu Phe Gln 305 310 315 320 Ala Leu His Cys Glu Lys Lys Tyr Leu Arg Ile Gln Asp Asp Thr Leu 325 330 335 Thr Gly Asn Ala Ser Ser Val Asp Ile Ala Thr Lys Glu Asn Met Glu 340 345 350 Ser Leu Ile Ser Ile Gly Gln Glu Leu Leu Asn Lys Pro Val Ala Arg 355 360 365 Val Asn Ile Asp Thr Gly Leu Tyr Glu Ser Cys Glu Gly Glu Gly Thr 370 375 380 Asn Ala Gln Ser Leu Ala Asp Phe Ala Lys Gln Leu Ser Asp Glu Arg 385 390 395 400 Lys Leu Arg Lys Ser Asn Leu Asn Ser Asn 405 410 293 337 PRT Zea mays 293 Met Gly Ser Ile Gly Arg Gly Thr Ala Asn Cys Ala Thr Val Pro Gln 1 5 10 15 Pro Pro Pro Ser Thr Gly Lys Leu Ile Thr Ile Leu Ser Ile Asp Gly 20 25 30 Gly Gly Ile Arg Gly Leu Ile Pro Ala Thr Ile Ile Ala Tyr Leu Glu 35 40 45 Ala Lys Leu Gln Glu Leu Asp Gly Pro Asp Ala Arg Ile Ala Asp Tyr 50 55 60 Phe Asp Val Ile Ala Gly Thr Ser Thr Gly Ala Leu Leu Ala Ser Met 65 70 75 80 Leu Ala Ala Pro Asp Glu Asn Asn Arg Pro Leu Phe Ala Ala Lys Asp 85 90 95 Leu Thr Thr Phe Tyr Leu Glu Asn Gly Pro Lys Ile Phe Pro Gln Lys 100 105 110 Lys Ala Gly Leu Leu Thr Pro Leu Arg Asn Leu Leu Gly Leu Val Arg 115 120 125 Gly Pro Lys Tyr Asp Gly Val Phe Leu His Asp Lys Ile Lys Ser Leu 130 135 140 Thr His Asp Val Arg Val Ala Asp Thr Val Thr Asn Val Ile Val Pro 145 150 155 160 Ala Phe Asp Val Lys Tyr Leu Gln Pro Ile Ile Phe Ser Thr Tyr Glu 165 170 175 Ala Lys Thr Asp Ala Leu Lys Asn Ala His Leu Ser Asp Ile Cys Ile 180 185 190 Ser Thr Ser Ala Ala Pro Thr Tyr Phe Pro Ala His Phe Phe Lys Thr 195 200 205 Glu Ala Thr Asp Gly Arg Pro Pro Arg Glu Tyr His Leu Val Asp Gly 210 215 220 Gly Val Ala Ala Asn Asn Pro Thr Met Val Ala Met Ser Met Leu Thr 225 230 235 240 Lys Glu Val His Arg Arg Asn Pro Asn Phe Asn Ala Gly Ser Pro Thr 245 250 255 Glu Tyr Thr Asn Tyr Leu Ile Ile Ser Val Gly Thr Gly Ser Ala Lys 260 265 270 Gln Ala Glu Lys Tyr Thr Ala Glu Gln Cys Ala Lys Trp Gly Leu Ile 275 280 285 Gln Trp Leu Tyr Asn Gly Gly Phe Thr Pro Ile Ile Asp Ile Phe Ser 290 295 300 His Ala Ser Ser Asp Met Val Asp Ile His Ala Ser Ile Leu Phe Gln 305 310 315 320 Ala Leu His Cys Glu Lys Lys Tyr Leu Arg Ile Gln Leu Tyr Tyr Ala 325 330 335 Gly
Classifications
U.S. Classification424/94.6, 435/419, 536/23.2, 435/198, 800/288, 435/69.1, 435/320.1
International ClassificationC12N9/18, C07K14/415, C12N15/29, C12N15/82, C12N9/14
Cooperative ClassificationY10S930/13, C12N9/14, C12N15/8242, C07K14/415, C12N15/8286, C12N9/18
European ClassificationC12N15/82C4, C12N9/18, C07K14/415, C12N15/82C8B6E, C12N9/14
Legal Events
DateCodeEventDescription
May 14, 2001ASAssignment
Owner name: MONSANTO TECHNOLOGY LLC, MISSOURI
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALIBHAI, MURTAZA F.;ASTWOOD, JAMES D.;MCWHERTER, CHARLESA.;AND OTHERS;REEL/FRAME:011807/0111;SIGNING DATES FROM 20010420 TO 20010503
Apr 30, 2007FPAYFee payment
Year of fee payment: 4
Apr 28, 2011FPAYFee payment
Year of fee payment: 8
Apr 28, 2015FPAYFee payment
Year of fee payment: 12